id	sid	tid	token	lemma	pos
cord-254777-h8hw4m9f	1	1	key	key	NN
cord-254777-h8hw4m9f	1	2	:	:	:
cord-254777-h8hw4m9f	2	1	cord-254777-h8hw4m9f	cord-254777-h8hw4m9f	NN
cord-254777-h8hw4m9f	2	2	authors	author	NNS
cord-254777-h8hw4m9f	2	3	:	:	:
cord-254777-h8hw4m9f	2	4	Tanner	Tanner	NNP
cord-254777-h8hw4m9f	2	5	,	,	,
cord-254777-h8hw4m9f	2	6	Tamara	Tamara	NNP
cord-254777-h8hw4m9f	2	7	;	;	:
cord-254777-h8hw4m9f	2	8	Wahezi	Wahezi	NNP
cord-254777-h8hw4m9f	2	9	,	,	,
cord-254777-h8hw4m9f	2	10	Dawn	Dawn	NNP
cord-254777-h8hw4m9f	2	11	M.	M.	NNP
cord-254777-h8hw4m9f	2	12	title	title	NN
cord-254777-h8hw4m9f	2	13	:	:	:
cord-254777-h8hw4m9f	2	14	Hyperinflammation	hyperinflammation	NN
cord-254777-h8hw4m9f	2	15	and	and	CC
cord-254777-h8hw4m9f	2	16	the	the	DT
cord-254777-h8hw4m9f	2	17	utility	utility	NN
cord-254777-h8hw4m9f	2	18	of	of	IN
cord-254777-h8hw4m9f	2	19	immunomodulatory	immunomodulatory	JJ
cord-254777-h8hw4m9f	2	20	medications	medication	NNS
cord-254777-h8hw4m9f	2	21	in	in	IN
cord-254777-h8hw4m9f	2	22	children	child	NNS
cord-254777-h8hw4m9f	2	23	with	with	IN
cord-254777-h8hw4m9f	2	24	COVID-19	covid-19	CD
cord-254777-h8hw4m9f	2	25	date	date	NN
cord-254777-h8hw4m9f	2	26	:	:	:
cord-254777-h8hw4m9f	2	27	2020	2020	CD
cord-254777-h8hw4m9f	2	28	-	-	HYPH
cord-254777-h8hw4m9f	2	29	07	07	CD
cord-254777-h8hw4m9f	2	30	-	-	HYPH
cord-254777-h8hw4m9f	2	31	29	29	CD
cord-254777-h8hw4m9f	2	32	journal	journal	NN
cord-254777-h8hw4m9f	2	33	:	:	:
cord-254777-h8hw4m9f	3	1	Paediatr	Paediatr	NNP
cord-254777-h8hw4m9f	3	2	Respir	Respir	NNP
cord-254777-h8hw4m9f	3	3	Rev	Rev	NNP
cord-254777-h8hw4m9f	3	4	DOI	DOI	NNP
cord-254777-h8hw4m9f	3	5	:	:	:
cord-254777-h8hw4m9f	3	6	10.1016	10.1016	CD
cord-254777-h8hw4m9f	3	7	/	/	SYM
cord-254777-h8hw4m9f	3	8	j.prrv.2020.07.003	j.prrv.2020.07.003	NNP
cord-254777-h8hw4m9f	3	9	sha	sha	NNP
cord-254777-h8hw4m9f	3	10	:	:	:
cord-254777-h8hw4m9f	4	1	f644e5c3d69582487a86effda5a3166df62ac23e	f644e5c3d69582487a86effda5a3166df62ac23e	NNP
cord-254777-h8hw4m9f	4	2	doc_id	doc_id	CD
cord-254777-h8hw4m9f	4	3	:	:	:
cord-254777-h8hw4m9f	5	1	254777	254777	CD
cord-254777-h8hw4m9f	5	2	cord_uid	cord_uid	NNS
cord-254777-h8hw4m9f	5	3	:	:	:
cord-254777-h8hw4m9f	5	4	h8hw4m9f	h8hw4m9f	NNS
cord-254777-h8hw4m9f	6	1	The	the	DT
cord-254777-h8hw4m9f	6	2	rapid	rapid	JJ
cord-254777-h8hw4m9f	6	3	spread	spread	NN
cord-254777-h8hw4m9f	6	4	of	of	IN
cord-254777-h8hw4m9f	6	5	SARS	SARS	NNP
cord-254777-h8hw4m9f	6	6	-	-	HYPH
cord-254777-h8hw4m9f	6	7	CoV-2	CoV-2	NNP
cord-254777-h8hw4m9f	6	8	infection	infection	NN
cord-254777-h8hw4m9f	6	9	globally	globally	RB
cord-254777-h8hw4m9f	6	10	coupled	couple	VBN
cord-254777-h8hw4m9f	6	11	with	with	IN
cord-254777-h8hw4m9f	6	12	the	the	DT
cord-254777-h8hw4m9f	6	13	relatively	relatively	RB
cord-254777-h8hw4m9f	6	14	high	high	JJ
cord-254777-h8hw4m9f	6	15	case	case	NN
cord-254777-h8hw4m9f	6	16	-	-	HYPH
cord-254777-h8hw4m9f	6	17	fatality	fatality	NN
cord-254777-h8hw4m9f	6	18	rate	rate	NN
cord-254777-h8hw4m9f	6	19	has	have	VBZ
cord-254777-h8hw4m9f	6	20	led	lead	VBN
cord-254777-h8hw4m9f	6	21	to	to	IN
cord-254777-h8hw4m9f	6	22	immediate	immediate	JJ
cord-254777-h8hw4m9f	6	23	need	need	NN
cord-254777-h8hw4m9f	6	24	for	for	IN
cord-254777-h8hw4m9f	6	25	therapeutic	therapeutic	JJ
cord-254777-h8hw4m9f	6	26	intervention	intervention	NN
cord-254777-h8hw4m9f	6	27	to	to	TO
cord-254777-h8hw4m9f	6	28	prevent	prevent	VB
cord-254777-h8hw4m9f	6	29	and	and	CC
cord-254777-h8hw4m9f	6	30	treat	treat	VB
cord-254777-h8hw4m9f	6	31	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	6	32	disease	disease	NN
cord-254777-h8hw4m9f	6	33	.	.	.
cord-254777-h8hw4m9f	7	1	There	there	EX
cord-254777-h8hw4m9f	7	2	is	be	VBZ
cord-254777-h8hw4m9f	7	3	accumulating	accumulate	VBG
cord-254777-h8hw4m9f	7	4	evidence	evidence	NN
cord-254777-h8hw4m9f	7	5	that	that	IN
cord-254777-h8hw4m9f	7	6	morbidity	morbidity	NN
cord-254777-h8hw4m9f	7	7	and	and	CC
cord-254777-h8hw4m9f	7	8	mortality	mortality	NN
cord-254777-h8hw4m9f	7	9	in	in	IN
cord-254777-h8hw4m9f	7	10	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	7	11	may	may	MD
cord-254777-h8hw4m9f	7	12	be	be	VB
cord-254777-h8hw4m9f	7	13	exacerbated	exacerbate	VBN
cord-254777-h8hw4m9f	7	14	by	by	IN
cord-254777-h8hw4m9f	7	15	a	a	DT
cord-254777-h8hw4m9f	7	16	dysregulated	dysregulate	VBN
cord-254777-h8hw4m9f	7	17	host	host	NN
cord-254777-h8hw4m9f	7	18	immune	immune	JJ
cord-254777-h8hw4m9f	7	19	response	response	NN
cord-254777-h8hw4m9f	7	20	resulting	result	VBG
cord-254777-h8hw4m9f	7	21	in	in	IN
cord-254777-h8hw4m9f	7	22	significant	significant	JJ
cord-254777-h8hw4m9f	7	23	hyperinflammation	hyperinflammation	NN
cord-254777-h8hw4m9f	7	24	and	and	CC
cord-254777-h8hw4m9f	7	25	cytokine	cytokine	NN
cord-254777-h8hw4m9f	7	26	release	release	NN
cord-254777-h8hw4m9f	7	27	.	.	.
cord-254777-h8hw4m9f	8	1	The	the	DT
cord-254777-h8hw4m9f	8	2	aim	aim	NN
cord-254777-h8hw4m9f	8	3	of	of	IN
cord-254777-h8hw4m9f	8	4	this	this	DT
cord-254777-h8hw4m9f	8	5	review	review	NN
cord-254777-h8hw4m9f	8	6	is	be	VBZ
cord-254777-h8hw4m9f	8	7	to	to	TO
cord-254777-h8hw4m9f	8	8	describe	describe	VB
cord-254777-h8hw4m9f	8	9	the	the	DT
cord-254777-h8hw4m9f	8	10	basis	basis	NN
cord-254777-h8hw4m9f	8	11	for	for	IN
cord-254777-h8hw4m9f	8	12	the	the	DT
cord-254777-h8hw4m9f	8	13	immune	immune	JJ
cord-254777-h8hw4m9f	8	14	dysregulation	dysregulation	NN
cord-254777-h8hw4m9f	8	15	caused	cause	VBN
cord-254777-h8hw4m9f	8	16	by	by	IN
cord-254777-h8hw4m9f	8	17	SARS	SARS	NNP
cord-254777-h8hw4m9f	8	18	-	-	HYPH
cord-254777-h8hw4m9f	8	19	CoV-2	CoV-2	NNP
cord-254777-h8hw4m9f	8	20	infection	infection	NN
cord-254777-h8hw4m9f	8	21	and	and	CC
cord-254777-h8hw4m9f	8	22	to	to	TO
cord-254777-h8hw4m9f	8	23	examine	examine	VB
cord-254777-h8hw4m9f	8	24	current	current	JJ
cord-254777-h8hw4m9f	8	25	investigations	investigation	NNS
cord-254777-h8hw4m9f	8	26	into	into	IN
cord-254777-h8hw4m9f	8	27	immunomodulatory	immunomodulatory	JJ
cord-254777-h8hw4m9f	8	28	therapies	therapy	NNS
cord-254777-h8hw4m9f	8	29	aimed	aim	VBN
cord-254777-h8hw4m9f	8	30	at	at	IN
cord-254777-h8hw4m9f	8	31	targeting	target	VBG
cord-254777-h8hw4m9f	8	32	the	the	DT
cord-254777-h8hw4m9f	8	33	excessive	excessive	JJ
cord-254777-h8hw4m9f	8	34	host	host	NN
cord-254777-h8hw4m9f	8	35	immune	immune	JJ
cord-254777-h8hw4m9f	8	36	response	response	NN
cord-254777-h8hw4m9f	8	37	.	.	.
cord-254777-h8hw4m9f	9	1	In	in	IN
cord-254777-h8hw4m9f	9	2	December	December	NNP
cord-254777-h8hw4m9f	9	3	2019	2019	CD
cord-254777-h8hw4m9f	9	4	,	,	,
cord-254777-h8hw4m9f	9	5	an	an	DT
cord-254777-h8hw4m9f	9	6	outbreak	outbreak	NN
cord-254777-h8hw4m9f	9	7	of	of	IN
cord-254777-h8hw4m9f	9	8	a	a	DT
cord-254777-h8hw4m9f	9	9	novel	novel	JJ
cord-254777-h8hw4m9f	9	10	coronavirus	coronavirus	NN
cord-254777-h8hw4m9f	9	11	,	,	,
cord-254777-h8hw4m9f	9	12	designated	designate	VBN
cord-254777-h8hw4m9f	9	13	as	as	IN
cord-254777-h8hw4m9f	9	14	severe	severe	JJ
cord-254777-h8hw4m9f	9	15	acute	acute	JJ
cord-254777-h8hw4m9f	9	16	respiratory	respiratory	JJ
cord-254777-h8hw4m9f	9	17	syndrome	syndrome	NN
cord-254777-h8hw4m9f	9	18	coronavirus	coronavirus	NN
cord-254777-h8hw4m9f	9	19	2	2	CD
cord-254777-h8hw4m9f	9	20	(	(	-LRB-
cord-254777-h8hw4m9f	9	21	SARS	SARS	NNP
cord-254777-h8hw4m9f	9	22	-	-	HYPH
cord-254777-h8hw4m9f	9	23	CoV-2	CoV-2	NNP
cord-254777-h8hw4m9f	9	24	)	)	-RRB-
cord-254777-h8hw4m9f	9	25	spread	spread	VBD
cord-254777-h8hw4m9f	9	26	rapidly	rapidly	RB
cord-254777-h8hw4m9f	9	27	throughout	throughout	IN
cord-254777-h8hw4m9f	9	28	Wuhan	Wuhan	NNP
cord-254777-h8hw4m9f	9	29	,	,	,
cord-254777-h8hw4m9f	9	30	China	China	NNP
cord-254777-h8hw4m9f	9	31	and	and	CC
cord-254777-h8hw4m9f	9	32	subsequently	subsequently	RB
cord-254777-h8hw4m9f	9	33	around	around	IN
cord-254777-h8hw4m9f	9	34	the	the	DT
cord-254777-h8hw4m9f	9	35	world	world	NN
cord-254777-h8hw4m9f	9	36	.	.	.
cord-254777-h8hw4m9f	10	1	Similar	similar	JJ
cord-254777-h8hw4m9f	10	2	to	to	IN
cord-254777-h8hw4m9f	10	3	prior	prior	JJ
cord-254777-h8hw4m9f	10	4	novel	novel	JJ
cord-254777-h8hw4m9f	10	5	coronavirus	coronavirus	NN
cord-254777-h8hw4m9f	10	6	infections	infection	NNS
cord-254777-h8hw4m9f	10	7	(	(	-LRB-
cord-254777-h8hw4m9f	10	8	SARS	SARS	NNP
cord-254777-h8hw4m9f	10	9	and	and	CC
cord-254777-h8hw4m9f	10	10	MERS	MERS	NNP
cord-254777-h8hw4m9f	10	11	)	)	-RRB-
cord-254777-h8hw4m9f	10	12	,	,	,
cord-254777-h8hw4m9f	10	13	infection	infection	NN
cord-254777-h8hw4m9f	10	14	with	with	IN
cord-254777-h8hw4m9f	10	15	SARS	SARS	NNP
cord-254777-h8hw4m9f	10	16	-	-	HYPH
cord-254777-h8hw4m9f	10	17	CoV-2	CoV-2	NNP
cord-254777-h8hw4m9f	10	18	leads	lead	VBZ
cord-254777-h8hw4m9f	10	19	to	to	IN
cord-254777-h8hw4m9f	10	20	a	a	DT
cord-254777-h8hw4m9f	10	21	severe	severe	JJ
cord-254777-h8hw4m9f	10	22	pneumonia	pneumonia	NN
cord-254777-h8hw4m9f	10	23	and	and	CC
cord-254777-h8hw4m9f	10	24	acute	acute	JJ
cord-254777-h8hw4m9f	10	25	respiratory	respiratory	JJ
cord-254777-h8hw4m9f	10	26	distress	distress	NN
cord-254777-h8hw4m9f	10	27	syndrome	syndrome	NN
cord-254777-h8hw4m9f	10	28	(	(	-LRB-
cord-254777-h8hw4m9f	10	29	ARDS	ARDS	NNP
cord-254777-h8hw4m9f	10	30	)	)	-RRB-
cord-254777-h8hw4m9f	10	31	in	in	IN
cord-254777-h8hw4m9f	10	32	a	a	DT
cord-254777-h8hw4m9f	10	33	subset	subset	NN
cord-254777-h8hw4m9f	10	34	of	of	IN
cord-254777-h8hw4m9f	10	35	patients	patient	NNS
cord-254777-h8hw4m9f	10	36	.	.	.
cord-254777-h8hw4m9f	11	1	In	in	IN
cord-254777-h8hw4m9f	11	2	February	February	NNP
cord-254777-h8hw4m9f	11	3	2020	2020	CD
cord-254777-h8hw4m9f	11	4	,	,	,
cord-254777-h8hw4m9f	11	5	the	the	DT
cord-254777-h8hw4m9f	11	6	World	World	NNP
cord-254777-h8hw4m9f	11	7	Health	Health	NNP
cord-254777-h8hw4m9f	11	8	Organization	Organization	NNP
cord-254777-h8hw4m9f	11	9	(	(	-LRB-
cord-254777-h8hw4m9f	11	10	WHO	who	WP
cord-254777-h8hw4m9f	11	11	)	)	-RRB-
cord-254777-h8hw4m9f	11	12	designated	designate	VBD
cord-254777-h8hw4m9f	11	13	the	the	DT
cord-254777-h8hw4m9f	11	14	disease	disease	NN
cord-254777-h8hw4m9f	11	15	associated	associate	VBN
cord-254777-h8hw4m9f	11	16	with	with	IN
cord-254777-h8hw4m9f	11	17	SARS	SARS	NNP
cord-254777-h8hw4m9f	11	18	-	-	HYPH
cord-254777-h8hw4m9f	11	19	CoV-2	CoV-2	NNP
cord-254777-h8hw4m9f	11	20	as	as	IN
cord-254777-h8hw4m9f	11	21	COVID-	covid-	NN
cord-254777-h8hw4m9f	11	22	19	19	CD
cord-254777-h8hw4m9f	11	23	.	.	.
cord-254777-h8hw4m9f	12	1	Mortality	mortality	NN
cord-254777-h8hw4m9f	12	2	in	in	IN
cord-254777-h8hw4m9f	12	3	patients	patient	NNS
cord-254777-h8hw4m9f	12	4	with	with	IN
cord-254777-h8hw4m9f	12	5	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	12	6	is	be	VBZ
cord-254777-h8hw4m9f	12	7	highest	high	JJS
cord-254777-h8hw4m9f	12	8	in	in	IN
cord-254777-h8hw4m9f	12	9	patients	patient	NNS
cord-254777-h8hw4m9f	12	10	with	with	IN
cord-254777-h8hw4m9f	12	11	ARDS	ARDS	NNP
cord-254777-h8hw4m9f	12	12	admitted	admit	VBD
cord-254777-h8hw4m9f	12	13	to	to	IN
cord-254777-h8hw4m9f	12	14	intensive	intensive	JJ
cord-254777-h8hw4m9f	12	15	care	care	NN
cord-254777-h8hw4m9f	12	16	units	unit	NNS
cord-254777-h8hw4m9f	12	17	and	and	CC
cord-254777-h8hw4m9f	12	18	is	be	VBZ
cord-254777-h8hw4m9f	12	19	often	often	RB
cord-254777-h8hw4m9f	12	20	exacerbated	exacerbate	VBN
cord-254777-h8hw4m9f	12	21	by	by	IN
cord-254777-h8hw4m9f	12	22	a	a	DT
cord-254777-h8hw4m9f	12	23	dysregulated	dysregulate	VBN
cord-254777-h8hw4m9f	12	24	immune	immune	JJ
cord-254777-h8hw4m9f	12	25	response	response	NN
cord-254777-h8hw4m9f	12	26	leading	lead	VBG
cord-254777-h8hw4m9f	12	27	to	to	IN
cord-254777-h8hw4m9f	12	28	significant	significant	JJ
cord-254777-h8hw4m9f	12	29	hyperinflammation	hyperinflammation	NN
cord-254777-h8hw4m9f	12	30	and	and	CC
cord-254777-h8hw4m9f	12	31	cytokine	cytokine	NN
cord-254777-h8hw4m9f	12	32	release	release	NN
cord-254777-h8hw4m9f	12	33	.	.	.
cord-254777-h8hw4m9f	13	1	Until	until	IN
cord-254777-h8hw4m9f	13	2	recently	recently	RB
cord-254777-h8hw4m9f	13	3	,	,	,
cord-254777-h8hw4m9f	13	4	children	child	NNS
cord-254777-h8hw4m9f	13	5	were	be	VBD
cord-254777-h8hw4m9f	13	6	thought	think	VBN
cord-254777-h8hw4m9f	13	7	to	to	TO
cord-254777-h8hw4m9f	13	8	be	be	VB
cord-254777-h8hw4m9f	13	9	spared	spare	VBN
cord-254777-h8hw4m9f	13	10	more	more	JJR
cord-254777-h8hw4m9f	13	11	severe	severe	JJ
cord-254777-h8hw4m9f	13	12	manifestations	manifestation	NNS
cord-254777-h8hw4m9f	13	13	.	.	.
cord-254777-h8hw4m9f	14	1	In	in	IN
cord-254777-h8hw4m9f	14	2	April	April	NNP
cord-254777-h8hw4m9f	14	3	2020	2020	CD
cord-254777-h8hw4m9f	14	4	,	,	,
cord-254777-h8hw4m9f	14	5	an	an	DT
cord-254777-h8hw4m9f	14	6	unanticipated	unanticipated	JJ
cord-254777-h8hw4m9f	14	7	inflammatory	inflammatory	JJ
cord-254777-h8hw4m9f	14	8	syndrome	syndrome	NN
cord-254777-h8hw4m9f	14	9	related	relate	VBN
cord-254777-h8hw4m9f	14	10	to	to	IN
cord-254777-h8hw4m9f	14	11	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	14	12	rapidly	rapidly	RB
cord-254777-h8hw4m9f	14	13	emerged	emerge	VBD
cord-254777-h8hw4m9f	14	14	in	in	IN
cord-254777-h8hw4m9f	14	15	children	child	NNS
cord-254777-h8hw4m9f	14	16	.	.	.
cord-254777-h8hw4m9f	15	1	This	this	DT
cord-254777-h8hw4m9f	15	2	entity	entity	NN
cord-254777-h8hw4m9f	15	3	has	have	VBZ
cord-254777-h8hw4m9f	15	4	now	now	RB
cord-254777-h8hw4m9f	15	5	been	be	VBN
cord-254777-h8hw4m9f	15	6	termed	term	VBN
cord-254777-h8hw4m9f	15	7	multi	multi	JJ
cord-254777-h8hw4m9f	15	8	-	-	JJ
cord-254777-h8hw4m9f	15	9	system	system	JJ
cord-254777-h8hw4m9f	15	10	inflammatory	inflammatory	JJ
cord-254777-h8hw4m9f	15	11	syndrome	syndrome	NN
cord-254777-h8hw4m9f	15	12	in	in	IN
cord-254777-h8hw4m9f	15	13	children	child	NNS
cord-254777-h8hw4m9f	15	14	(	(	-LRB-
cord-254777-h8hw4m9f	15	15	MIS	MIS	NNP
cord-254777-h8hw4m9f	15	16	-	-	HYPH
cord-254777-h8hw4m9f	15	17	C	C	NNP
cord-254777-h8hw4m9f	15	18	)	)	-RRB-
cord-254777-h8hw4m9f	15	19	by	by	IN
cord-254777-h8hw4m9f	15	20	the	the	DT
cord-254777-h8hw4m9f	15	21	Centers	Centers	NNPS
cord-254777-h8hw4m9f	15	22	for	for	IN
cord-254777-h8hw4m9f	15	23	Disease	Disease	NNP
cord-254777-h8hw4m9f	15	24	Control	Control	NNP
cord-254777-h8hw4m9f	15	25	(	(	-LRB-
cord-254777-h8hw4m9f	15	26	CDC	CDC	NNP
cord-254777-h8hw4m9f	15	27	)	)	-RRB-
cord-254777-h8hw4m9f	15	28	(	(	-LRB-
cord-254777-h8hw4m9f	15	29	also	also	RB
cord-254777-h8hw4m9f	15	30	known	know	VBN
cord-254777-h8hw4m9f	15	31	as	as	IN
cord-254777-h8hw4m9f	15	32	pediatric	pediatric	JJ
cord-254777-h8hw4m9f	15	33	multi	multi	JJ
cord-254777-h8hw4m9f	15	34	-	-	JJ
cord-254777-h8hw4m9f	15	35	system	system	JJ
cord-254777-h8hw4m9f	15	36	inflammatory	inflammatory	JJ
cord-254777-h8hw4m9f	15	37	syndrome	syndrome	NN
cord-254777-h8hw4m9f	15	38	(	(	-LRB-
cord-254777-h8hw4m9f	15	39	PMIS	PMIS	NNP
cord-254777-h8hw4m9f	15	40	)	)	-RRB-
cord-254777-h8hw4m9f	15	41	)	)	-RRB-
cord-254777-h8hw4m9f	15	42	.	.	.
cord-254777-h8hw4m9f	16	1	Since	since	IN
cord-254777-h8hw4m9f	16	2	first	first	RB
cord-254777-h8hw4m9f	16	3	described	describe	VBN
cord-254777-h8hw4m9f	16	4	in	in	IN
cord-254777-h8hw4m9f	16	5	the	the	DT
cord-254777-h8hw4m9f	16	6	United	United	NNP
cord-254777-h8hw4m9f	16	7	Kingdom	Kingdom	NNP
cord-254777-h8hw4m9f	16	8	in	in	IN
cord-254777-h8hw4m9f	16	9	April	April	NNP
cord-254777-h8hw4m9f	16	10	2020	2020	CD
cord-254777-h8hw4m9f	16	11	,	,	,
cord-254777-h8hw4m9f	16	12	there	there	EX
cord-254777-h8hw4m9f	16	13	has	have	VBZ
cord-254777-h8hw4m9f	16	14	been	be	VBN
cord-254777-h8hw4m9f	16	15	a	a	DT
cord-254777-h8hw4m9f	16	16	rapid	rapid	JJ
cord-254777-h8hw4m9f	16	17	increase	increase	NN
cord-254777-h8hw4m9f	16	18	in	in	IN
cord-254777-h8hw4m9f	16	19	reported	report	VBN
cord-254777-h8hw4m9f	16	20	cases	case	NNS
cord-254777-h8hw4m9f	16	21	in	in	IN
cord-254777-h8hw4m9f	16	22	several	several	JJ
cord-254777-h8hw4m9f	16	23	other	other	JJ
cord-254777-h8hw4m9f	16	24	countries	country	NNS
cord-254777-h8hw4m9f	16	25	.	.	.
cord-254777-h8hw4m9f	17	1	Presentations	presentation	NNS
cord-254777-h8hw4m9f	17	2	of	of	IN
cord-254777-h8hw4m9f	17	3	MIS	MIS	NNP
cord-254777-h8hw4m9f	17	4	-	-	HYPH
cord-254777-h8hw4m9f	17	5	C	C	NNP
cord-254777-h8hw4m9f	17	6	are	be	VBP
cord-254777-h8hw4m9f	17	7	variable	variable	JJ
cord-254777-h8hw4m9f	17	8	,	,	,
cord-254777-h8hw4m9f	17	9	with	with	IN
cord-254777-h8hw4m9f	17	10	features	feature	NNS
cord-254777-h8hw4m9f	17	11	representative	representative	NN
cord-254777-h8hw4m9f	17	12	of	of	IN
cord-254777-h8hw4m9f	17	13	Kawasaki	Kawasaki	NNP
cord-254777-h8hw4m9f	17	14	disease	disease	NN
cord-254777-h8hw4m9f	17	15	(	(	-LRB-
cord-254777-h8hw4m9f	17	16	KD	KD	NNP
cord-254777-h8hw4m9f	17	17	)	)	-RRB-
cord-254777-h8hw4m9f	17	18	,	,	,
cord-254777-h8hw4m9f	17	19	sepsis	sepsis	NN
cord-254777-h8hw4m9f	17	20	,	,	,
cord-254777-h8hw4m9f	17	21	toxic	toxic	JJ
cord-254777-h8hw4m9f	17	22	shock	shock	NN
cord-254777-h8hw4m9f	17	23	syndrome	syndrome	NN
cord-254777-h8hw4m9f	17	24	(	(	-LRB-
cord-254777-h8hw4m9f	17	25	TSS	TSS	NNP
cord-254777-h8hw4m9f	17	26	)	)	-RRB-
cord-254777-h8hw4m9f	17	27	and	and	CC
cord-254777-h8hw4m9f	17	28	secondary	secondary	JJ
cord-254777-h8hw4m9f	17	29	hemophagocytic	hemophagocytic	NNP
cord-254777-h8hw4m9f	17	30	lymphohistiocytosis	lymphohistiocytosis	NNP
cord-254777-h8hw4m9f	17	31	(	(	-LRB-
cord-254777-h8hw4m9f	17	32	sHLH	sHLH	NNP
cord-254777-h8hw4m9f	17	33	)	)	-RRB-
cord-254777-h8hw4m9f	17	34	.	.	.
cord-254777-h8hw4m9f	18	1	It	-PRON-	PRP
cord-254777-h8hw4m9f	18	2	is	be	VBZ
cord-254777-h8hw4m9f	18	3	unknown	unknown	JJ
cord-254777-h8hw4m9f	18	4	to	to	IN
cord-254777-h8hw4m9f	18	5	what	what	WDT
cord-254777-h8hw4m9f	18	6	extent	extent	NN
cord-254777-h8hw4m9f	18	7	patients	patient	NNS
cord-254777-h8hw4m9f	18	8	affected	affect	VBN
cord-254777-h8hw4m9f	18	9	with	with	IN
cord-254777-h8hw4m9f	18	10	MIS	MIS	NNP
cord-254777-h8hw4m9f	18	11	-	-	HYPH
cord-254777-h8hw4m9f	18	12	C	C	NNP
cord-254777-h8hw4m9f	18	13	have	have	VBP
cord-254777-h8hw4m9f	18	14	pathophysiology	pathophysiology	NN
cord-254777-h8hw4m9f	18	15	similar	similar	JJ
cord-254777-h8hw4m9f	18	16	to	to	IN
cord-254777-h8hw4m9f	18	17	these	these	DT
cord-254777-h8hw4m9f	18	18	known	know	VBN
cord-254777-h8hw4m9f	18	19	clinical	clinical	JJ
cord-254777-h8hw4m9f	18	20	entities	entity	NNS
cord-254777-h8hw4m9f	18	21	and	and	CC
cord-254777-h8hw4m9f	18	22	to	to	TO
cord-254777-h8hw4m9f	18	23	what	what	WDT
cord-254777-h8hw4m9f	18	24	extent	extent	NN
cord-254777-h8hw4m9f	18	25	they	-PRON-	PRP
cord-254777-h8hw4m9f	18	26	might	may	MD
cord-254777-h8hw4m9f	18	27	respond	respond	VB
cord-254777-h8hw4m9f	18	28	to	to	IN
cord-254777-h8hw4m9f	18	29	typical	typical	JJ
cord-254777-h8hw4m9f	18	30	medications	medication	NNS
cord-254777-h8hw4m9f	18	31	used	use	VBN
cord-254777-h8hw4m9f	18	32	in	in	IN
cord-254777-h8hw4m9f	18	33	these	these	DT
cord-254777-h8hw4m9f	18	34	conditions	condition	NNS
cord-254777-h8hw4m9f	18	35	.	.	.
cord-254777-h8hw4m9f	19	1	The	the	DT
cord-254777-h8hw4m9f	19	2	rapid	rapid	JJ
cord-254777-h8hw4m9f	19	3	spread	spread	NN
cord-254777-h8hw4m9f	19	4	of	of	IN
cord-254777-h8hw4m9f	19	5	SARS	SARS	NNP
cord-254777-h8hw4m9f	19	6	-	-	HYPH
cord-254777-h8hw4m9f	19	7	CoV-2	CoV-2	NNP
cord-254777-h8hw4m9f	19	8	infection	infection	NN
cord-254777-h8hw4m9f	19	9	globally	globally	RB
cord-254777-h8hw4m9f	19	10	and	and	CC
cord-254777-h8hw4m9f	19	11	the	the	DT
cord-254777-h8hw4m9f	19	12	relatively	relatively	RB
cord-254777-h8hw4m9f	19	13	high	high	JJ
cord-254777-h8hw4m9f	19	14	case	case	NN
cord-254777-h8hw4m9f	19	15	-	-	HYPH
cord-254777-h8hw4m9f	19	16	fatality	fatality	NN
cord-254777-h8hw4m9f	19	17	rate	rate	NN
cord-254777-h8hw4m9f	19	18	has	have	VBZ
cord-254777-h8hw4m9f	19	19	led	lead	VBN
cord-254777-h8hw4m9f	19	20	to	to	IN
cord-254777-h8hw4m9f	19	21	immediate	immediate	JJ
cord-254777-h8hw4m9f	19	22	need	need	NN
cord-254777-h8hw4m9f	19	23	for	for	IN
cord-254777-h8hw4m9f	19	24	therapeutic	therapeutic	JJ
cord-254777-h8hw4m9f	19	25	intervention	intervention	NN
cord-254777-h8hw4m9f	19	26	to	to	TO
cord-254777-h8hw4m9f	19	27	prevent	prevent	VB
cord-254777-h8hw4m9f	19	28	and	and	CC
cord-254777-h8hw4m9f	19	29	treat	treat	VB
cord-254777-h8hw4m9f	19	30	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	19	31	disease	disease	NN
cord-254777-h8hw4m9f	19	32	.	.	.
cord-254777-h8hw4m9f	20	1	Many	many	JJ
cord-254777-h8hw4m9f	20	2	agents	agent	NNS
cord-254777-h8hw4m9f	20	3	are	be	VBP
cord-254777-h8hw4m9f	20	4	currently	currently	RB
cord-254777-h8hw4m9f	20	5	under	under	IN
cord-254777-h8hw4m9f	20	6	investigation	investigation	NN
cord-254777-h8hw4m9f	20	7	in	in	IN
cord-254777-h8hw4m9f	20	8	an	an	DT
cord-254777-h8hw4m9f	20	9	effort	effort	NN
cord-254777-h8hw4m9f	20	10	to	to	TO
cord-254777-h8hw4m9f	20	11	target	target	VB
cord-254777-h8hw4m9f	20	12	different	different	JJ
cord-254777-h8hw4m9f	20	13	pathways	pathway	NNS
cord-254777-h8hw4m9f	20	14	of	of	IN
cord-254777-h8hw4m9f	20	15	viral	viral	JJ
cord-254777-h8hw4m9f	20	16	infection	infection	NN
cord-254777-h8hw4m9f	20	17	and	and	CC
cord-254777-h8hw4m9f	20	18	host	host	NN
cord-254777-h8hw4m9f	20	19	response	response	NN
cord-254777-h8hw4m9f	20	20	.	.	.
cord-254777-h8hw4m9f	21	1	This	this	DT
cord-254777-h8hw4m9f	21	2	review	review	NN
cord-254777-h8hw4m9f	21	3	aims	aim	VBZ
cord-254777-h8hw4m9f	21	4	to	to	TO
cord-254777-h8hw4m9f	21	5	describe	describe	VB
cord-254777-h8hw4m9f	21	6	our	-PRON-	PRP$
cord-254777-h8hw4m9f	21	7	current	current	JJ
cord-254777-h8hw4m9f	21	8	understanding	understanding	NN
cord-254777-h8hw4m9f	21	9	of	of	IN
cord-254777-h8hw4m9f	21	10	the	the	DT
cord-254777-h8hw4m9f	21	11	hyperinflammatory	hyperinflammatory	JJ
cord-254777-h8hw4m9f	21	12	response	response	NN
cord-254777-h8hw4m9f	21	13	and	and	CC
cord-254777-h8hw4m9f	21	14	the	the	DT
cord-254777-h8hw4m9f	21	15	immunomodulatory	immunomodulatory	JJ
cord-254777-h8hw4m9f	21	16	targets	target	NNS
cord-254777-h8hw4m9f	21	17	.	.	.
cord-254777-h8hw4m9f	22	1	We	-PRON-	PRP
cord-254777-h8hw4m9f	22	2	will	will	MD
cord-254777-h8hw4m9f	22	3	review	review	VB
cord-254777-h8hw4m9f	22	4	the	the	DT
cord-254777-h8hw4m9f	22	5	existing	exist	VBG
cord-254777-h8hw4m9f	22	6	data	datum	NNS
cord-254777-h8hw4m9f	22	7	,	,	,
cord-254777-h8hw4m9f	22	8	with	with	IN
cord-254777-h8hw4m9f	22	9	the	the	DT
cord-254777-h8hw4m9f	22	10	acknowledgment	acknowledgment	NN
cord-254777-h8hw4m9f	22	11	that	that	IN
cord-254777-h8hw4m9f	22	12	new	new	JJ
cord-254777-h8hw4m9f	22	13	information	information	NN
cord-254777-h8hw4m9f	22	14	becomes	become	VBZ
cord-254777-h8hw4m9f	22	15	available	available	JJ
cord-254777-h8hw4m9f	22	16	every	every	DT
cord-254777-h8hw4m9f	22	17	day	day	NN
cord-254777-h8hw4m9f	22	18	and	and	CC
cord-254777-h8hw4m9f	22	19	may	may	MD
cord-254777-h8hw4m9f	22	20	not	not	RB
cord-254777-h8hw4m9f	22	21	be	be	VB
cord-254777-h8hw4m9f	22	22	included	include	VBN
cord-254777-h8hw4m9f	22	23	within	within	IN
cord-254777-h8hw4m9f	22	24	the	the	DT
cord-254777-h8hw4m9f	22	25	timeframe	timeframe	NN
cord-254777-h8hw4m9f	22	26	of	of	IN
cord-254777-h8hw4m9f	22	27	this	this	DT
cord-254777-h8hw4m9f	22	28	review	review	NN
cord-254777-h8hw4m9f	22	29	.	.	.
cord-254777-h8hw4m9f	23	1	The	the	DT
cord-254777-h8hw4m9f	23	2	proposed	propose	VBN
cord-254777-h8hw4m9f	23	3	mechanism	mechanism	NN
cord-254777-h8hw4m9f	23	4	of	of	IN
cord-254777-h8hw4m9f	23	5	severe	severe	JJ
cord-254777-h8hw4m9f	23	6	infection	infection	NN
cord-254777-h8hw4m9f	23	7	with	with	IN
cord-254777-h8hw4m9f	23	8	SARS	SARS	NNP
cord-254777-h8hw4m9f	23	9	-	-	HYPH
cord-254777-h8hw4m9f	23	10	CoV-2	CoV-2	NNP
cord-254777-h8hw4m9f	23	11	has	have	VBZ
cord-254777-h8hw4m9f	23	12	been	be	VBN
cord-254777-h8hw4m9f	23	13	sub	sub	NN
cord-254777-h8hw4m9f	23	14	-	-	HYPH
cord-254777-h8hw4m9f	23	15	divided	divided	JJ
cord-254777-h8hw4m9f	23	16	into	into	IN
cord-254777-h8hw4m9f	23	17	the	the	DT
cord-254777-h8hw4m9f	23	18	viral	viral	JJ
cord-254777-h8hw4m9f	23	19	replication	replication	NN
cord-254777-h8hw4m9f	23	20	phase	phase	NN
cord-254777-h8hw4m9f	23	21	and	and	CC
cord-254777-h8hw4m9f	23	22	the	the	DT
cord-254777-h8hw4m9f	23	23	hyperinflammatory	hyperinflammatory	JJ
cord-254777-h8hw4m9f	23	24	phase	phase	NN
cord-254777-h8hw4m9f	23	25	.	.	.
cord-254777-h8hw4m9f	24	1	These	these	DT
cord-254777-h8hw4m9f	24	2	phases	phase	NNS
cord-254777-h8hw4m9f	24	3	correspond	correspond	VBP
cord-254777-h8hw4m9f	24	4	to	to	IN
cord-254777-h8hw4m9f	24	5	three	three	CD
cord-254777-h8hw4m9f	24	6	clinical	clinical	JJ
cord-254777-h8hw4m9f	24	7	stages	stage	NNS
cord-254777-h8hw4m9f	24	8	:	:	:
cord-254777-h8hw4m9f	24	9	early	early	JJ
cord-254777-h8hw4m9f	24	10	infection	infection	NN
cord-254777-h8hw4m9f	24	11	,	,	,
cord-254777-h8hw4m9f	24	12	pulmonary	pulmonary	JJ
cord-254777-h8hw4m9f	24	13	phase	phase	NN
cord-254777-h8hw4m9f	24	14	,	,	,
cord-254777-h8hw4m9f	24	15	and	and	CC
cord-254777-h8hw4m9f	24	16	hyperinflammatory	hyperinflammatory	NN
cord-254777-h8hw4m9f	24	17	phase	phase	NN
cord-254777-h8hw4m9f	24	18	[	[	-LRB-
cord-254777-h8hw4m9f	24	19	1	1	CD
cord-254777-h8hw4m9f	24	20	]	]	-RRB-
cord-254777-h8hw4m9f	24	21	.	.	.
cord-254777-h8hw4m9f	25	1	During	during	IN
cord-254777-h8hw4m9f	25	2	viral	viral	JJ
cord-254777-h8hw4m9f	25	3	replication	replication	NN
cord-254777-h8hw4m9f	25	4	,	,	,
cord-254777-h8hw4m9f	25	5	SARS	SARS	NNP
cord-254777-h8hw4m9f	25	6	-	-	HYPH
cord-254777-h8hw4m9f	25	7	CoV-2	CoV-2	NNP
cord-254777-h8hw4m9f	25	8	infects	infect	VBZ
cord-254777-h8hw4m9f	25	9	airway	airway	NN
cord-254777-h8hw4m9f	25	10	epithelial	epithelial	JJ
cord-254777-h8hw4m9f	25	11	cells	cell	NNS
cord-254777-h8hw4m9f	25	12	through	through	IN
cord-254777-h8hw4m9f	25	13	interactions	interaction	NNS
cord-254777-h8hw4m9f	25	14	with	with	IN
cord-254777-h8hw4m9f	25	15	the	the	DT
cord-254777-h8hw4m9f	25	16	trans	trans	NN
cord-254777-h8hw4m9f	25	17	-	-	NN
cord-254777-h8hw4m9f	25	18	membrane	membrane	NN
cord-254777-h8hw4m9f	25	19	enzyme	enzyme	NN
cord-254777-h8hw4m9f	25	20	ACE2	ACE2	NNP
cord-254777-h8hw4m9f	25	21	[	[	-LRB-
cord-254777-h8hw4m9f	25	22	2	2	CD
cord-254777-h8hw4m9f	25	23	]	]	-RRB-
cord-254777-h8hw4m9f	25	24	.	.	.
cord-254777-h8hw4m9f	26	1	The	the	DT
cord-254777-h8hw4m9f	26	2	virus	virus	NN
cord-254777-h8hw4m9f	26	3	evades	evade	VBZ
cord-254777-h8hw4m9f	26	4	innate	innate	JJ
cord-254777-h8hw4m9f	26	5	immune	immune	JJ
cord-254777-h8hw4m9f	26	6	response	response	NN
cord-254777-h8hw4m9f	26	7	by	by	IN
cord-254777-h8hw4m9f	26	8	suppressing	suppress	VBG
cord-254777-h8hw4m9f	26	9	early	early	JJ
cord-254777-h8hw4m9f	26	10	pro	pro	JJ
cord-254777-h8hw4m9f	26	11	-	-	JJ
cord-254777-h8hw4m9f	26	12	inflammatory	inflammatory	JJ
cord-254777-h8hw4m9f	26	13	responses	response	NNS
cord-254777-h8hw4m9f	26	14	through	through	IN
cord-254777-h8hw4m9f	26	15	type	type	NN
cord-254777-h8hw4m9f	26	16	I	-PRON-	PRP
cord-254777-h8hw4m9f	26	17	interferons	interferon	NNS
cord-254777-h8hw4m9f	26	18	(	(	-LRB-
cord-254777-h8hw4m9f	26	19	IFN	IFN	NNP
cord-254777-h8hw4m9f	26	20	)	)	-RRB-
cord-254777-h8hw4m9f	26	21	and	and	CC
cord-254777-h8hw4m9f	26	22	pro	pro	JJ
cord-254777-h8hw4m9f	26	23	-	-	JJ
cord-254777-h8hw4m9f	26	24	inflammatory	inflammatory	JJ
cord-254777-h8hw4m9f	26	25	effector	effector	NN
cord-254777-h8hw4m9f	26	26	cytokines	cytokine	NNS
cord-254777-h8hw4m9f	26	27	(	(	-LRB-
cord-254777-h8hw4m9f	26	28	IL-1	IL-1	NNP
cord-254777-h8hw4m9f	26	29	,	,	,
cord-254777-h8hw4m9f	26	30	IL-6	IL-6	NNP
cord-254777-h8hw4m9f	26	31	and	and	CC
cord-254777-h8hw4m9f	26	32	TNF	TNF	NNP
cord-254777-h8hw4m9f	26	33	-	-	HYPH
cord-254777-h8hw4m9f	26	34	α	α	NNP
cord-254777-h8hw4m9f	26	35	)	)	-RRB-
cord-254777-h8hw4m9f	26	36	.	.	.
cord-254777-h8hw4m9f	27	1	Infected	infected	JJ
cord-254777-h8hw4m9f	27	2	cells	cell	NNS
cord-254777-h8hw4m9f	27	3	undergo	undergo	VBP
cord-254777-h8hw4m9f	27	4	cell	cell	NN
cord-254777-h8hw4m9f	27	5	death	death	NN
cord-254777-h8hw4m9f	27	6	and	and	CC
cord-254777-h8hw4m9f	27	7	release	release	NN
cord-254777-h8hw4m9f	27	8	virus	virus	NN
cord-254777-h8hw4m9f	27	9	particles	particle	NNS
cord-254777-h8hw4m9f	27	10	together	together	RB
cord-254777-h8hw4m9f	27	11	with	with	IN
cord-254777-h8hw4m9f	27	12	intracellular	intracellular	JJ
cord-254777-h8hw4m9f	27	13	components	component	NNS
cord-254777-h8hw4m9f	27	14	,	,	,
cord-254777-h8hw4m9f	27	15	which	which	WDT
cord-254777-h8hw4m9f	27	16	trigger	trigger	VBP
cord-254777-h8hw4m9f	27	17	innate	innate	JJ
cord-254777-h8hw4m9f	27	18	immune	immune	JJ
cord-254777-h8hw4m9f	27	19	activation	activation	NN
cord-254777-h8hw4m9f	27	20	and	and	CC
cord-254777-h8hw4m9f	27	21	expression	expression	NN
cord-254777-h8hw4m9f	27	22	of	of	IN
cord-254777-h8hw4m9f	27	23	pro	pro	JJ
cord-254777-h8hw4m9f	27	24	-	-	JJ
cord-254777-h8hw4m9f	27	25	inflammatory	inflammatory	JJ
cord-254777-h8hw4m9f	27	26	cytokines	cytokine	NNS
cord-254777-h8hw4m9f	27	27	.	.	.
cord-254777-h8hw4m9f	28	1	Stimulated	stimulate	VBN
cord-254777-h8hw4m9f	28	2	monocytes	monocyte	NNS
cord-254777-h8hw4m9f	28	3	/	/	SYM
cord-254777-h8hw4m9f	28	4	macrophages	macrophage	NNS
cord-254777-h8hw4m9f	28	5	and	and	CC
cord-254777-h8hw4m9f	28	6	neutrophils	neutrophil	NNS
cord-254777-h8hw4m9f	28	7	exhibit	exhibit	VBP
cord-254777-h8hw4m9f	28	8	strong	strong	JJ
cord-254777-h8hw4m9f	28	9	and	and	CC
cord-254777-h8hw4m9f	28	10	poorly	poorly	RB
cord-254777-h8hw4m9f	28	11	controlled	control	VBN
cord-254777-h8hw4m9f	28	12	inflammatory	inflammatory	JJ
cord-254777-h8hw4m9f	28	13	reaction	reaction	NN
cord-254777-h8hw4m9f	28	14	,	,	,
cord-254777-h8hw4m9f	28	15	resulting	result	VBG
cord-254777-h8hw4m9f	28	16	in	in	IN
cord-254777-h8hw4m9f	28	17	tissue	tissue	NN
cord-254777-h8hw4m9f	28	18	damage	damage	NN
cord-254777-h8hw4m9f	28	19	and	and	CC
cord-254777-h8hw4m9f	28	20	systemic	systemic	JJ
cord-254777-h8hw4m9f	28	21	inflammation	inflammation	NN
cord-254777-h8hw4m9f	28	22	.	.	.
cord-254777-h8hw4m9f	29	1	This	this	DT
cord-254777-h8hw4m9f	29	2	,	,	,
cord-254777-h8hw4m9f	29	3	in	in	IN
cord-254777-h8hw4m9f	29	4	turn	turn	NN
cord-254777-h8hw4m9f	29	5	,	,	,
cord-254777-h8hw4m9f	29	6	leads	lead	VBZ
cord-254777-h8hw4m9f	29	7	to	to	IN
cord-254777-h8hw4m9f	29	8	activation	activation	NN
cord-254777-h8hw4m9f	29	9	of	of	IN
cord-254777-h8hw4m9f	29	10	the	the	DT
cord-254777-h8hw4m9f	29	11	adaptive	adaptive	JJ
cord-254777-h8hw4m9f	29	12	immune	immune	JJ
cord-254777-h8hw4m9f	29	13	system	system	NN
cord-254777-h8hw4m9f	29	14	likely	likely	RB
cord-254777-h8hw4m9f	29	15	driven	drive	VBN
cord-254777-h8hw4m9f	29	16	by	by	IN
cord-254777-h8hw4m9f	29	17	T	t	NN
cord-254777-h8hw4m9f	29	18	lymphocytes	lymphocyte	NNS
cord-254777-h8hw4m9f	29	19	[	[	-LRB-
cord-254777-h8hw4m9f	29	20	2	2	CD
cord-254777-h8hw4m9f	29	21	]	]	-RRB-
cord-254777-h8hw4m9f	29	22	.	.	.
cord-254777-h8hw4m9f	30	1	Evidence	evidence	NN
cord-254777-h8hw4m9f	30	2	of	of	IN
cord-254777-h8hw4m9f	30	3	immune	immune	JJ
cord-254777-h8hw4m9f	30	4	dysregulation	dysregulation	NN
cord-254777-h8hw4m9f	30	5	in	in	IN
cord-254777-h8hw4m9f	30	6	SARS	SARS	NNP
cord-254777-h8hw4m9f	30	7	-	-	HYPH
cord-254777-h8hw4m9f	30	8	CoV-2	CoV-2	NNP
cord-254777-h8hw4m9f	30	9	infection	infection	NN
cord-254777-h8hw4m9f	30	10	shares	share	NNS
cord-254777-h8hw4m9f	30	11	similar	similar	JJ
cord-254777-h8hw4m9f	30	12	features	feature	VBZ
cord-254777-h8hw4m9f	30	13	to	to	IN
cord-254777-h8hw4m9f	30	14	conditions	condition	NNS
cord-254777-h8hw4m9f	30	15	associated	associate	VBN
cord-254777-h8hw4m9f	30	16	with	with	IN
cord-254777-h8hw4m9f	30	17	"	"	``
cord-254777-h8hw4m9f	30	18	cytokine	cytokine	NN
cord-254777-h8hw4m9f	30	19	storm	storm	NN
cord-254777-h8hw4m9f	30	20	"	"	''
cord-254777-h8hw4m9f	30	21	.	.	.
cord-254777-h8hw4m9f	31	1	This	this	DT
cord-254777-h8hw4m9f	31	2	umbrella	umbrella	NN
cord-254777-h8hw4m9f	31	3	term	term	NN
cord-254777-h8hw4m9f	31	4	is	be	VBZ
cord-254777-h8hw4m9f	31	5	used	use	VBN
cord-254777-h8hw4m9f	31	6	to	to	TO
cord-254777-h8hw4m9f	31	7	describe	describe	VB
cord-254777-h8hw4m9f	31	8	the	the	DT
cord-254777-h8hw4m9f	31	9	immune	immune	JJ
cord-254777-h8hw4m9f	31	10	system	system	NN
cord-254777-h8hw4m9f	31	11	response	response	NN
cord-254777-h8hw4m9f	31	12	to	to	IN
cord-254777-h8hw4m9f	31	13	a	a	DT
cord-254777-h8hw4m9f	31	14	stimulus	stimulus	NN
cord-254777-h8hw4m9f	31	15	with	with	IN
cord-254777-h8hw4m9f	31	16	a	a	DT
cord-254777-h8hw4m9f	31	17	dysregulated	dysregulated	JJ
cord-254777-h8hw4m9f	31	18	and	and	CC
cord-254777-h8hw4m9f	31	19	excessive	excessive	JJ
cord-254777-h8hw4m9f	31	20	release	release	NN
cord-254777-h8hw4m9f	31	21	of	of	IN
cord-254777-h8hw4m9f	31	22	inflammatory	inflammatory	JJ
cord-254777-h8hw4m9f	31	23	molecules	molecule	NNS
cord-254777-h8hw4m9f	31	24	,	,	,
cord-254777-h8hw4m9f	31	25	resulting	result	VBG
cord-254777-h8hw4m9f	31	26	in	in	IN
cord-254777-h8hw4m9f	31	27	organ	organ	NN
cord-254777-h8hw4m9f	31	28	dysfunction	dysfunction	NN
cord-254777-h8hw4m9f	31	29	and	and	CC
cord-254777-h8hw4m9f	31	30	damage	damage	NN
cord-254777-h8hw4m9f	31	31	.	.	.
cord-254777-h8hw4m9f	32	1	Cytokine	cytokine	NN
cord-254777-h8hw4m9f	32	2	storm	storm	NN
cord-254777-h8hw4m9f	32	3	syndromes	syndrome	NNS
cord-254777-h8hw4m9f	32	4	include	include	VBP
cord-254777-h8hw4m9f	32	5	various	various	JJ
cord-254777-h8hw4m9f	32	6	entities	entity	NNS
cord-254777-h8hw4m9f	32	7	,	,	,
cord-254777-h8hw4m9f	32	8	depending	depend	VBG
cord-254777-h8hw4m9f	32	9	on	on	IN
cord-254777-h8hw4m9f	32	10	the	the	DT
cord-254777-h8hw4m9f	32	11	inciting	incite	VBG
cord-254777-h8hw4m9f	32	12	factor	factor	NN
cord-254777-h8hw4m9f	32	13	:	:	:
cord-254777-h8hw4m9f	32	14	primary	primary	JJ
cord-254777-h8hw4m9f	32	15	Hemophagocytic	Hemophagocytic	NNP
cord-254777-h8hw4m9f	32	16	Lymphohistiocytosis	Lymphohistiocytosis	NNP
cord-254777-h8hw4m9f	32	17	[	[	-LRB-
cord-254777-h8hw4m9f	32	18	HLH	HLH	NNP
cord-254777-h8hw4m9f	32	19	]	]	-RRB-
cord-254777-h8hw4m9f	32	20	in	in	IN
cord-254777-h8hw4m9f	32	21	children	child	NNS
cord-254777-h8hw4m9f	32	22	with	with	IN
cord-254777-h8hw4m9f	32	23	specific	specific	JJ
cord-254777-h8hw4m9f	32	24	genetic	genetic	JJ
cord-254777-h8hw4m9f	32	25	mutations	mutation	NNS
cord-254777-h8hw4m9f	32	26	;	;	,
cord-254777-h8hw4m9f	32	27	secondary	secondary	JJ
cord-254777-h8hw4m9f	32	28	HLH	HLH	NNP
cord-254777-h8hw4m9f	32	29	due	due	IN
cord-254777-h8hw4m9f	32	30	to	to	IN
cord-254777-h8hw4m9f	32	31	infection	infection	NN
cord-254777-h8hw4m9f	32	32	or	or	CC
cord-254777-h8hw4m9f	32	33	malignancy	malignancy	NN
cord-254777-h8hw4m9f	32	34	,	,	,
cord-254777-h8hw4m9f	32	35	macrophage	macrophage	NN
cord-254777-h8hw4m9f	32	36	activation	activation	NN
cord-254777-h8hw4m9f	32	37	syndrome	syndrome	NN
cord-254777-h8hw4m9f	32	38	due	due	JJ
cord-254777-h8hw4m9f	32	39	to	to	IN
cord-254777-h8hw4m9f	32	40	rheumatologic	rheumatologic	JJ
cord-254777-h8hw4m9f	32	41	disease	disease	NN
cord-254777-h8hw4m9f	32	42	and	and	CC
cord-254777-h8hw4m9f	32	43	cytokine	cytokine	NN
cord-254777-h8hw4m9f	32	44	release	release	NN
cord-254777-h8hw4m9f	32	45	syndrome	syndrome	NN
cord-254777-h8hw4m9f	32	46	(	(	-LRB-
cord-254777-h8hw4m9f	32	47	CRS	CRS	NNP
cord-254777-h8hw4m9f	32	48	)	)	-RRB-
cord-254777-h8hw4m9f	32	49	when	when	WRB
cord-254777-h8hw4m9f	32	50	hyperinflammation	hyperinflammation	NN
cord-254777-h8hw4m9f	32	51	is	be	VBZ
cord-254777-h8hw4m9f	32	52	due	due	JJ
cord-254777-h8hw4m9f	32	53	to	to	IN
cord-254777-h8hw4m9f	32	54	CAR	car	NN
cord-254777-h8hw4m9f	32	55	T	t	NN
cord-254777-h8hw4m9f	32	56	-	-	HYPH
cord-254777-h8hw4m9f	32	57	cell	cell	NN
cord-254777-h8hw4m9f	32	58	therapy	therapy	NN
cord-254777-h8hw4m9f	32	59	.	.	.
cord-254777-h8hw4m9f	33	1	All	all	DT
cord-254777-h8hw4m9f	33	2	of	of	IN
cord-254777-h8hw4m9f	33	3	these	these	DT
cord-254777-h8hw4m9f	33	4	conditions	condition	NNS
cord-254777-h8hw4m9f	33	5	have	have	VBP
cord-254777-h8hw4m9f	33	6	common	common	JJ
cord-254777-h8hw4m9f	33	7	clinical	clinical	JJ
cord-254777-h8hw4m9f	33	8	and	and	CC
cord-254777-h8hw4m9f	33	9	laboratory	laboratory	NN
cord-254777-h8hw4m9f	33	10	characteristics	characteristic	NNS
cord-254777-h8hw4m9f	33	11	,	,	,
cord-254777-h8hw4m9f	33	12	such	such	JJ
cord-254777-h8hw4m9f	33	13	as	as	IN
cord-254777-h8hw4m9f	33	14	fever	fever	NN
cord-254777-h8hw4m9f	33	15	,	,	,
cord-254777-h8hw4m9f	33	16	hypotension	hypotension	NN
cord-254777-h8hw4m9f	33	17	,	,	,
cord-254777-h8hw4m9f	33	18	rash	rash	JJ
cord-254777-h8hw4m9f	33	19	,	,	,
cord-254777-h8hw4m9f	33	20	liver	liver	NN
cord-254777-h8hw4m9f	33	21	dysfunction	dysfunction	NN
cord-254777-h8hw4m9f	33	22	,	,	,
cord-254777-h8hw4m9f	33	23	elevated	elevated	JJ
cord-254777-h8hw4m9f	33	24	ferritin	ferritin	NN
cord-254777-h8hw4m9f	33	25	,	,	,
cord-254777-h8hw4m9f	33	26	cytopenias	cytopenia	NNS
cord-254777-h8hw4m9f	33	27	,	,	,
cord-254777-h8hw4m9f	33	28	low	low	JJ
cord-254777-h8hw4m9f	33	29	fibrinogen	fibrinogen	NN
cord-254777-h8hw4m9f	33	30	,	,	,
cord-254777-h8hw4m9f	33	31	high	high	JJ
cord-254777-h8hw4m9f	33	32	markers	marker	NNS
cord-254777-h8hw4m9f	33	33	of	of	IN
cord-254777-h8hw4m9f	33	34	inflammation	inflammation	NN
cord-254777-h8hw4m9f	33	35	and	and	CC
cord-254777-h8hw4m9f	33	36	elevated	elevated	JJ
cord-254777-h8hw4m9f	33	37	pro	pro	JJ
cord-254777-h8hw4m9f	33	38	-	-	JJ
cord-254777-h8hw4m9f	33	39	inflammatory	inflammatory	JJ
cord-254777-h8hw4m9f	33	40	cytokines	cytokine	NNS
cord-254777-h8hw4m9f	33	41	(	(	-LRB-
cord-254777-h8hw4m9f	33	42	particularly	particularly	RB
cord-254777-h8hw4m9f	33	43	IL-6	IL-6	NNP
cord-254777-h8hw4m9f	33	44	and	and	CC
cord-254777-h8hw4m9f	33	45	IL-18	IL-18	NNP
cord-254777-h8hw4m9f	33	46	)	)	-RRB-
cord-254777-h8hw4m9f	33	47	.	.	.
cord-254777-h8hw4m9f	34	1	Features	feature	NNS
cord-254777-h8hw4m9f	34	2	of	of	IN
cord-254777-h8hw4m9f	34	3	cytokine	cytokine	NN
cord-254777-h8hw4m9f	34	4	storm	storm	NN
cord-254777-h8hw4m9f	34	5	in	in	IN
cord-254777-h8hw4m9f	34	6	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	34	7	are	be	VBP
cord-254777-h8hw4m9f	34	8	usually	usually	RB
cord-254777-h8hw4m9f	34	9	evident	evident	JJ
cord-254777-h8hw4m9f	34	10	in	in	IN
cord-254777-h8hw4m9f	34	11	the	the	DT
cord-254777-h8hw4m9f	34	12	second	second	JJ
cord-254777-h8hw4m9f	34	13	week	week	NN
cord-254777-h8hw4m9f	34	14	of	of	IN
cord-254777-h8hw4m9f	34	15	illness	illness	NN
cord-254777-h8hw4m9f	34	16	.	.	.
cord-254777-h8hw4m9f	35	1	While	while	IN
cord-254777-h8hw4m9f	35	2	there	there	EX
cord-254777-h8hw4m9f	35	3	are	be	VBP
cord-254777-h8hw4m9f	35	4	common	common	JJ
cord-254777-h8hw4m9f	35	5	findings	finding	NNS
cord-254777-h8hw4m9f	35	6	between	between	IN
cord-254777-h8hw4m9f	35	7	SARS	SARS	NNP
cord-254777-h8hw4m9f	35	8	-	-	HYPH
cord-254777-h8hw4m9f	35	9	CoV-2	CoV-2	NNP
cord-254777-h8hw4m9f	35	10	cytokine	cytokine	NN
cord-254777-h8hw4m9f	35	11	storm	storm	NN
cord-254777-h8hw4m9f	35	12	and	and	CC
cord-254777-h8hw4m9f	35	13	viral	viral	JJ
cord-254777-h8hw4m9f	35	14	induced	induce	VBN
cord-254777-h8hw4m9f	35	15	sHLH	shlh	JJ
cord-254777-h8hw4m9f	35	16	,	,	,
cord-254777-h8hw4m9f	35	17	there	there	EX
cord-254777-h8hw4m9f	35	18	are	be	VBP
cord-254777-h8hw4m9f	35	19	also	also	RB
cord-254777-h8hw4m9f	35	20	a	a	DT
cord-254777-h8hw4m9f	35	21	few	few	JJ
cord-254777-h8hw4m9f	35	22	striking	striking	JJ
cord-254777-h8hw4m9f	35	23	differences	difference	NNS
cord-254777-h8hw4m9f	35	24	.	.	.
cord-254777-h8hw4m9f	36	1	One	one	CD
cord-254777-h8hw4m9f	36	2	of	of	IN
cord-254777-h8hw4m9f	36	3	the	the	DT
cord-254777-h8hw4m9f	36	4	most	most	RBS
cord-254777-h8hw4m9f	36	5	important	important	JJ
cord-254777-h8hw4m9f	36	6	differences	difference	NNS
cord-254777-h8hw4m9f	36	7	is	be	VBZ
cord-254777-h8hw4m9f	36	8	that	that	IN
cord-254777-h8hw4m9f	36	9	ferritin	ferritin	NN
cord-254777-h8hw4m9f	36	10	is	be	VBZ
cord-254777-h8hw4m9f	36	11	only	only	RB
cord-254777-h8hw4m9f	36	12	modestly	modestly	RB
cord-254777-h8hw4m9f	36	13	elevated	elevate	VBN
cord-254777-h8hw4m9f	36	14	in	in	IN
cord-254777-h8hw4m9f	36	15	SARS	SARS	NNP
cord-254777-h8hw4m9f	36	16	-	-	HYPH
cord-254777-h8hw4m9f	36	17	CoV-2	CoV-2	NNP
cord-254777-h8hw4m9f	36	18	inflammatory	inflammatory	JJ
cord-254777-h8hw4m9f	36	19	state	state	NN
cord-254777-h8hw4m9f	36	20	,	,	,
cord-254777-h8hw4m9f	36	21	whereas	whereas	IN
cord-254777-h8hw4m9f	36	22	significant	significant	JJ
cord-254777-h8hw4m9f	36	23	hyperferritinemia	hyperferritinemia	NN
cord-254777-h8hw4m9f	36	24	is	be	VBZ
cord-254777-h8hw4m9f	36	25	a	a	DT
cord-254777-h8hw4m9f	36	26	defining	define	VBG
cord-254777-h8hw4m9f	36	27	feature	feature	NN
cord-254777-h8hw4m9f	36	28	in	in	IN
cord-254777-h8hw4m9f	36	29	sHLH	sHLH	NNP
cord-254777-h8hw4m9f	36	30	.	.	.
cord-254777-h8hw4m9f	37	1	In	in	IN
cord-254777-h8hw4m9f	37	2	addition	addition	NN
cord-254777-h8hw4m9f	37	3	,	,	,
cord-254777-h8hw4m9f	37	4	the	the	DT
cord-254777-h8hw4m9f	37	5	predilection	predilection	NN
cord-254777-h8hw4m9f	37	6	for	for	IN
cord-254777-h8hw4m9f	37	7	severe	severe	JJ
cord-254777-h8hw4m9f	37	8	respiratory	respiratory	JJ
cord-254777-h8hw4m9f	37	9	involvement	involvement	NN
cord-254777-h8hw4m9f	37	10	is	be	VBZ
cord-254777-h8hw4m9f	37	11	more	more	RBR
cord-254777-h8hw4m9f	37	12	predominant	predominant	JJ
cord-254777-h8hw4m9f	37	13	in	in	IN
cord-254777-h8hw4m9f	37	14	cytokine	cytokine	NN
cord-254777-h8hw4m9f	37	15	storm	storm	NN
cord-254777-h8hw4m9f	37	16	secondary	secondary	JJ
cord-254777-h8hw4m9f	37	17	to	to	IN
cord-254777-h8hw4m9f	37	18	SARS	SARS	NNP
cord-254777-h8hw4m9f	37	19	-	-	HYPH
cord-254777-h8hw4m9f	37	20	CoV-2	CoV-2	NNP
cord-254777-h8hw4m9f	37	21	[	[	-LRB-
cord-254777-h8hw4m9f	37	22	3	3	CD
cord-254777-h8hw4m9f	37	23	]	]	-RRB-
cord-254777-h8hw4m9f	37	24	.	.	.
cord-254777-h8hw4m9f	38	1	Furthermore	furthermore	RB
cord-254777-h8hw4m9f	38	2	,	,	,
cord-254777-h8hw4m9f	38	3	fibrinogen	fibrinogen	NN
cord-254777-h8hw4m9f	38	4	(	(	-LRB-
cord-254777-h8hw4m9f	38	5	often	often	RB
cord-254777-h8hw4m9f	38	6	low	low	JJ
cord-254777-h8hw4m9f	38	7	in	in	IN
cord-254777-h8hw4m9f	38	8	sHLH	sHLH	NNP
cord-254777-h8hw4m9f	38	9	)	)	-RRB-
cord-254777-h8hw4m9f	38	10	is	be	VBZ
cord-254777-h8hw4m9f	38	11	consistently	consistently	RB
cord-254777-h8hw4m9f	38	12	elevated	elevate	VBN
cord-254777-h8hw4m9f	38	13	in	in	IN
cord-254777-h8hw4m9f	38	14	severe	severe	JJ
cord-254777-h8hw4m9f	38	15	SARS	SARS	NNP
cord-254777-h8hw4m9f	38	16	-	-	HYPH
cord-254777-h8hw4m9f	38	17	CoV-2	CoV-2	NNP
cord-254777-h8hw4m9f	38	18	infection	infection	NN
cord-254777-h8hw4m9f	38	19	and	and	CC
cord-254777-h8hw4m9f	38	20	in	in	IN
cord-254777-h8hw4m9f	38	21	contrast	contrast	NN
cord-254777-h8hw4m9f	38	22	to	to	IN
cord-254777-h8hw4m9f	38	23	the	the	DT
cord-254777-h8hw4m9f	38	24	leukopenia	leukopenia	NN
cord-254777-h8hw4m9f	38	25	seen	see	VBN
cord-254777-h8hw4m9f	38	26	in	in	IN
cord-254777-h8hw4m9f	39	1	sHLH	shlh	JJ
cord-254777-h8hw4m9f	39	2	,	,	,
cord-254777-h8hw4m9f	39	3	severe	severe	JJ
cord-254777-h8hw4m9f	39	4	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	39	5	infection	infection	NN
cord-254777-h8hw4m9f	39	6	is	be	VBZ
cord-254777-h8hw4m9f	39	7	associated	associate	VBN
cord-254777-h8hw4m9f	39	8	with	with	IN
cord-254777-h8hw4m9f	39	9	leukocytosis	leukocytosis	NN
cord-254777-h8hw4m9f	39	10	[	[	-LRB-
cord-254777-h8hw4m9f	39	11	4	4	CD
cord-254777-h8hw4m9f	39	12	]	]	-RRB-
cord-254777-h8hw4m9f	39	13	.	.	.
cord-254777-h8hw4m9f	40	1	Other	other	JJ
cord-254777-h8hw4m9f	40	2	features	feature	NNS
cord-254777-h8hw4m9f	40	3	of	of	IN
cord-254777-h8hw4m9f	40	4	sHLH	shlh	JJ
cord-254777-h8hw4m9f	40	5	such	such	JJ
cord-254777-h8hw4m9f	40	6	as	as	IN
cord-254777-h8hw4m9f	40	7	hypertriglyceridemia	hypertriglyceridemia	NN
cord-254777-h8hw4m9f	40	8	,	,	,
cord-254777-h8hw4m9f	40	9	splenomegaly	splenomegaly	NN
cord-254777-h8hw4m9f	40	10	,	,	,
cord-254777-h8hw4m9f	40	11	hepatomegaly	hepatomegaly	NNP
cord-254777-h8hw4m9f	40	12	,	,	,
cord-254777-h8hw4m9f	40	13	bone	bone	NN
cord-254777-h8hw4m9f	40	14	marrow	marrow	NN
cord-254777-h8hw4m9f	40	15	hemophagocytosis	hemophagocytosis	NN
cord-254777-h8hw4m9f	40	16	have	have	VBP
cord-254777-h8hw4m9f	40	17	yet	yet	RB
cord-254777-h8hw4m9f	40	18	to	to	TO
cord-254777-h8hw4m9f	40	19	be	be	VB
cord-254777-h8hw4m9f	40	20	described	describe	VBN
cord-254777-h8hw4m9f	40	21	in	in	IN
cord-254777-h8hw4m9f	40	22	cohort	cohort	NN
cord-254777-h8hw4m9f	40	23	studies	study	NNS
cord-254777-h8hw4m9f	40	24	of	of	IN
cord-254777-h8hw4m9f	40	25	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	40	26	.	.	.
cord-254777-h8hw4m9f	41	1	Another	another	DT
cord-254777-h8hw4m9f	41	2	proposed	propose	VBN
cord-254777-h8hw4m9f	41	3	mechanism	mechanism	NN
cord-254777-h8hw4m9f	41	4	for	for	IN
cord-254777-h8hw4m9f	41	5	hyperinflammation	hyperinflammation	NN
cord-254777-h8hw4m9f	41	6	secondary	secondary	JJ
cord-254777-h8hw4m9f	41	7	to	to	IN
cord-254777-h8hw4m9f	41	8	SARS	SARS	NNP
cord-254777-h8hw4m9f	41	9	-	-	HYPH
cord-254777-h8hw4m9f	41	10	CoV-2	CoV-2	NNP
cord-254777-h8hw4m9f	41	11	infection	infection	NN
cord-254777-h8hw4m9f	41	12	includes	include	VBZ
cord-254777-h8hw4m9f	41	13	the	the	DT
cord-254777-h8hw4m9f	41	14	concept	concept	NN
cord-254777-h8hw4m9f	41	15	of	of	IN
cord-254777-h8hw4m9f	41	16	antibody	antibody	NN
cord-254777-h8hw4m9f	41	17	-	-	HYPH
cord-254777-h8hw4m9f	41	18	dependent	dependent	JJ
cord-254777-h8hw4m9f	41	19	enhancement	enhancement	NN
cord-254777-h8hw4m9f	41	20	(	(	-LRB-
cord-254777-h8hw4m9f	41	21	ADE	ADE	NNP
cord-254777-h8hw4m9f	41	22	)	)	-RRB-
cord-254777-h8hw4m9f	41	23	.	.	.
cord-254777-h8hw4m9f	42	1	ADE	ADE	NNP
cord-254777-h8hw4m9f	42	2	is	be	VBZ
cord-254777-h8hw4m9f	42	3	a	a	DT
cord-254777-h8hw4m9f	42	4	phenomenon	phenomenon	NN
cord-254777-h8hw4m9f	42	5	occurring	occur	VBG
cord-254777-h8hw4m9f	42	6	in	in	IN
cord-254777-h8hw4m9f	42	7	viral	viral	JJ
cord-254777-h8hw4m9f	42	8	infections	infection	NNS
cord-254777-h8hw4m9f	42	9	,	,	,
cord-254777-h8hw4m9f	42	10	in	in	IN
cord-254777-h8hw4m9f	42	11	which	which	WDT
cord-254777-h8hw4m9f	42	12	early	early	RB
cord-254777-h8hw4m9f	42	13	neutralizing	neutralize	VBG
cord-254777-h8hw4m9f	42	14	antibodies	antibody	NNS
cord-254777-h8hw4m9f	42	15	promote	promote	VBP
cord-254777-h8hw4m9f	42	16	cellular	cellular	JJ
cord-254777-h8hw4m9f	42	17	uptake	uptake	NN
cord-254777-h8hw4m9f	42	18	of	of	IN
cord-254777-h8hw4m9f	42	19	virus	virus	NN
cord-254777-h8hw4m9f	42	20	particles	particle	NNS
cord-254777-h8hw4m9f	42	21	bound	bind	VBN
cord-254777-h8hw4m9f	42	22	in	in	IN
cord-254777-h8hw4m9f	42	23	immune	immune	JJ
cord-254777-h8hw4m9f	42	24	complexes	complex	NNS
cord-254777-h8hw4m9f	42	25	,	,	,
cord-254777-h8hw4m9f	42	26	through	through	IN
cord-254777-h8hw4m9f	42	27	their	-PRON-	PRP$
cord-254777-h8hw4m9f	42	28	binding	binding	NN
cord-254777-h8hw4m9f	42	29	to	to	IN
cord-254777-h8hw4m9f	42	30	Fcγ	Fcγ	NNP
cord-254777-h8hw4m9f	42	31	receptors	receptor	NNS
cord-254777-h8hw4m9f	42	32	.	.	.
cord-254777-h8hw4m9f	43	1	This	this	DT
cord-254777-h8hw4m9f	43	2	process	process	NN
cord-254777-h8hw4m9f	43	3	contributes	contribute	VBZ
cord-254777-h8hw4m9f	43	4	to	to	IN
cord-254777-h8hw4m9f	43	5	persistent	persistent	JJ
cord-254777-h8hw4m9f	43	6	viral	viral	JJ
cord-254777-h8hw4m9f	43	7	replication	replication	NN
cord-254777-h8hw4m9f	43	8	in	in	IN
cord-254777-h8hw4m9f	43	9	immune	immune	JJ
cord-254777-h8hw4m9f	43	10	cells	cell	NNS
cord-254777-h8hw4m9f	43	11	,	,	,
cord-254777-h8hw4m9f	43	12	as	as	RB
cord-254777-h8hw4m9f	43	13	well	well	RB
cord-254777-h8hw4m9f	43	14	as	as	IN
cord-254777-h8hw4m9f	43	15	immune	immune	JJ
cord-254777-h8hw4m9f	43	16	complex	complex	NN
cord-254777-h8hw4m9f	43	17	mediated	mediate	VBN
cord-254777-h8hw4m9f	43	18	inflammatory	inflammatory	JJ
cord-254777-h8hw4m9f	43	19	response	response	NN
cord-254777-h8hw4m9f	43	20	,	,	,
cord-254777-h8hw4m9f	43	21	leading	lead	VBG
cord-254777-h8hw4m9f	43	22	to	to	IN
cord-254777-h8hw4m9f	43	23	end	end	VB
cord-254777-h8hw4m9f	43	24	organ	organ	NN
cord-254777-h8hw4m9f	43	25	damage	damage	NN
cord-254777-h8hw4m9f	43	26	such	such	JJ
cord-254777-h8hw4m9f	43	27	as	as	IN
cord-254777-h8hw4m9f	43	28	ARDS	ARDS	NNP
cord-254777-h8hw4m9f	43	29	[	[	-LRB-
cord-254777-h8hw4m9f	43	30	2	2	CD
cord-254777-h8hw4m9f	43	31	]	]	-RRB-
cord-254777-h8hw4m9f	43	32	.	.	.
cord-254777-h8hw4m9f	44	1	ADE	ADE	NNP
cord-254777-h8hw4m9f	44	2	has	have	VBZ
cord-254777-h8hw4m9f	44	3	been	be	VBN
cord-254777-h8hw4m9f	44	4	classically	classically	RB
cord-254777-h8hw4m9f	44	5	described	describe	VBN
cord-254777-h8hw4m9f	44	6	in	in	IN
cord-254777-h8hw4m9f	44	7	infection	infection	NN
cord-254777-h8hw4m9f	44	8	with	with	IN
cord-254777-h8hw4m9f	44	9	Dengue	Dengue	NNP
cord-254777-h8hw4m9f	44	10	virus	virus	NN
cord-254777-h8hw4m9f	44	11	,	,	,
cord-254777-h8hw4m9f	44	12	in	in	IN
cord-254777-h8hw4m9f	44	13	which	which	WDT
cord-254777-h8hw4m9f	44	14	patients	patient	NNS
cord-254777-h8hw4m9f	44	15	re	re	NN
cord-254777-h8hw4m9f	44	16	-	-	VBN
cord-254777-h8hw4m9f	44	17	infected	infect	VBN
cord-254777-h8hw4m9f	44	18	with	with	IN
cord-254777-h8hw4m9f	44	19	a	a	DT
cord-254777-h8hw4m9f	44	20	different	different	JJ
cord-254777-h8hw4m9f	44	21	serotype	serotype	NN
cord-254777-h8hw4m9f	44	22	of	of	IN
cord-254777-h8hw4m9f	44	23	the	the	DT
cord-254777-h8hw4m9f	44	24	virus	virus	NN
cord-254777-h8hw4m9f	44	25	run	run	VBP
cord-254777-h8hw4m9f	44	26	a	a	DT
cord-254777-h8hw4m9f	44	27	more	more	RBR
cord-254777-h8hw4m9f	44	28	severe	severe	JJ
cord-254777-h8hw4m9f	44	29	course	course	NN
cord-254777-h8hw4m9f	44	30	of	of	IN
cord-254777-h8hw4m9f	44	31	infection	infection	NN
cord-254777-h8hw4m9f	44	32	[	[	-LRB-
cord-254777-h8hw4m9f	44	33	5	5	CD
cord-254777-h8hw4m9f	44	34	]	]	-RRB-
cord-254777-h8hw4m9f	44	35	.	.	.
cord-254777-h8hw4m9f	45	1	In	in	IN
cord-254777-h8hw4m9f	45	2	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	45	3	,	,	,
cord-254777-h8hw4m9f	45	4	it	-PRON-	PRP
cord-254777-h8hw4m9f	45	5	has	have	VBZ
cord-254777-h8hw4m9f	45	6	been	be	VBN
cord-254777-h8hw4m9f	45	7	hypothesized	hypothesize	VBN
cord-254777-h8hw4m9f	45	8	that	that	IN
cord-254777-h8hw4m9f	45	9	ADE	ADE	NNP
cord-254777-h8hw4m9f	45	10	might	may	MD
cord-254777-h8hw4m9f	45	11	play	play	VB
cord-254777-h8hw4m9f	45	12	a	a	DT
cord-254777-h8hw4m9f	45	13	role	role	NN
cord-254777-h8hw4m9f	45	14	in	in	IN
cord-254777-h8hw4m9f	45	15	severe	severe	JJ
cord-254777-h8hw4m9f	45	16	infection	infection	NN
cord-254777-h8hw4m9f	45	17	in	in	IN
cord-254777-h8hw4m9f	45	18	patients	patient	NNS
cord-254777-h8hw4m9f	45	19	previously	previously	RB
cord-254777-h8hw4m9f	45	20	infected	infect	VBN
cord-254777-h8hw4m9f	45	21	with	with	IN
cord-254777-h8hw4m9f	45	22	other	other	JJ
cord-254777-h8hw4m9f	45	23	coronaviruses	coronaviruse	NNS
cord-254777-h8hw4m9f	45	24	,	,	,
cord-254777-h8hw4m9f	45	25	including	include	VBG
cord-254777-h8hw4m9f	45	26	agents	agent	NNS
cord-254777-h8hw4m9f	45	27	of	of	IN
cord-254777-h8hw4m9f	45	28	the	the	DT
cord-254777-h8hw4m9f	45	29	common	common	JJ
cord-254777-h8hw4m9f	45	30	cold	cold	NN
cord-254777-h8hw4m9f	45	31	and	and	CC
cord-254777-h8hw4m9f	45	32	SARS	SARS	NNP
cord-254777-h8hw4m9f	45	33	-	-	HYPH
cord-254777-h8hw4m9f	45	34	CoV	CoV	NNP
cord-254777-h8hw4m9f	45	35	[	[	-LRB-
cord-254777-h8hw4m9f	45	36	5	5	CD
cord-254777-h8hw4m9f	45	37	]	]	-RRB-
cord-254777-h8hw4m9f	45	38	.	.	.
cord-254777-h8hw4m9f	46	1	The	the	DT
cord-254777-h8hw4m9f	46	2	concept	concept	NN
cord-254777-h8hw4m9f	46	3	of	of	IN
cord-254777-h8hw4m9f	46	4	ADE	ADE	NNP
cord-254777-h8hw4m9f	46	5	has	have	VBZ
cord-254777-h8hw4m9f	46	6	been	be	VBN
cord-254777-h8hw4m9f	46	7	proposed	propose	VBN
cord-254777-h8hw4m9f	46	8	as	as	IN
cord-254777-h8hw4m9f	46	9	the	the	DT
cord-254777-h8hw4m9f	46	10	potential	potential	JJ
cord-254777-h8hw4m9f	46	11	etiology	etiology	NN
cord-254777-h8hw4m9f	46	12	for	for	IN
cord-254777-h8hw4m9f	46	13	clinical	clinical	JJ
cord-254777-h8hw4m9f	46	14	manifestations	manifestation	NNS
cord-254777-h8hw4m9f	46	15	reported	report	VBN
cord-254777-h8hw4m9f	46	16	in	in	IN
cord-254777-h8hw4m9f	46	17	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	46	18	including	include	VBG
cord-254777-h8hw4m9f	46	19	immune	immune	JJ
cord-254777-h8hw4m9f	46	20	complex	complex	JJ
cord-254777-h8hw4m9f	46	21	mediated	mediate	VBN
cord-254777-h8hw4m9f	46	22	vasculitis	vasculitis	NN
cord-254777-h8hw4m9f	46	23	,	,	,
cord-254777-h8hw4m9f	46	24	manifesting	manifest	VBG
cord-254777-h8hw4m9f	46	25	as	as	IN
cord-254777-h8hw4m9f	46	26	vasculitic	vasculitic	JJ
cord-254777-h8hw4m9f	46	27	skin	skin	NN
cord-254777-h8hw4m9f	46	28	lesions	lesion	NNS
cord-254777-h8hw4m9f	46	29	,	,	,
cord-254777-h8hw4m9f	46	30	small	small	JJ
cord-254777-h8hw4m9f	46	31	vessel	vessel	NN
cord-254777-h8hw4m9f	46	32	microthrombi	microthrombi	NN
cord-254777-h8hw4m9f	46	33	and	and	CC
cord-254777-h8hw4m9f	46	34	infarctions	infarction	NNS
cord-254777-h8hw4m9f	46	35	.	.	.
cord-254777-h8hw4m9f	47	1	Histopathologic	Histopathologic	NNP
cord-254777-h8hw4m9f	47	2	features	feature	NNS
cord-254777-h8hw4m9f	47	3	are	be	VBP
cord-254777-h8hw4m9f	47	4	consistent	consistent	JJ
cord-254777-h8hw4m9f	47	5	with	with	IN
cord-254777-h8hw4m9f	47	6	immune	immune	JJ
cord-254777-h8hw4m9f	47	7	complex	complex	NN
cord-254777-h8hw4m9f	47	8	mediated	mediate	VBN
cord-254777-h8hw4m9f	47	9	vasculitis	vasculitis	NN
cord-254777-h8hw4m9f	47	10	,	,	,
cord-254777-h8hw4m9f	47	11	with	with	IN
cord-254777-h8hw4m9f	47	12	the	the	DT
cord-254777-h8hw4m9f	47	13	infiltration	infiltration	NN
cord-254777-h8hw4m9f	47	14	of	of	IN
cord-254777-h8hw4m9f	47	15	monocytes	monocyte	NNS
cord-254777-h8hw4m9f	47	16	and	and	CC
cord-254777-h8hw4m9f	47	17	lymphocytes	lymphocyte	NNS
cord-254777-h8hw4m9f	47	18	in	in	IN
cord-254777-h8hw4m9f	47	19	and	and	CC
cord-254777-h8hw4m9f	47	20	around	around	IN
cord-254777-h8hw4m9f	47	21	blood	blood	NN
cord-254777-h8hw4m9f	47	22	vessels	vessel	NNS
cord-254777-h8hw4m9f	47	23	,	,	,
cord-254777-h8hw4m9f	47	24	wall	wall	NN
cord-254777-h8hw4m9f	47	25	thickening	thickening	NN
cord-254777-h8hw4m9f	47	26	,	,	,
cord-254777-h8hw4m9f	47	27	and	and	CC
cord-254777-h8hw4m9f	47	28	focal	focal	JJ
cord-254777-h8hw4m9f	47	29	hemorrhage	hemorrhage	NN
cord-254777-h8hw4m9f	47	30	[	[	-LRB-
cord-254777-h8hw4m9f	47	31	2	2	CD
cord-254777-h8hw4m9f	47	32	]	]	-RRB-
cord-254777-h8hw4m9f	47	33	.	.	.
cord-254777-h8hw4m9f	48	1	The	the	DT
cord-254777-h8hw4m9f	48	2	presence	presence	NN
cord-254777-h8hw4m9f	48	3	of	of	IN
cord-254777-h8hw4m9f	48	4	acral	acral	NNP
cord-254777-h8hw4m9f	48	5	perniosis	perniosis	NNP
cord-254777-h8hw4m9f	48	6	,	,	,
cord-254777-h8hw4m9f	48	7	or	or	CC
cord-254777-h8hw4m9f	48	8	chilblains	chilblain	NNS
cord-254777-h8hw4m9f	48	9	,	,	,
cord-254777-h8hw4m9f	48	10	in	in	IN
cord-254777-h8hw4m9f	48	11	both	both	DT
cord-254777-h8hw4m9f	48	12	adult	adult	NN
cord-254777-h8hw4m9f	48	13	and	and	CC
cord-254777-h8hw4m9f	48	14	pediatric	pediatric	JJ
cord-254777-h8hw4m9f	48	15	patients	patient	NNS
cord-254777-h8hw4m9f	48	16	with	with	IN
cord-254777-h8hw4m9f	48	17	SARS	SARS	NNP
cord-254777-h8hw4m9f	48	18	-	-	HYPH
cord-254777-h8hw4m9f	48	19	CoV-2	CoV-2	NNP
cord-254777-h8hw4m9f	48	20	infection	infection	NN
cord-254777-h8hw4m9f	48	21	seems	seem	VBZ
cord-254777-h8hw4m9f	48	22	to	to	TO
cord-254777-h8hw4m9f	48	23	be	be	VB
cord-254777-h8hw4m9f	48	24	additional	additional	JJ
cord-254777-h8hw4m9f	48	25	evidence	evidence	NN
cord-254777-h8hw4m9f	48	26	for	for	IN
cord-254777-h8hw4m9f	48	27	inflammatory	inflammatory	JJ
cord-254777-h8hw4m9f	48	28	vasculitis	vasculitis	NN
cord-254777-h8hw4m9f	48	29	[	[	-LRB-
cord-254777-h8hw4m9f	48	30	6	6	CD
cord-254777-h8hw4m9f	48	31	]	]	-RRB-
cord-254777-h8hw4m9f	48	32	.	.	.
cord-254777-h8hw4m9f	49	1	Although	although	IN
cord-254777-h8hw4m9f	49	2	still	still	RB
cord-254777-h8hw4m9f	49	3	under	under	IN
cord-254777-h8hw4m9f	49	4	investigation	investigation	NN
cord-254777-h8hw4m9f	49	5	,	,	,
cord-254777-h8hw4m9f	49	6	ADE	ADE	NNP
cord-254777-h8hw4m9f	49	7	has	have	VBZ
cord-254777-h8hw4m9f	49	8	been	be	VBN
cord-254777-h8hw4m9f	49	9	proposed	propose	VBN
cord-254777-h8hw4m9f	49	10	as	as	IN
cord-254777-h8hw4m9f	49	11	a	a	DT
cord-254777-h8hw4m9f	49	12	potential	potential	JJ
cord-254777-h8hw4m9f	49	13	mechanism	mechanism	NN
cord-254777-h8hw4m9f	49	14	underlying	underlie	VBG
cord-254777-h8hw4m9f	49	15	the	the	DT
cord-254777-h8hw4m9f	49	16	newly	newly	RB
cord-254777-h8hw4m9f	49	17	described	describe	VBN
cord-254777-h8hw4m9f	49	18	MIS	MIS	NNP
cord-254777-h8hw4m9f	49	19	-	-	HYPH
cord-254777-h8hw4m9f	49	20	C	C	NNP
cord-254777-h8hw4m9f	49	21	,	,	,
cord-254777-h8hw4m9f	49	22	based	base	VBN
cord-254777-h8hw4m9f	49	23	on	on	IN
cord-254777-h8hw4m9f	49	24	the	the	DT
cord-254777-h8hw4m9f	49	25	observation	observation	NN
cord-254777-h8hw4m9f	49	26	that	that	IN
cord-254777-h8hw4m9f	49	27	a	a	DT
cord-254777-h8hw4m9f	49	28	majority	majority	NN
cord-254777-h8hw4m9f	49	29	of	of	IN
cord-254777-h8hw4m9f	49	30	the	the	DT
cord-254777-h8hw4m9f	49	31	patients	patient	NNS
cord-254777-h8hw4m9f	49	32	have	have	VBP
cord-254777-h8hw4m9f	49	33	evidence	evidence	NN
cord-254777-h8hw4m9f	49	34	of	of	IN
cord-254777-h8hw4m9f	49	35	existing	exist	VBG
cord-254777-h8hw4m9f	49	36	antibodies	antibody	NNS
cord-254777-h8hw4m9f	49	37	to	to	IN
cord-254777-h8hw4m9f	49	38	SARS	SARS	NNP
cord-254777-h8hw4m9f	49	39	-	-	HYPH
cord-254777-h8hw4m9f	49	40	CoV-2	CoV-2	NNP
cord-254777-h8hw4m9f	49	41	and	and	CC
cord-254777-h8hw4m9f	49	42	the	the	DT
cord-254777-h8hw4m9f	49	43	inflammatory	inflammatory	JJ
cord-254777-h8hw4m9f	49	44	condition	condition	NN
cord-254777-h8hw4m9f	49	45	seems	seem	VBZ
cord-254777-h8hw4m9f	49	46	to	to	TO
cord-254777-h8hw4m9f	49	47	lag	lag	VB
cord-254777-h8hw4m9f	49	48	behind	behind	IN
cord-254777-h8hw4m9f	49	49	the	the	DT
cord-254777-h8hw4m9f	49	50	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	49	51	infection	infection	NN
cord-254777-h8hw4m9f	49	52	peak	peak	NN
cord-254777-h8hw4m9f	49	53	by	by	IN
cord-254777-h8hw4m9f	49	54	approximately	approximately	RB
cord-254777-h8hw4m9f	49	55	4	4	CD
cord-254777-h8hw4m9f	49	56	-	-	SYM
cord-254777-h8hw4m9f	49	57	6	6	CD
cord-254777-h8hw4m9f	49	58	weeks	week	NNS
cord-254777-h8hw4m9f	49	59	.	.	.
cord-254777-h8hw4m9f	50	1	Clinical	clinical	JJ
cord-254777-h8hw4m9f	50	2	features	feature	NNS
cord-254777-h8hw4m9f	50	3	of	of	IN
cord-254777-h8hw4m9f	50	4	infection	infection	NN
cord-254777-h8hw4m9f	50	5	with	with	IN
cord-254777-h8hw4m9f	50	6	SARS	SARS	NNP
cord-254777-h8hw4m9f	50	7	-	-	HYPH
cord-254777-h8hw4m9f	50	8	CoV-2	CoV-2	NNP
cord-254777-h8hw4m9f	50	9	vary	vary	VBP
cord-254777-h8hw4m9f	50	10	wildly	wildly	RB
cord-254777-h8hw4m9f	50	11	.	.	.
cord-254777-h8hw4m9f	51	1	In	in	IN
cord-254777-h8hw4m9f	51	2	a	a	DT
cord-254777-h8hw4m9f	51	3	report	report	NN
cord-254777-h8hw4m9f	51	4	of	of	IN
cord-254777-h8hw4m9f	51	5	the	the	DT
cord-254777-h8hw4m9f	51	6	largest	large	JJS
cord-254777-h8hw4m9f	51	7	case	case	NN
cord-254777-h8hw4m9f	51	8	series	series	NN
cord-254777-h8hw4m9f	51	9	to	to	IN
cord-254777-h8hw4m9f	51	10	date	date	NN
cord-254777-h8hw4m9f	51	11	of	of	IN
cord-254777-h8hw4m9f	51	12	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	51	13	in	in	IN
cord-254777-h8hw4m9f	51	14	Mainland	Mainland	NNP
cord-254777-h8hw4m9f	51	15	China	China	NNP
cord-254777-h8hw4m9f	51	16	reported	report	VBN
cord-254777-h8hw4m9f	51	17	by	by	IN
cord-254777-h8hw4m9f	51	18	the	the	DT
cord-254777-h8hw4m9f	51	19	Chinese	Chinese	NNP
cord-254777-h8hw4m9f	51	20	Center	Center	NNP
cord-254777-h8hw4m9f	51	21	for	for	IN
cord-254777-h8hw4m9f	51	22	Disease	Disease	NNP
cord-254777-h8hw4m9f	51	23	Control	Control	NNP
cord-254777-h8hw4m9f	51	24	,	,	,
cord-254777-h8hw4m9f	51	25	81	81	CD
cord-254777-h8hw4m9f	51	26	%	%	NN
cord-254777-h8hw4m9f	51	27	of	of	IN
cord-254777-h8hw4m9f	51	28	patients	patient	NNS
cord-254777-h8hw4m9f	51	29	had	have	VBD
cord-254777-h8hw4m9f	51	30	mild	mild	JJ
cord-254777-h8hw4m9f	51	31	disease	disease	NN
cord-254777-h8hw4m9f	51	32	,	,	,
cord-254777-h8hw4m9f	51	33	14	14	CD
cord-254777-h8hw4m9f	51	34	%	%	NN
cord-254777-h8hw4m9f	51	35	severe	severe	JJ
cord-254777-h8hw4m9f	51	36	and	and	CC
cord-254777-h8hw4m9f	51	37	5	5	CD
cord-254777-h8hw4m9f	51	38	%	%	NN
cord-254777-h8hw4m9f	51	39	critical	critical	JJ
cord-254777-h8hw4m9f	51	40	[	[	-LRB-
cord-254777-h8hw4m9f	51	41	7	7	CD
cord-254777-h8hw4m9f	51	42	]	]	-RRB-
cord-254777-h8hw4m9f	51	43	.	.	.
cord-254777-h8hw4m9f	52	1	Common	common	JJ
cord-254777-h8hw4m9f	52	2	symptoms	symptom	NNS
cord-254777-h8hw4m9f	52	3	at	at	IN
cord-254777-h8hw4m9f	52	4	presentation	presentation	NN
cord-254777-h8hw4m9f	52	5	include	include	VBP
cord-254777-h8hw4m9f	52	6	fever	fever	NN
cord-254777-h8hw4m9f	52	7	,	,	,
cord-254777-h8hw4m9f	52	8	cough	cough	NN
cord-254777-h8hw4m9f	52	9	,	,	,
cord-254777-h8hw4m9f	52	10	sore	sore	JJ
cord-254777-h8hw4m9f	52	11	throat	throat	NN
cord-254777-h8hw4m9f	52	12	,	,	,
cord-254777-h8hw4m9f	52	13	myalgia	myalgia	NN
cord-254777-h8hw4m9f	52	14	or	or	CC
cord-254777-h8hw4m9f	52	15	fatigue	fatigue	NN
cord-254777-h8hw4m9f	52	16	,	,	,
cord-254777-h8hw4m9f	52	17	sputum	sputum	NN
cord-254777-h8hw4m9f	52	18	production	production	NN
cord-254777-h8hw4m9f	52	19	[	[	-LRB-
cord-254777-h8hw4m9f	52	20	8	8	CD
cord-254777-h8hw4m9f	52	21	,	,	,
cord-254777-h8hw4m9f	52	22	9	9	CD
cord-254777-h8hw4m9f	52	23	]	]	-RRB-
cord-254777-h8hw4m9f	52	24	.	.	.
cord-254777-h8hw4m9f	53	1	Similarly	similarly	RB
cord-254777-h8hw4m9f	53	2	,	,	,
cord-254777-h8hw4m9f	53	3	an	an	DT
cord-254777-h8hw4m9f	53	4	observational	observational	JJ
cord-254777-h8hw4m9f	53	5	cohort	cohort	NN
cord-254777-h8hw4m9f	53	6	study	study	NN
cord-254777-h8hw4m9f	53	7	from	from	IN
cord-254777-h8hw4m9f	53	8	the	the	DT
cord-254777-h8hw4m9f	53	9	United	United	NNP
cord-254777-h8hw4m9f	53	10	States	States	NNP
cord-254777-h8hw4m9f	53	11	(	(	-LRB-
cord-254777-h8hw4m9f	53	12	US	US	NNP
cord-254777-h8hw4m9f	53	13	)	)	-RRB-
cord-254777-h8hw4m9f	53	14	describes	describe	VBZ
cord-254777-h8hw4m9f	53	15	shortness	shortness	NN
cord-254777-h8hw4m9f	53	16	of	of	IN
cord-254777-h8hw4m9f	53	17	breath	breath	NN
cord-254777-h8hw4m9f	53	18	,	,	,
cord-254777-h8hw4m9f	53	19	fever	fever	NN
cord-254777-h8hw4m9f	53	20	and	and	CC
cord-254777-h8hw4m9f	53	21	cough	cough	NN
cord-254777-h8hw4m9f	53	22	as	as	IN
cord-254777-h8hw4m9f	53	23	the	the	DT
cord-254777-h8hw4m9f	53	24	most	most	RBS
cord-254777-h8hw4m9f	53	25	common	common	JJ
cord-254777-h8hw4m9f	53	26	presenting	present	VBG
cord-254777-h8hw4m9f	53	27	symptoms	symptom	NNS
cord-254777-h8hw4m9f	53	28	of	of	IN
cord-254777-h8hw4m9f	53	29	patients	patient	NNS
cord-254777-h8hw4m9f	53	30	hospitalized	hospitalize	VBN
cord-254777-h8hw4m9f	53	31	with	with	IN
cord-254777-h8hw4m9f	53	32	COVID-19	covid-19	JJ
cord-254777-h8hw4m9f	53	33	infection	infection	NN
cord-254777-h8hw4m9f	53	34	[	[	-LRB-
cord-254777-h8hw4m9f	53	35	10	10	CD
cord-254777-h8hw4m9f	53	36	]	]	-RRB-
cord-254777-h8hw4m9f	53	37	.	.	.
cord-254777-h8hw4m9f	54	1	Of	of	IN
cord-254777-h8hw4m9f	54	2	the	the	DT
cord-254777-h8hw4m9f	54	3	1150	1150	CD
cord-254777-h8hw4m9f	54	4	admitted	admit	VBD
cord-254777-h8hw4m9f	54	5	patients	patient	NNS
cord-254777-h8hw4m9f	54	6	in	in	IN
cord-254777-h8hw4m9f	54	7	this	this	DT
cord-254777-h8hw4m9f	54	8	cohort	cohort	NN
cord-254777-h8hw4m9f	54	9	,	,	,
cord-254777-h8hw4m9f	54	10	257	257	CD
cord-254777-h8hw4m9f	54	11	(	(	-LRB-
cord-254777-h8hw4m9f	54	12	22	22	CD
cord-254777-h8hw4m9f	54	13	%	%	NN
cord-254777-h8hw4m9f	54	14	)	)	-RRB-
cord-254777-h8hw4m9f	54	15	were	be	VBD
cord-254777-h8hw4m9f	54	16	critically	critically	RB
cord-254777-h8hw4m9f	54	17	ill	ill	JJ
cord-254777-h8hw4m9f	54	18	and	and	CC
cord-254777-h8hw4m9f	54	19	212	212	CD
cord-254777-h8hw4m9f	54	20	(	(	-LRB-
cord-254777-h8hw4m9f	54	21	82	82	CD
cord-254777-h8hw4m9f	54	22	%	%	NN
cord-254777-h8hw4m9f	54	23	)	)	-RRB-
cord-254777-h8hw4m9f	54	24	had	have	VBD
cord-254777-h8hw4m9f	54	25	at	at	IN
cord-254777-h8hw4m9f	54	26	least	least	JJS
cord-254777-h8hw4m9f	54	27	another	another	DT
cord-254777-h8hw4m9f	54	28	chronic	chronic	JJ
cord-254777-h8hw4m9f	54	29	illness	illness	NN
cord-254777-h8hw4m9f	54	30	.	.	.
cord-254777-h8hw4m9f	55	1	Multiple	multiple	JJ
cord-254777-h8hw4m9f	55	2	studies	study	NNS
cord-254777-h8hw4m9f	55	3	have	have	VBP
cord-254777-h8hw4m9f	55	4	analyzed	analyze	VBN
cord-254777-h8hw4m9f	55	5	risk	risk	NN
cord-254777-h8hw4m9f	55	6	factors	factor	NNS
cord-254777-h8hw4m9f	55	7	for	for	IN
cord-254777-h8hw4m9f	55	8	severe	severe	JJ
cord-254777-h8hw4m9f	55	9	disease	disease	NN
cord-254777-h8hw4m9f	55	10	in	in	IN
cord-254777-h8hw4m9f	55	11	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	55	12	infection	infection	NN
cord-254777-h8hw4m9f	55	13	and	and	CC
cord-254777-h8hw4m9f	55	14	showed	show	VBD
cord-254777-h8hw4m9f	55	15	evidence	evidence	NN
cord-254777-h8hw4m9f	55	16	that	that	IN
cord-254777-h8hw4m9f	55	17	hyperinflammation	hyperinflammation	NN
cord-254777-h8hw4m9f	55	18	(	(	-LRB-
cord-254777-h8hw4m9f	55	19	elevated	elevated	JJ
cord-254777-h8hw4m9f	55	20	levels	level	NNS
cord-254777-h8hw4m9f	55	21	of	of	IN
cord-254777-h8hw4m9f	55	22	ferritin	ferritin	NN
cord-254777-h8hw4m9f	55	23	,	,	,
cord-254777-h8hw4m9f	55	24	D	d	NN
cord-254777-h8hw4m9f	55	25	-	-	HYPH
cord-254777-h8hw4m9f	55	26	dimer	dimer	NN
cord-254777-h8hw4m9f	55	27	,	,	,
cord-254777-h8hw4m9f	55	28	LDH	LDH	NNP
cord-254777-h8hw4m9f	55	29	,	,	,
cord-254777-h8hw4m9f	55	30	IL-6	IL-6	NNP
cord-254777-h8hw4m9f	55	31	and	and	CC
cord-254777-h8hw4m9f	55	32	lower	low	JJR
cord-254777-h8hw4m9f	55	33	lymphocyte	lymphocyte	NN
cord-254777-h8hw4m9f	55	34	count	count	NN
cord-254777-h8hw4m9f	55	35	)	)	-RRB-
cord-254777-h8hw4m9f	55	36	was	be	VBD
cord-254777-h8hw4m9f	55	37	seen	see	VBN
cord-254777-h8hw4m9f	55	38	in	in	IN
cord-254777-h8hw4m9f	55	39	patients	patient	NNS
cord-254777-h8hw4m9f	55	40	with	with	IN
cord-254777-h8hw4m9f	55	41	severe	severe	JJ
cord-254777-h8hw4m9f	55	42	disease	disease	NN
cord-254777-h8hw4m9f	55	43	,	,	,
cord-254777-h8hw4m9f	55	44	as	as	RB
cord-254777-h8hw4m9f	55	45	well	well	RB
cord-254777-h8hw4m9f	55	46	as	as	IN
cord-254777-h8hw4m9f	55	47	non	non	NNS
cord-254777-h8hw4m9f	55	48	-	-	NNS
cord-254777-h8hw4m9f	55	49	survivors	survivor	NNS
cord-254777-h8hw4m9f	55	50	[	[	-LRB-
cord-254777-h8hw4m9f	55	51	8	8	CD
cord-254777-h8hw4m9f	55	52	,	,	,
cord-254777-h8hw4m9f	55	53	11	11	CD
cord-254777-h8hw4m9f	55	54	,	,	,
cord-254777-h8hw4m9f	55	55	12	12	CD
cord-254777-h8hw4m9f	55	56	]	]	-RRB-
cord-254777-h8hw4m9f	55	57	.	.	.
cord-254777-h8hw4m9f	56	1	Chen	Chen	NNP
cord-254777-h8hw4m9f	56	2	G	G	NNP
cord-254777-h8hw4m9f	56	3	et	et	NNP
cord-254777-h8hw4m9f	56	4	al	al	NNP
cord-254777-h8hw4m9f	56	5	described	describe	VBD
cord-254777-h8hw4m9f	56	6	markedly	markedly	RB
cord-254777-h8hw4m9f	56	7	higher	high	JJR
cord-254777-h8hw4m9f	56	8	levels	level	NNS
cord-254777-h8hw4m9f	56	9	of	of	IN
cord-254777-h8hw4m9f	56	10	IL-2R	IL-2R	NNP
cord-254777-h8hw4m9f	56	11	,	,	,
cord-254777-h8hw4m9f	56	12	IL-6	IL-6	NNP
cord-254777-h8hw4m9f	56	13	,	,	,
cord-254777-h8hw4m9f	56	14	IL-10	IL-10	NNP
cord-254777-h8hw4m9f	56	15	,	,	,
cord-254777-h8hw4m9f	56	16	and	and	CC
cord-254777-h8hw4m9f	56	17	TNF	TNF	NNP
cord-254777-h8hw4m9f	56	18	-	-	HYPH
cord-254777-h8hw4m9f	56	19	α	α	NNP
cord-254777-h8hw4m9f	56	20	and	and	CC
cord-254777-h8hw4m9f	56	21	lower	low	JJR
cord-254777-h8hw4m9f	56	22	T	t	NN
cord-254777-h8hw4m9f	56	23	lymphocytes	lymphocyte	NNS
cord-254777-h8hw4m9f	56	24	(	(	-LRB-
cord-254777-h8hw4m9f	56	25	both	both	DT
cord-254777-h8hw4m9f	56	26	CD4	CD4	NNP
cord-254777-h8hw4m9f	56	27	and	and	CC
cord-254777-h8hw4m9f	56	28	CD8	CD8	NNP
cord-254777-h8hw4m9f	56	29	+	+	CC
cord-254777-h8hw4m9f	56	30	)	)	-RRB-
cord-254777-h8hw4m9f	57	1	in	in	IN
cord-254777-h8hw4m9f	57	2	patients	patient	NNS
cord-254777-h8hw4m9f	57	3	with	with	IN
cord-254777-h8hw4m9f	57	4	severe	severe	JJ
cord-254777-h8hw4m9f	57	5	COVID-19	covid-19	JJ
cord-254777-h8hw4m9f	57	6	[	[	-LRB-
cord-254777-h8hw4m9f	57	7	13	13	CD
cord-254777-h8hw4m9f	57	8	]	]	-RRB-
cord-254777-h8hw4m9f	57	9	.	.	.
cord-254777-h8hw4m9f	58	1	Similarly	similarly	RB
cord-254777-h8hw4m9f	58	2	,	,	,
cord-254777-h8hw4m9f	58	3	two	two	CD
cord-254777-h8hw4m9f	58	4	meta	meta	JJ
cord-254777-h8hw4m9f	58	5	-	-	HYPH
cord-254777-h8hw4m9f	58	6	analyses	analysis	NNS
cord-254777-h8hw4m9f	58	7	have	have	VBP
cord-254777-h8hw4m9f	58	8	shown	show	VBN
cord-254777-h8hw4m9f	58	9	that	that	IN
cord-254777-h8hw4m9f	58	10	patients	patient	NNS
cord-254777-h8hw4m9f	58	11	with	with	IN
cord-254777-h8hw4m9f	58	12	severe	severe	JJ
cord-254777-h8hw4m9f	58	13	/	/	SYM
cord-254777-h8hw4m9f	58	14	critical	critical	JJ
cord-254777-h8hw4m9f	58	15	disease	disease	NN
cord-254777-h8hw4m9f	58	16	were	be	VBD
cord-254777-h8hw4m9f	58	17	characterized	characterize	VBN
cord-254777-h8hw4m9f	58	18	by	by	IN
cord-254777-h8hw4m9f	58	19	low	low	JJ
cord-254777-h8hw4m9f	58	20	lymphocyte	lymphocyte	NN
cord-254777-h8hw4m9f	58	21	counts	count	NNS
cord-254777-h8hw4m9f	58	22	(	(	-LRB-
cord-254777-h8hw4m9f	58	23	especially	especially	RB
cord-254777-h8hw4m9f	58	24	T	T	NNP
cord-254777-h8hw4m9f	58	25	lymphocytes	lymphocyte	NNS
cord-254777-h8hw4m9f	58	26	)	)	-RRB-
cord-254777-h8hw4m9f	58	27	,	,	,
cord-254777-h8hw4m9f	58	28	high	high	JJ
cord-254777-h8hw4m9f	58	29	markers	marker	NNS
cord-254777-h8hw4m9f	58	30	of	of	IN
cord-254777-h8hw4m9f	58	31	inflammation	inflammation	NN
cord-254777-h8hw4m9f	58	32	(	(	-LRB-
cord-254777-h8hw4m9f	58	33	C	c	NN
cord-254777-h8hw4m9f	58	34	-	-	HYPH
cord-254777-h8hw4m9f	58	35	reactive	reactive	JJ
cord-254777-h8hw4m9f	58	36	protein	protein	NN
cord-254777-h8hw4m9f	58	37	(	(	-LRB-
cord-254777-h8hw4m9f	58	38	CRP	CRP	NNP
cord-254777-h8hw4m9f	58	39	)	)	-RRB-
cord-254777-h8hw4m9f	58	40	,	,	,
cord-254777-h8hw4m9f	58	41	ESR	ESR	NNP
cord-254777-h8hw4m9f	58	42	,	,	,
cord-254777-h8hw4m9f	58	43	IL6	il6	NN
cord-254777-h8hw4m9f	58	44	,	,	,
cord-254777-h8hw4m9f	58	45	procalcitonin	procalcitonin	NNP
cord-254777-h8hw4m9f	58	46	)	)	-RRB-
cord-254777-h8hw4m9f	58	47	,	,	,
cord-254777-h8hw4m9f	58	48	elevation	elevation	NN
cord-254777-h8hw4m9f	58	49	in	in	IN
cord-254777-h8hw4m9f	58	50	liver	liver	NN
cord-254777-h8hw4m9f	58	51	enzymes	enzyme	NNS
cord-254777-h8hw4m9f	58	52	,	,	,
cord-254777-h8hw4m9f	58	53	abnormal	abnormal	JJ
cord-254777-h8hw4m9f	58	54	coagulation	coagulation	NN
cord-254777-h8hw4m9f	58	55	and	and	CC
cord-254777-h8hw4m9f	58	56	kidney	kidney	NN
cord-254777-h8hw4m9f	58	57	function	function	NN
cord-254777-h8hw4m9f	58	58	,	,	,
cord-254777-h8hw4m9f	58	59	as	as	RB
cord-254777-h8hw4m9f	58	60	well	well	RB
cord-254777-h8hw4m9f	58	61	as	as	IN
cord-254777-h8hw4m9f	58	62	elevation	elevation	NN
cord-254777-h8hw4m9f	58	63	in	in	IN
cord-254777-h8hw4m9f	58	64	biomarkers	biomarker	NNS
cord-254777-h8hw4m9f	58	65	of	of	IN
cord-254777-h8hw4m9f	58	66	myocardial	myocardial	JJ
cord-254777-h8hw4m9f	58	67	function	function	NN
cord-254777-h8hw4m9f	58	68	(	(	-LRB-
cord-254777-h8hw4m9f	58	69	including	include	VBG
cord-254777-h8hw4m9f	58	70	troponin	troponin	JJ
cord-254777-h8hw4m9f	58	71	and	and	CC
cord-254777-h8hw4m9f	58	72	creatine	creatine	NN
cord-254777-h8hw4m9f	58	73	kinase	kinase	NN
cord-254777-h8hw4m9f	58	74	)	)	-RRB-
cord-254777-h8hw4m9f	58	75	[	[	-LRB-
cord-254777-h8hw4m9f	58	76	14	14	CD
cord-254777-h8hw4m9f	58	77	,	,	,
cord-254777-h8hw4m9f	58	78	15	15	CD
cord-254777-h8hw4m9f	58	79	]	]	-RRB-
cord-254777-h8hw4m9f	58	80	.	.	.
cord-254777-h8hw4m9f	59	1	To	to	IN
cord-254777-h8hw4m9f	59	2	date	date	NN
cord-254777-h8hw4m9f	59	3	,	,	,
cord-254777-h8hw4m9f	59	4	most	most	JJS
cord-254777-h8hw4m9f	59	5	cases	case	NNS
cord-254777-h8hw4m9f	59	6	of	of	IN
cord-254777-h8hw4m9f	59	7	COVID-19	covid-19	CD
cord-254777-h8hw4m9f	59	8	in	in	IN
cord-254777-h8hw4m9f	59	9	children	child	NNS
cord-254777-h8hw4m9f	59	10	were	be	VBD
cord-254777-h8hw4m9f	59	11	thought	think	VBN
cord-254777-h8hw4m9f	59	12	to	to	TO
cord-254777-h8hw4m9f	59	13	be	be	VB
cord-254777-h8hw4m9f	59	14	asymptomatic	asymptomatic	JJ
cord-254777-h8hw4m9f	59	15	or	or	CC
cord-254777-h8hw4m9f	59	16	have	have	VBP
cord-254777-h8hw4m9f	59	17	mild	mild	JJ
cord-254777-h8hw4m9f	59	18	presentation	presentation	NN
cord-254777-h8hw4m9f	59	19	.	.	.
cord-254777-h8hw4m9f	60	1	In	in	IN
cord-254777-h8hw4m9f	60	2	a	a	DT
cord-254777-h8hw4m9f	60	3	systematic	systematic	JJ
cord-254777-h8hw4m9f	60	4	review	review	NN
cord-254777-h8hw4m9f	60	5	of	of	IN
cord-254777-h8hw4m9f	60	6	18	18	CD
cord-254777-h8hw4m9f	60	7	studies	study	NNS
cord-254777-h8hw4m9f	60	8	in	in	IN
cord-254777-h8hw4m9f	60	9	China	China	NNP
cord-254777-h8hw4m9f	60	10	with	with	IN
cord-254777-h8hw4m9f	60	11	1065	1065	CD
cord-254777-h8hw4m9f	60	12	participants	participant	NNS
cord-254777-h8hw4m9f	60	13	,	,	,
cord-254777-h8hw4m9f	60	14	children	child	NNS
cord-254777-h8hw4m9f	60	15	at	at	IN
cord-254777-h8hw4m9f	60	16	any	any	DT
cord-254777-h8hw4m9f	60	17	age	age	NN
cord-254777-h8hw4m9f	60	18	were	be	VBD
cord-254777-h8hw4m9f	60	19	found	find	VBN
cord-254777-h8hw4m9f	60	20	to	to	TO
cord-254777-h8hw4m9f	60	21	be	be	VB
cord-254777-h8hw4m9f	60	22	asymptomatic	asymptomatic	JJ
cord-254777-h8hw4m9f	60	23	or	or	CC
cord-254777-h8hw4m9f	60	24	present	present	JJ
cord-254777-h8hw4m9f	60	25	with	with	IN
cord-254777-h8hw4m9f	60	26	mild	mild	JJ
cord-254777-h8hw4m9f	60	27	respiratory	respiratory	JJ
cord-254777-h8hw4m9f	60	28	symptoms	symptom	NNS
cord-254777-h8hw4m9f	60	29	,	,	,
cord-254777-h8hw4m9f	60	30	namely	namely	RB
cord-254777-h8hw4m9f	60	31	fever	fever	NN
cord-254777-h8hw4m9f	60	32	,	,	,
cord-254777-h8hw4m9f	60	33	dry	dry	JJ
cord-254777-h8hw4m9f	60	34	cough	cough	NN
cord-254777-h8hw4m9f	60	35	,	,	,
cord-254777-h8hw4m9f	60	36	and	and	CC
cord-254777-h8hw4m9f	60	37	fatigue	fatigue	NN
cord-254777-h8hw4m9f	60	38	[	[	-LRB-
cord-254777-h8hw4m9f	60	39	16	16	CD
cord-254777-h8hw4m9f	60	40	]	]	-RRB-
cord-254777-h8hw4m9f	60	41	.	.	.
cord-254777-h8hw4m9f	61	1	Similarly	similarly	RB
cord-254777-h8hw4m9f	61	2	,	,	,
cord-254777-h8hw4m9f	61	3	Dong	Dong	NNP
cord-254777-h8hw4m9f	61	4	et	et	NNP
cord-254777-h8hw4m9f	61	5	al	al	NNP
cord-254777-h8hw4m9f	61	6	reported	report	VBD
cord-254777-h8hw4m9f	61	7	a	a	DT
cord-254777-h8hw4m9f	61	8	Chinese	chinese	JJ
cord-254777-h8hw4m9f	61	9	nationwide	nationwide	JJ
cord-254777-h8hw4m9f	61	10	case	case	NN
cord-254777-h8hw4m9f	61	11	series	series	NN
cord-254777-h8hw4m9f	61	12	of	of	IN
cord-254777-h8hw4m9f	61	13	2135	2135	CD
cord-254777-h8hw4m9f	61	14	patients	patient	NNS
cord-254777-h8hw4m9f	61	15	with	with	IN
cord-254777-h8hw4m9f	61	16	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	61	17	[	[	-LRB-
cord-254777-h8hw4m9f	61	18	17	17	CD
cord-254777-h8hw4m9f	61	19	]	]	-RRB-
cord-254777-h8hw4m9f	61	20	.	.	.
cord-254777-h8hw4m9f	62	1	Most	Most	JJS
cord-254777-h8hw4m9f	62	2	patients	patient	NNS
cord-254777-h8hw4m9f	62	3	(	(	-LRB-
cord-254777-h8hw4m9f	62	4	>	>	NFP
cord-254777-h8hw4m9f	62	5	90	90	CD
cord-254777-h8hw4m9f	62	6	%	%	NN
cord-254777-h8hw4m9f	62	7	)	)	-RRB-
cord-254777-h8hw4m9f	62	8	were	be	VBD
cord-254777-h8hw4m9f	62	9	asymptomatic	asymptomatic	JJ
cord-254777-h8hw4m9f	62	10	or	or	CC
cord-254777-h8hw4m9f	62	11	had	have	VBD
cord-254777-h8hw4m9f	62	12	mild	mild	JJ
cord-254777-h8hw4m9f	62	13	-	-	HYPH
cord-254777-h8hw4m9f	62	14	moderate	moderate	JJ
cord-254777-h8hw4m9f	62	15	cases	case	NNS
cord-254777-h8hw4m9f	62	16	.	.	.
cord-254777-h8hw4m9f	63	1	Infants	infant	NNS
cord-254777-h8hw4m9f	63	2	were	be	VBD
cord-254777-h8hw4m9f	63	3	found	find	VBN
cord-254777-h8hw4m9f	63	4	to	to	TO
cord-254777-h8hw4m9f	63	5	be	be	VB
cord-254777-h8hw4m9f	63	6	more	more	RBR
cord-254777-h8hw4m9f	63	7	likely	likely	JJ
cord-254777-h8hw4m9f	63	8	to	to	TO
cord-254777-h8hw4m9f	63	9	be	be	VB
cord-254777-h8hw4m9f	63	10	severely	severely	RB
cord-254777-h8hw4m9f	63	11	affected	affect	VBN
cord-254777-h8hw4m9f	63	12	.	.	.
cord-254777-h8hw4m9f	64	1	Almost	almost	RB
cord-254777-h8hw4m9f	64	2	all	all	DT
cord-254777-h8hw4m9f	64	3	children	child	NNS
cord-254777-h8hw4m9f	64	4	recovered	recover	VBD
cord-254777-h8hw4m9f	64	5	,	,	,
cord-254777-h8hw4m9f	64	6	with	with	IN
cord-254777-h8hw4m9f	64	7	only	only	RB
cord-254777-h8hw4m9f	64	8	one	one	CD
cord-254777-h8hw4m9f	64	9	fatality	fatality	NN
cord-254777-h8hw4m9f	64	10	reported	report	VBD
cord-254777-h8hw4m9f	64	11	.	.	.
cord-254777-h8hw4m9f	65	1	Chilblains	chilblain	NNS
cord-254777-h8hw4m9f	65	2	have	have	VBP
cord-254777-h8hw4m9f	65	3	also	also	RB
cord-254777-h8hw4m9f	65	4	been	be	VBN
cord-254777-h8hw4m9f	65	5	described	describe	VBN
cord-254777-h8hw4m9f	65	6	in	in	IN
cord-254777-h8hw4m9f	65	7	both	both	DT
cord-254777-h8hw4m9f	65	8	children	child	NNS
cord-254777-h8hw4m9f	65	9	and	and	CC
cord-254777-h8hw4m9f	65	10	adults	adult	NNS
cord-254777-h8hw4m9f	65	11	.	.	.
cord-254777-h8hw4m9f	66	1	Two	two	CD
cord-254777-h8hw4m9f	66	2	small	small	JJ
cord-254777-h8hw4m9f	66	3	series	series	NN
cord-254777-h8hw4m9f	66	4	from	from	IN
cord-254777-h8hw4m9f	66	5	Italy	Italy	NNP
cord-254777-h8hw4m9f	66	6	and	and	CC
cord-254777-h8hw4m9f	66	7	the	the	DT
cord-254777-h8hw4m9f	66	8	US	US	NNP
cord-254777-h8hw4m9f	66	9	describe	describe	VBP
cord-254777-h8hw4m9f	66	10	cases	case	NNS
cord-254777-h8hw4m9f	66	11	of	of	IN
cord-254777-h8hw4m9f	66	12	acral	acral	JJ
cord-254777-h8hw4m9f	66	13	purpura	purpura	NN
cord-254777-h8hw4m9f	66	14	in	in	IN
cord-254777-h8hw4m9f	66	15	children	child	NNS
cord-254777-h8hw4m9f	66	16	either	either	CC
cord-254777-h8hw4m9f	66	17	diagnosed	diagnose	VBD
cord-254777-h8hw4m9f	66	18	with	with	IN
cord-254777-h8hw4m9f	66	19	,	,	,
cord-254777-h8hw4m9f	66	20	or	or	CC
cord-254777-h8hw4m9f	66	21	with	with	IN
cord-254777-h8hw4m9f	66	22	strong	strong	JJ
cord-254777-h8hw4m9f	66	23	suspicion	suspicion	NN
cord-254777-h8hw4m9f	66	24	for	for	IN
cord-254777-h8hw4m9f	66	25	,	,	,
cord-254777-h8hw4m9f	66	26	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	66	27	[	[	-LRB-
cord-254777-h8hw4m9f	66	28	18	18	CD
cord-254777-h8hw4m9f	66	29	,	,	,
cord-254777-h8hw4m9f	66	30	19	19	CD
cord-254777-h8hw4m9f	66	31	]	]	-RRB-
cord-254777-h8hw4m9f	66	32	.	.	.
cord-254777-h8hw4m9f	67	1	All	all	DT
cord-254777-h8hw4m9f	67	2	pediatric	pediatric	JJ
cord-254777-h8hw4m9f	67	3	cases	case	NNS
cord-254777-h8hw4m9f	67	4	described	describe	VBN
cord-254777-h8hw4m9f	67	5	seemed	seem	VBD
cord-254777-h8hw4m9f	67	6	to	to	TO
cord-254777-h8hw4m9f	67	7	have	have	VB
cord-254777-h8hw4m9f	67	8	a	a	DT
cord-254777-h8hw4m9f	67	9	relatively	relatively	RB
cord-254777-h8hw4m9f	67	10	mild	mild	JJ
cord-254777-h8hw4m9f	67	11	form	form	NN
cord-254777-h8hw4m9f	67	12	of	of	IN
cord-254777-h8hw4m9f	67	13	viral	viral	JJ
cord-254777-h8hw4m9f	67	14	infection	infection	NN
cord-254777-h8hw4m9f	67	15	.	.	.
cord-254777-h8hw4m9f	68	1	This	this	DT
cord-254777-h8hw4m9f	68	2	was	be	VBD
cord-254777-h8hw4m9f	68	3	hypothesized	hypothesize	VBN
cord-254777-h8hw4m9f	68	4	to	to	TO
cord-254777-h8hw4m9f	68	5	be	be	VB
cord-254777-h8hw4m9f	68	6	due	due	JJ
cord-254777-h8hw4m9f	68	7	to	to	IN
cord-254777-h8hw4m9f	68	8	a	a	DT
cord-254777-h8hw4m9f	68	9	robust	robust	JJ
cord-254777-h8hw4m9f	68	10	type	type	NN
cord-254777-h8hw4m9f	69	1	I	-PRON-	PRP
cord-254777-h8hw4m9f	69	2	IFN	IFN	NNP
cord-254777-h8hw4m9f	69	3	response	response	NN
cord-254777-h8hw4m9f	69	4	after	after	IN
cord-254777-h8hw4m9f	69	5	viral	viral	JJ
cord-254777-h8hw4m9f	69	6	exposure	exposure	NN
cord-254777-h8hw4m9f	69	7	which	which	WDT
cord-254777-h8hw4m9f	69	8	may	may	MD
cord-254777-h8hw4m9f	69	9	both	both	RB
cord-254777-h8hw4m9f	69	10	protect	protect	VB
cord-254777-h8hw4m9f	69	11	from	from	IN
cord-254777-h8hw4m9f	69	12	progressive	progressive	JJ
cord-254777-h8hw4m9f	69	13	infection	infection	NN
cord-254777-h8hw4m9f	69	14	and	and	CC
cord-254777-h8hw4m9f	69	15	precipitate	precipitate	VB
cord-254777-h8hw4m9f	69	16	inflammatory	inflammatory	JJ
cord-254777-h8hw4m9f	69	17	perniosis	perniosis	NN
cord-254777-h8hw4m9f	69	18	through	through	IN
cord-254777-h8hw4m9f	69	19	the	the	DT
cord-254777-h8hw4m9f	69	20	same	same	JJ
cord-254777-h8hw4m9f	69	21	pathway	pathway	NN
cord-254777-h8hw4m9f	69	22	[	[	-LRB-
cord-254777-h8hw4m9f	69	23	19	19	CD
cord-254777-h8hw4m9f	69	24	]	]	-RRB-
cord-254777-h8hw4m9f	69	25	.	.	.
cord-254777-h8hw4m9f	70	1	In	in	IN
cord-254777-h8hw4m9f	70	2	contrast	contrast	NN
cord-254777-h8hw4m9f	70	3	,	,	,
cord-254777-h8hw4m9f	70	4	recently	recently	RB
cord-254777-h8hw4m9f	70	5	published	publish	VBN
cord-254777-h8hw4m9f	70	6	data	datum	NNS
cord-254777-h8hw4m9f	70	7	from	from	IN
cord-254777-h8hw4m9f	70	8	the	the	DT
cord-254777-h8hw4m9f	70	9	US	US	NNP
cord-254777-h8hw4m9f	70	10	describe	describe	VB
cord-254777-h8hw4m9f	70	11	a	a	DT
cord-254777-h8hw4m9f	70	12	subgroup	subgroup	NN
cord-254777-h8hw4m9f	70	13	of	of	IN
cord-254777-h8hw4m9f	70	14	pediatric	pediatric	JJ
cord-254777-h8hw4m9f	70	15	patients	patient	NNS
cord-254777-h8hw4m9f	70	16	with	with	IN
cord-254777-h8hw4m9f	70	17	severe	severe	JJ
cord-254777-h8hw4m9f	70	18	disease	disease	NN
cord-254777-h8hw4m9f	70	19	.	.	.
cord-254777-h8hw4m9f	71	1	Chao	Chao	NNP
cord-254777-h8hw4m9f	71	2	et	et	NNP
cord-254777-h8hw4m9f	71	3	al	al	NNP
cord-254777-h8hw4m9f	71	4	and	and	CC
cord-254777-h8hw4m9f	71	5	DeBiasi	DeBiasi	NNP
cord-254777-h8hw4m9f	71	6	et	et	NNP
cord-254777-h8hw4m9f	71	7	al	al	NNP
cord-254777-h8hw4m9f	71	8	report	report	NN
cord-254777-h8hw4m9f	71	9	data	datum	NNS
cord-254777-h8hw4m9f	71	10	from	from	IN
cord-254777-h8hw4m9f	71	11	two	two	CD
cord-254777-h8hw4m9f	71	12	major	major	JJ
cord-254777-h8hw4m9f	71	13	epicenters	epicenter	NNS
cord-254777-h8hw4m9f	71	14	of	of	IN
cord-254777-h8hw4m9f	71	15	disease	disease	NN
cord-254777-h8hw4m9f	71	16	in	in	IN
cord-254777-h8hw4m9f	71	17	the	the	DT
cord-254777-h8hw4m9f	71	18	US	US	NNP
cord-254777-h8hw4m9f	71	19	,	,	,
cord-254777-h8hw4m9f	71	20	including	include	VBG
cord-254777-h8hw4m9f	71	21	pediatric	pediatric	JJ
cord-254777-h8hw4m9f	71	22	patients	patient	NNS
cord-254777-h8hw4m9f	71	23	admitted	admit	VBN
cord-254777-h8hw4m9f	71	24	to	to	IN
cord-254777-h8hw4m9f	71	25	hospitals	hospital	NNS
cord-254777-h8hw4m9f	71	26	in	in	IN
cord-254777-h8hw4m9f	71	27	NY	NY	NNP
cord-254777-h8hw4m9f	71	28	and	and	CC
cord-254777-h8hw4m9f	71	29	Washington	Washington	NNP
cord-254777-h8hw4m9f	71	30	,	,	,
cord-254777-h8hw4m9f	71	31	DC	DC	NNP
cord-254777-h8hw4m9f	71	32	[	[	-LRB-
cord-254777-h8hw4m9f	71	33	20	20	CD
cord-254777-h8hw4m9f	71	34	,	,	,
cord-254777-h8hw4m9f	71	35	21	21	CD
cord-254777-h8hw4m9f	71	36	]	]	-RRB-
cord-254777-h8hw4m9f	71	37	.	.	.
cord-254777-h8hw4m9f	72	1	Of	of	IN
cord-254777-h8hw4m9f	72	2	these	these	DT
cord-254777-h8hw4m9f	72	3	patients	patient	NNS
cord-254777-h8hw4m9f	72	4	,	,	,
cord-254777-h8hw4m9f	72	5	28	28	CD
cord-254777-h8hw4m9f	72	6	%	%	NN
cord-254777-h8hw4m9f	72	7	and	and	CC
cord-254777-h8hw4m9f	72	8	20	20	CD
cord-254777-h8hw4m9f	72	9	%	%	NN
cord-254777-h8hw4m9f	72	10	of	of	IN
cord-254777-h8hw4m9f	72	11	patients	patient	NNS
cord-254777-h8hw4m9f	72	12	respectively	respectively	RB
cord-254777-h8hw4m9f	72	13	were	be	VBD
cord-254777-h8hw4m9f	72	14	found	find	VBN
cord-254777-h8hw4m9f	72	15	to	to	TO
cord-254777-h8hw4m9f	72	16	have	have	VB
cord-254777-h8hw4m9f	72	17	severe	severe	JJ
cord-254777-h8hw4m9f	72	18	disease	disease	NN
cord-254777-h8hw4m9f	72	19	,	,	,
cord-254777-h8hw4m9f	72	20	with	with	IN
cord-254777-h8hw4m9f	72	21	a	a	DT
cord-254777-h8hw4m9f	72	22	need	need	NN
cord-254777-h8hw4m9f	72	23	for	for	IN
cord-254777-h8hw4m9f	72	24	respiratory	respiratory	JJ
cord-254777-h8hw4m9f	72	25	support	support	NN
cord-254777-h8hw4m9f	72	26	.	.	.
cord-254777-h8hw4m9f	73	1	In	in	IN
cord-254777-h8hw4m9f	73	2	NY	NY	NNP
cord-254777-h8hw4m9f	73	3	,	,	,
cord-254777-h8hw4m9f	73	4	admission	admission	NN
cord-254777-h8hw4m9f	73	5	to	to	IN
cord-254777-h8hw4m9f	73	6	the	the	DT
cord-254777-h8hw4m9f	73	7	intensive	intensive	JJ
cord-254777-h8hw4m9f	73	8	care	care	NN
cord-254777-h8hw4m9f	73	9	unit	unit	NN
cord-254777-h8hw4m9f	73	10	was	be	VBD
cord-254777-h8hw4m9f	73	11	associated	associate	VBN
cord-254777-h8hw4m9f	73	12	with	with	IN
cord-254777-h8hw4m9f	73	13	higher	high	JJR
cord-254777-h8hw4m9f	73	14	levels	level	NNS
cord-254777-h8hw4m9f	73	15	of	of	IN
cord-254777-h8hw4m9f	73	16	CRP	crp	NN
cord-254777-h8hw4m9f	73	17	,	,	,
cord-254777-h8hw4m9f	73	18	procalcitonin	procalcitonin	NNS
cord-254777-h8hw4m9f	73	19	,	,	,
cord-254777-h8hw4m9f	73	20	pro	pro	JJ
cord-254777-h8hw4m9f	73	21	-	-	JJ
cord-254777-h8hw4m9f	73	22	BNP	bnp	JJ
cord-254777-h8hw4m9f	73	23	and	and	CC
cord-254777-h8hw4m9f	73	24	platelet	platelet	NN
cord-254777-h8hw4m9f	73	25	levels	level	NNS
cord-254777-h8hw4m9f	73	26	[	[	-LRB-
cord-254777-h8hw4m9f	73	27	20	20	CD
cord-254777-h8hw4m9f	73	28	]	]	-RRB-
cord-254777-h8hw4m9f	73	29	.	.	.
cord-254777-h8hw4m9f	74	1	In	in	IN
cord-254777-h8hw4m9f	74	2	the	the	DT
cord-254777-h8hw4m9f	74	3	DC	DC	NNP
cord-254777-h8hw4m9f	74	4	cohort	cohort	NN
cord-254777-h8hw4m9f	74	5	,	,	,
cord-254777-h8hw4m9f	74	6	the	the	DT
cord-254777-h8hw4m9f	74	7	age	age	NN
cord-254777-h8hw4m9f	74	8	for	for	IN
cord-254777-h8hw4m9f	74	9	critically	critically	RB
cord-254777-h8hw4m9f	74	10	ill	ill	JJ
cord-254777-h8hw4m9f	74	11	children	child	NNS
cord-254777-h8hw4m9f	74	12	was	be	VBD
cord-254777-h8hw4m9f	74	13	considerably	considerably	RB
cord-254777-h8hw4m9f	74	14	higher	high	JJR
cord-254777-h8hw4m9f	74	15	compared	compare	VBN
cord-254777-h8hw4m9f	74	16	with	with	IN
cord-254777-h8hw4m9f	74	17	non	non	JJ
cord-254777-h8hw4m9f	74	18	-	-	JJ
cord-254777-h8hw4m9f	74	19	critically	critically	RB
cord-254777-h8hw4m9f	74	20	ill	ill	JJ
cord-254777-h8hw4m9f	74	21	patients	patient	NNS
cord-254777-h8hw4m9f	74	22	.	.	.
cord-254777-h8hw4m9f	75	1	MIS	MIS	NNP
cord-254777-h8hw4m9f	75	2	-	-	HYPH
cord-254777-h8hw4m9f	75	3	C	C	NNP
cord-254777-h8hw4m9f	75	4	appears	appear	VBZ
cord-254777-h8hw4m9f	75	5	to	to	TO
cord-254777-h8hw4m9f	75	6	have	have	VB
cord-254777-h8hw4m9f	75	7	a	a	DT
cord-254777-h8hw4m9f	75	8	clinical	clinical	JJ
cord-254777-h8hw4m9f	75	9	spectrum	spectrum	NN
cord-254777-h8hw4m9f	75	10	of	of	IN
cord-254777-h8hw4m9f	75	11	disease	disease	NN
cord-254777-h8hw4m9f	75	12	,	,	,
cord-254777-h8hw4m9f	75	13	broadly	broadly	RB
cord-254777-h8hw4m9f	75	14	divided	divide	VBD
cord-254777-h8hw4m9f	75	15	into	into	IN
cord-254777-h8hw4m9f	75	16	two	two	CD
cord-254777-h8hw4m9f	75	17	subsets	subset	NNS
cord-254777-h8hw4m9f	75	18	of	of	IN
cord-254777-h8hw4m9f	75	19	patients	patient	NNS
cord-254777-h8hw4m9f	75	20	:	:	:
cord-254777-h8hw4m9f	75	21	(	(	-LRB-
cord-254777-h8hw4m9f	75	22	1	1	LS
cord-254777-h8hw4m9f	75	23	)	)	-RRB-
cord-254777-h8hw4m9f	75	24	those	those	DT
cord-254777-h8hw4m9f	75	25	that	that	WDT
cord-254777-h8hw4m9f	75	26	present	present	JJ
cord-254777-h8hw4m9f	75	27	with	with	IN
cord-254777-h8hw4m9f	75	28	classic	classic	JJ
cord-254777-h8hw4m9f	75	29	or	or	CC
cord-254777-h8hw4m9f	75	30	atypical	atypical	JJ
cord-254777-h8hw4m9f	75	31	KD	KD	NNP
cord-254777-h8hw4m9f	75	32	features	feature	NNS
cord-254777-h8hw4m9f	75	33	,	,	,
cord-254777-h8hw4m9f	75	34	including	include	VBG
cord-254777-h8hw4m9f	75	35	reports	report	NNS
cord-254777-h8hw4m9f	75	36	of	of	IN
cord-254777-h8hw4m9f	75	37	dilated	dilated	JJ
cord-254777-h8hw4m9f	75	38	coronary	coronary	JJ
cord-254777-h8hw4m9f	75	39	arteries	artery	NNS
cord-254777-h8hw4m9f	75	40	and	and	CC
cord-254777-h8hw4m9f	75	41	(	(	-LRB-
cord-254777-h8hw4m9f	75	42	2	2	LS
cord-254777-h8hw4m9f	75	43	)	)	-RRB-
cord-254777-h8hw4m9f	75	44	those	those	DT
cord-254777-h8hw4m9f	75	45	that	that	WDT
cord-254777-h8hw4m9f	75	46	present	present	VBP
cord-254777-h8hw4m9f	75	47	with	with	IN
cord-254777-h8hw4m9f	75	48	a	a	DT
cord-254777-h8hw4m9f	75	49	phenotype	phenotype	NN
cord-254777-h8hw4m9f	75	50	of	of	IN
cord-254777-h8hw4m9f	75	51	sepsis	sepsis	NN
cord-254777-h8hw4m9f	75	52	,	,	,
cord-254777-h8hw4m9f	75	53	cardiovascular	cardiovascular	JJ
cord-254777-h8hw4m9f	75	54	shock	shock	NN
cord-254777-h8hw4m9f	75	55	or	or	CC
cord-254777-h8hw4m9f	75	56	cardiac	cardiac	JJ
cord-254777-h8hw4m9f	75	57	dysfunction	dysfunction	NN
cord-254777-h8hw4m9f	75	58	.	.	.
cord-254777-h8hw4m9f	76	1	In	in	IN
cord-254777-h8hw4m9f	76	2	contrast	contrast	NN
cord-254777-h8hw4m9f	76	3	with	with	IN
cord-254777-h8hw4m9f	76	4	adults	adult	NNS
cord-254777-h8hw4m9f	76	5	and	and	CC
cord-254777-h8hw4m9f	76	6	children	child	NNS
cord-254777-h8hw4m9f	76	7	from	from	IN
cord-254777-h8hw4m9f	76	8	initial	initial	JJ
cord-254777-h8hw4m9f	76	9	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	76	10	cohorts	cohort	NNS
cord-254777-h8hw4m9f	76	11	,	,	,
cord-254777-h8hw4m9f	76	12	most	most	JJS
cord-254777-h8hw4m9f	76	13	of	of	IN
cord-254777-h8hw4m9f	76	14	these	these	DT
cord-254777-h8hw4m9f	76	15	children	child	NNS
cord-254777-h8hw4m9f	76	16	do	do	VBP
cord-254777-h8hw4m9f	76	17	not	not	RB
cord-254777-h8hw4m9f	76	18	have	have	VB
cord-254777-h8hw4m9f	76	19	underlying	underlying	JJ
cord-254777-h8hw4m9f	76	20	medical	medical	JJ
cord-254777-h8hw4m9f	76	21	conditions	condition	NNS
cord-254777-h8hw4m9f	76	22	.	.	.
cord-254777-h8hw4m9f	77	1	A	a	DT
cord-254777-h8hw4m9f	77	2	slight	slight	JJ
cord-254777-h8hw4m9f	77	3	male	male	JJ
cord-254777-h8hw4m9f	77	4	predominance	predominance	NN
cord-254777-h8hw4m9f	77	5	has	have	VBZ
cord-254777-h8hw4m9f	77	6	been	be	VBN
cord-254777-h8hw4m9f	77	7	described	describe	VBN
cord-254777-h8hw4m9f	77	8	,	,	,
cord-254777-h8hw4m9f	77	9	with	with	IN
cord-254777-h8hw4m9f	77	10	median	median	JJ
cord-254777-h8hw4m9f	77	11	ages	age	NNS
cord-254777-h8hw4m9f	77	12	reported	report	VBN
cord-254777-h8hw4m9f	77	13	between	between	IN
cord-254777-h8hw4m9f	77	14	7.5	7.5	CD
cord-254777-h8hw4m9f	77	15	to	to	TO
cord-254777-h8hw4m9f	77	16	10	10	CD
cord-254777-h8hw4m9f	77	17	years	year	NNS
cord-254777-h8hw4m9f	77	18	old	old	JJ
cord-254777-h8hw4m9f	77	19	(	(	-LRB-
cord-254777-h8hw4m9f	77	20	Table	table	NN
cord-254777-h8hw4m9f	77	21	1	1	CD
cord-254777-h8hw4m9f	77	22	)	)	-RRB-
cord-254777-h8hw4m9f	77	23	[	[	-LRB-
cord-254777-h8hw4m9f	77	24	22	22	CD
cord-254777-h8hw4m9f	77	25	]	]	-RRB-
cord-254777-h8hw4m9f	77	26	[	[	-LRB-
cord-254777-h8hw4m9f	77	27	23	23	CD
cord-254777-h8hw4m9f	77	28	]	]	-RRB-
cord-254777-h8hw4m9f	77	29	[	[	-LRB-
cord-254777-h8hw4m9f	77	30	24	24	CD
cord-254777-h8hw4m9f	77	31	]	]	-RRB-
cord-254777-h8hw4m9f	77	32	[	[	-LRB-
cord-254777-h8hw4m9f	77	33	25	25	CD
cord-254777-h8hw4m9f	77	34	]	]	-RRB-
cord-254777-h8hw4m9f	77	35	.	.	.
cord-254777-h8hw4m9f	78	1	Supportive	supportive	JJ
cord-254777-h8hw4m9f	78	2	clinical	clinical	JJ
cord-254777-h8hw4m9f	78	3	features	feature	NNS
cord-254777-h8hw4m9f	78	4	described	describe	VBN
cord-254777-h8hw4m9f	78	5	include	include	VBP
cord-254777-h8hw4m9f	78	6	persistent	persistent	JJ
cord-254777-h8hw4m9f	78	7	fever	fever	NN
cord-254777-h8hw4m9f	78	8	>	>	XX
cord-254777-h8hw4m9f	78	9	38.5	38.5	CD
cord-254777-h8hw4m9f	78	10	C	c	NN
cord-254777-h8hw4m9f	78	11	,	,	,
cord-254777-h8hw4m9f	78	12	variable	variable	JJ
cord-254777-h8hw4m9f	78	13	rash	rash	NN
cord-254777-h8hw4m9f	78	14	,	,	,
cord-254777-h8hw4m9f	78	15	conjunctivitis	conjunctivitis	NN
cord-254777-h8hw4m9f	78	16	,	,	,
cord-254777-h8hw4m9f	78	17	peripheral	peripheral	JJ
cord-254777-h8hw4m9f	78	18	edema	edema	NN
cord-254777-h8hw4m9f	78	19	,	,	,
cord-254777-h8hw4m9f	78	20	severe	severe	JJ
cord-254777-h8hw4m9f	78	21	abdominal	abdominal	JJ
cord-254777-h8hw4m9f	78	22	pain	pain	NN
cord-254777-h8hw4m9f	78	23	and	and	CC
cord-254777-h8hw4m9f	78	24	diarrhea	diarrhea	NN
cord-254777-h8hw4m9f	78	25	.	.	.
cord-254777-h8hw4m9f	79	1	Interestingly	interestingly	RB
cord-254777-h8hw4m9f	79	2	,	,	,
cord-254777-h8hw4m9f	79	3	respiratory	respiratory	JJ
cord-254777-h8hw4m9f	79	4	distress	distress	NN
cord-254777-h8hw4m9f	79	5	does	do	VBZ
cord-254777-h8hw4m9f	79	6	not	not	RB
cord-254777-h8hw4m9f	79	7	seem	seem	VB
cord-254777-h8hw4m9f	79	8	to	to	TO
cord-254777-h8hw4m9f	79	9	be	be	VB
cord-254777-h8hw4m9f	79	10	one	one	CD
cord-254777-h8hw4m9f	79	11	of	of	IN
cord-254777-h8hw4m9f	79	12	the	the	DT
cord-254777-h8hw4m9f	79	13	main	main	JJ
cord-254777-h8hw4m9f	79	14	presenting	present	VBG
cord-254777-h8hw4m9f	79	15	symptoms	symptom	NNS
cord-254777-h8hw4m9f	79	16	,	,	,
cord-254777-h8hw4m9f	79	17	although	although	IN
cord-254777-h8hw4m9f	79	18	a	a	DT
cord-254777-h8hw4m9f	79	19	proportion	proportion	NN
cord-254777-h8hw4m9f	79	20	of	of	IN
cord-254777-h8hw4m9f	79	21	patients	patient	NNS
cord-254777-h8hw4m9f	79	22	do	do	VBP
cord-254777-h8hw4m9f	79	23	require	require	VB
cord-254777-h8hw4m9f	79	24	respiratory	respiratory	JJ
cord-254777-h8hw4m9f	79	25	support	support	NN
cord-254777-h8hw4m9f	79	26	.	.	.
cord-254777-h8hw4m9f	80	1	More	more	RBR
cord-254777-h8hw4m9f	80	2	significantly	significantly	RB
cord-254777-h8hw4m9f	80	3	,	,	,
cord-254777-h8hw4m9f	80	4	a	a	DT
cord-254777-h8hw4m9f	80	5	large	large	JJ
cord-254777-h8hw4m9f	80	6	percentage	percentage	NN
cord-254777-h8hw4m9f	80	7	of	of	IN
cord-254777-h8hw4m9f	80	8	these	these	DT
cord-254777-h8hw4m9f	80	9	children	child	NNS
cord-254777-h8hw4m9f	80	10	present	present	JJ
cord-254777-h8hw4m9f	80	11	with	with	IN
cord-254777-h8hw4m9f	80	12	hypotension	hypotension	NN
cord-254777-h8hw4m9f	80	13	and	and	CC
cord-254777-h8hw4m9f	80	14	shock	shock	NN
cord-254777-h8hw4m9f	80	15	.	.	.
cord-254777-h8hw4m9f	81	1	Echocardiogram	Echocardiogram	NNP
cord-254777-h8hw4m9f	81	2	findings	finding	NNS
cord-254777-h8hw4m9f	81	3	include	include	VBP
cord-254777-h8hw4m9f	81	4	ventricular	ventricular	JJ
cord-254777-h8hw4m9f	81	5	dysfunction	dysfunction	NN
cord-254777-h8hw4m9f	81	6	and	and	CC
cord-254777-h8hw4m9f	81	7	coronary	coronary	JJ
cord-254777-h8hw4m9f	81	8	artery	artery	NN
cord-254777-h8hw4m9f	81	9	abnormalities	abnormality	NNS
cord-254777-h8hw4m9f	81	10	.	.	.
cord-254777-h8hw4m9f	82	1	Patients	patient	NNS
cord-254777-h8hw4m9f	82	2	with	with	IN
cord-254777-h8hw4m9f	82	3	MIS	MIS	NNP
cord-254777-h8hw4m9f	82	4	-	-	HYPH
cord-254777-h8hw4m9f	82	5	C	C	NNP
cord-254777-h8hw4m9f	82	6	also	also	RB
cord-254777-h8hw4m9f	82	7	have	have	VBP
cord-254777-h8hw4m9f	82	8	evidence	evidence	NN
cord-254777-h8hw4m9f	82	9	of	of	IN
cord-254777-h8hw4m9f	82	10	severe	severe	JJ
cord-254777-h8hw4m9f	82	11	inflammatory	inflammatory	JJ
cord-254777-h8hw4m9f	82	12	state	state	NN
cord-254777-h8hw4m9f	82	13	,	,	,
cord-254777-h8hw4m9f	82	14	with	with	IN
cord-254777-h8hw4m9f	82	15	elevation	elevation	NN
cord-254777-h8hw4m9f	82	16	in	in	IN
cord-254777-h8hw4m9f	82	17	CRP	CRP	NNP
cord-254777-h8hw4m9f	82	18	,	,	,
cord-254777-h8hw4m9f	82	19	ferritin	ferritin	NN
cord-254777-h8hw4m9f	82	20	,	,	,
cord-254777-h8hw4m9f	82	21	D	d	NN
cord-254777-h8hw4m9f	82	22	-	-	HYPH
cord-254777-h8hw4m9f	82	23	dimer	dimer	NN
cord-254777-h8hw4m9f	82	24	,	,	,
cord-254777-h8hw4m9f	82	25	LDH	LDH	NNP
cord-254777-h8hw4m9f	82	26	,	,	,
cord-254777-h8hw4m9f	82	27	pro	pro	JJ
cord-254777-h8hw4m9f	82	28	-	-	JJ
cord-254777-h8hw4m9f	82	29	BNP	bnp	JJ
cord-254777-h8hw4m9f	82	30	and	and	CC
cord-254777-h8hw4m9f	82	31	cardiac	cardiac	JJ
cord-254777-h8hw4m9f	82	32	enzymes	enzyme	NNS
cord-254777-h8hw4m9f	82	33	.	.	.
cord-254777-h8hw4m9f	83	1	Patients	patient	NNS
cord-254777-h8hw4m9f	83	2	may	may	MD
cord-254777-h8hw4m9f	83	3	additionally	additionally	RB
cord-254777-h8hw4m9f	83	4	have	have	VB
cord-254777-h8hw4m9f	83	5	elevated	elevate	VBN
cord-254777-h8hw4m9f	83	6	procalcitonin	procalcitonin	NNS
cord-254777-h8hw4m9f	83	7	,	,	,
cord-254777-h8hw4m9f	83	8	liver	liver	NN
cord-254777-h8hw4m9f	83	9	transaminases	transaminase	NNS
cord-254777-h8hw4m9f	83	10	,	,	,
cord-254777-h8hw4m9f	83	11	anemia	anemia	NN
cord-254777-h8hw4m9f	83	12	,	,	,
cord-254777-h8hw4m9f	83	13	along	along	IN
cord-254777-h8hw4m9f	83	14	with	with	IN
cord-254777-h8hw4m9f	83	15	either	either	DT
cord-254777-h8hw4m9f	83	16	thrombocytopenia	thrombocytopenia	NN
cord-254777-h8hw4m9f	83	17	or	or	CC
cord-254777-h8hw4m9f	83	18	thrombocytosis	thrombocytosis	NN
cord-254777-h8hw4m9f	83	19	[	[	-LRB-
cord-254777-h8hw4m9f	83	20	22	22	CD
cord-254777-h8hw4m9f	83	21	,	,	,
cord-254777-h8hw4m9f	83	22	23	23	CD
cord-254777-h8hw4m9f	83	23	]	]	-RRB-
cord-254777-h8hw4m9f	83	24	.	.	.
cord-254777-h8hw4m9f	84	1	Fortunately	fortunately	RB
cord-254777-h8hw4m9f	84	2	,	,	,
cord-254777-h8hw4m9f	84	3	most	most	JJS
cord-254777-h8hw4m9f	84	4	children	child	NNS
cord-254777-h8hw4m9f	84	5	with	with	IN
cord-254777-h8hw4m9f	84	6	MIS	MIS	NNP
cord-254777-h8hw4m9f	84	7	-	-	HYPH
cord-254777-h8hw4m9f	84	8	C	C	NNP
cord-254777-h8hw4m9f	84	9	have	have	VBP
cord-254777-h8hw4m9f	84	10	recovered	recover	VBN
cord-254777-h8hw4m9f	84	11	,	,	,
cord-254777-h8hw4m9f	84	12	however	however	RB
cord-254777-h8hw4m9f	84	13	few	few	JJ
cord-254777-h8hw4m9f	84	14	deaths	death	NNS
cord-254777-h8hw4m9f	84	15	have	have	VBP
cord-254777-h8hw4m9f	84	16	been	be	VBN
cord-254777-h8hw4m9f	84	17	reported	report	VBN
cord-254777-h8hw4m9f	84	18	[	[	-LRB-
cord-254777-h8hw4m9f	84	19	22	22	CD
cord-254777-h8hw4m9f	84	20	]	]	-RRB-
cord-254777-h8hw4m9f	84	21	.	.	.
cord-254777-h8hw4m9f	85	1	Although	although	IN
cord-254777-h8hw4m9f	85	2	some	some	DT
cord-254777-h8hw4m9f	85	3	children	child	NNS
cord-254777-h8hw4m9f	85	4	are	be	VBP
cord-254777-h8hw4m9f	85	5	SARS	SARS	NNP
cord-254777-h8hw4m9f	85	6	-	-	HYPH
cord-254777-h8hw4m9f	85	7	CoV-2	CoV-2	NNP
cord-254777-h8hw4m9f	85	8	PCR	PCR	NNP
cord-254777-h8hw4m9f	85	9	positive	positive	JJ
cord-254777-h8hw4m9f	85	10	,	,	,
cord-254777-h8hw4m9f	85	11	most	most	JJS
cord-254777-h8hw4m9f	85	12	are	be	VBP
cord-254777-h8hw4m9f	85	13	PCR	PCR	NNP
cord-254777-h8hw4m9f	85	14	negative	negative	JJ
cord-254777-h8hw4m9f	85	15	and	and	CC
cord-254777-h8hw4m9f	85	16	IgG	IgG	NNP
cord-254777-h8hw4m9f	85	17	antibody	antibody	NN
cord-254777-h8hw4m9f	85	18	positive	positive	JJ
cord-254777-h8hw4m9f	85	19	,	,	,
cord-254777-h8hw4m9f	85	20	supporting	support	VBG
cord-254777-h8hw4m9f	85	21	the	the	DT
cord-254777-h8hw4m9f	85	22	hypothesis	hypothesis	NN
cord-254777-h8hw4m9f	85	23	that	that	IN
cord-254777-h8hw4m9f	85	24	MIS	MIS	NNP
cord-254777-h8hw4m9f	85	25	-	-	HYPH
cord-254777-h8hw4m9f	85	26	C	C	NNP
cord-254777-h8hw4m9f	85	27	might	may	MD
cord-254777-h8hw4m9f	85	28	represent	represent	VB
cord-254777-h8hw4m9f	85	29	a	a	DT
cord-254777-h8hw4m9f	85	30	delayed	delay	VBN
cord-254777-h8hw4m9f	85	31	inflammatory	inflammatory	JJ
cord-254777-h8hw4m9f	85	32	process	process	NN
cord-254777-h8hw4m9f	85	33	.	.	.
cord-254777-h8hw4m9f	86	1	The	the	DT
cord-254777-h8hw4m9f	86	2	use	use	NN
cord-254777-h8hw4m9f	86	3	of	of	IN
cord-254777-h8hw4m9f	86	4	steroids	steroid	NNS
cord-254777-h8hw4m9f	86	5	in	in	IN
cord-254777-h8hw4m9f	86	6	treatment	treatment	NN
cord-254777-h8hw4m9f	86	7	of	of	IN
cord-254777-h8hw4m9f	86	8	SARS	SARS	NNP
cord-254777-h8hw4m9f	86	9	-	-	HYPH
cord-254777-h8hw4m9f	86	10	CoV-2	CoV-2	NNP
cord-254777-h8hw4m9f	86	11	is	be	VBZ
cord-254777-h8hw4m9f	86	12	controversial	controversial	JJ
cord-254777-h8hw4m9f	86	13	.	.	.
cord-254777-h8hw4m9f	87	1	Steroids	steroid	NNS
cord-254777-h8hw4m9f	87	2	suppress	suppress	VBP
cord-254777-h8hw4m9f	87	3	lung	lung	NN
cord-254777-h8hw4m9f	87	4	inflammation	inflammation	NN
cord-254777-h8hw4m9f	87	5	and	and	CC
cord-254777-h8hw4m9f	87	6	cytokine	cytokine	NN
cord-254777-h8hw4m9f	87	7	storm	storm	NN
cord-254777-h8hw4m9f	87	8	but	but	CC
cord-254777-h8hw4m9f	87	9	can	can	MD
cord-254777-h8hw4m9f	87	10	also	also	RB
cord-254777-h8hw4m9f	87	11	increase	increase	VB
cord-254777-h8hw4m9f	87	12	secondary	secondary	JJ
cord-254777-h8hw4m9f	87	13	infection	infection	NN
cord-254777-h8hw4m9f	87	14	rate	rate	NN
cord-254777-h8hw4m9f	87	15	and	and	CC
cord-254777-h8hw4m9f	87	16	delay	delay	VB
cord-254777-h8hw4m9f	87	17	viral	viral	JJ
cord-254777-h8hw4m9f	87	18	clearance	clearance	NN
cord-254777-h8hw4m9f	87	19	.	.	.
cord-254777-h8hw4m9f	88	1	Steroids	steroid	NNS
cord-254777-h8hw4m9f	88	2	are	be	VBP
cord-254777-h8hw4m9f	88	3	recommended	recommend	VBN
cord-254777-h8hw4m9f	88	4	by	by	IN
cord-254777-h8hw4m9f	88	5	Society	Society	NNP
cord-254777-h8hw4m9f	88	6	of	of	IN
cord-254777-h8hw4m9f	88	7	Critical	Critical	NNP
cord-254777-h8hw4m9f	88	8	Care	Care	NNP
cord-254777-h8hw4m9f	88	9	Medicine	Medicine	NNP
cord-254777-h8hw4m9f	88	10	(	(	-LRB-
cord-254777-h8hw4m9f	88	11	SCCM	SCCM	NNP
cord-254777-h8hw4m9f	88	12	)	)	-RRB-
cord-254777-h8hw4m9f	88	13	and	and	CC
cord-254777-h8hw4m9f	88	14	European	European	NNP
cord-254777-h8hw4m9f	88	15	Society	Society	NNP
cord-254777-h8hw4m9f	88	16	of	of	IN
cord-254777-h8hw4m9f	88	17	Intensive	Intensive	NNP
cord-254777-h8hw4m9f	88	18	Care	Care	NNP
cord-254777-h8hw4m9f	88	19	Medicine	Medicine	NNP
cord-254777-h8hw4m9f	88	20	(	(	-LRB-
cord-254777-h8hw4m9f	88	21	ESICM	ESICM	NNP
cord-254777-h8hw4m9f	88	22	)	)	-RRB-
cord-254777-h8hw4m9f	88	23	for	for	IN
cord-254777-h8hw4m9f	88	24	patients	patient	NNS
cord-254777-h8hw4m9f	88	25	with	with	IN
cord-254777-h8hw4m9f	88	26	early	early	JJ
cord-254777-h8hw4m9f	88	27	moderate	moderate	JJ
cord-254777-h8hw4m9f	88	28	to	to	IN
cord-254777-h8hw4m9f	88	29	severe	severe	JJ
cord-254777-h8hw4m9f	88	30	ARDS	ARDS	NNP
cord-254777-h8hw4m9f	88	31	[	[	-LRB-
cord-254777-h8hw4m9f	88	32	26	26	CD
cord-254777-h8hw4m9f	88	33	]	]	-RRB-
cord-254777-h8hw4m9f	88	34	.	.	.
cord-254777-h8hw4m9f	89	1	For	for	IN
cord-254777-h8hw4m9f	89	2	treatment	treatment	NN
cord-254777-h8hw4m9f	89	3	of	of	IN
cord-254777-h8hw4m9f	89	4	sepsis	sepsis	NN
cord-254777-h8hw4m9f	89	5	and	and	CC
cord-254777-h8hw4m9f	89	6	septic	septic	JJ
cord-254777-h8hw4m9f	89	7	shock	shock	NN
cord-254777-h8hw4m9f	89	8	,	,	,
cord-254777-h8hw4m9f	89	9	corticosteroids	corticosteroid	NNS
cord-254777-h8hw4m9f	89	10	may	may	MD
cord-254777-h8hw4m9f	89	11	be	be	VB
cord-254777-h8hw4m9f	89	12	used	use	VBN
cord-254777-h8hw4m9f	89	13	in	in	IN
cord-254777-h8hw4m9f	89	14	patients	patient	NNS
cord-254777-h8hw4m9f	89	15	refractory	refractory	JJ
cord-254777-h8hw4m9f	89	16	to	to	IN
cord-254777-h8hw4m9f	89	17	fluid	fluid	NN
cord-254777-h8hw4m9f	89	18	and	and	CC
cord-254777-h8hw4m9f	89	19	vasopressor	vasopressor	NN
cord-254777-h8hw4m9f	89	20	therapy	therapy	NN
cord-254777-h8hw4m9f	89	21	,	,	,
cord-254777-h8hw4m9f	89	22	however	however	RB
cord-254777-h8hw4m9f	89	23	guidelines	guideline	NNS
cord-254777-h8hw4m9f	89	24	emphasize	emphasize	VBP
cord-254777-h8hw4m9f	89	25	using	use	VBG
cord-254777-h8hw4m9f	89	26	low	low	JJ
cord-254777-h8hw4m9f	89	27	dosages	dosage	NNS
cord-254777-h8hw4m9f	89	28	and	and	CC
cord-254777-h8hw4m9f	89	29	short	short	JJ
cord-254777-h8hw4m9f	89	30	-	-	HYPH
cord-254777-h8hw4m9f	89	31	term	term	NN
cord-254777-h8hw4m9f	89	32	application	application	NN
cord-254777-h8hw4m9f	89	33	[	[	-LRB-
cord-254777-h8hw4m9f	89	34	27	27	CD
cord-254777-h8hw4m9f	89	35	]	]	-RRB-
cord-254777-h8hw4m9f	89	36	.	.	.
cord-254777-h8hw4m9f	90	1	Steroids	steroid	NNS
cord-254777-h8hw4m9f	90	2	were	be	VBD
cord-254777-h8hw4m9f	90	3	the	the	DT
cord-254777-h8hw4m9f	90	4	main	main	JJ
cord-254777-h8hw4m9f	90	5	immunomodulatory	immunomodulatory	JJ
cord-254777-h8hw4m9f	90	6	medication	medication	NN
cord-254777-h8hw4m9f	90	7	used	use	VBN
cord-254777-h8hw4m9f	90	8	during	during	IN
cord-254777-h8hw4m9f	90	9	the	the	DT
cord-254777-h8hw4m9f	90	10	2003	2003	CD
cord-254777-h8hw4m9f	90	11	SARS	SARS	NNP
cord-254777-h8hw4m9f	90	12	epidemic	epidemic	NN
cord-254777-h8hw4m9f	90	13	,	,	,
cord-254777-h8hw4m9f	90	14	however	however	WRB
cord-254777-h8hw4m9f	90	15	later	later	RB
cord-254777-h8hw4m9f	90	16	studies	study	NNS
cord-254777-h8hw4m9f	90	17	did	do	VBD
cord-254777-h8hw4m9f	90	18	not	not	RB
cord-254777-h8hw4m9f	90	19	show	show	VB
cord-254777-h8hw4m9f	90	20	beneficial	beneficial	JJ
cord-254777-h8hw4m9f	90	21	effects	effect	NNS
cord-254777-h8hw4m9f	90	22	and	and	CC
cord-254777-h8hw4m9f	90	23	delayed	delay	VBN
cord-254777-h8hw4m9f	90	24	viral	viral	JJ
cord-254777-h8hw4m9f	90	25	clearance	clearance	NN
cord-254777-h8hw4m9f	90	26	.	.	.
cord-254777-h8hw4m9f	91	1	Similarly	similarly	RB
cord-254777-h8hw4m9f	91	2	,	,	,
cord-254777-h8hw4m9f	91	3	a	a	DT
cord-254777-h8hw4m9f	91	4	review	review	NN
cord-254777-h8hw4m9f	91	5	by	by	IN
cord-254777-h8hw4m9f	91	6	Russel	Russel	NNP
cord-254777-h8hw4m9f	91	7	et	et	NNP
cord-254777-h8hw4m9f	91	8	al	al	NNP
cord-254777-h8hw4m9f	91	9	[	[	-LRB-
cord-254777-h8hw4m9f	91	10	28	28	CD
cord-254777-h8hw4m9f	91	11	]	]	-RRB-
cord-254777-h8hw4m9f	91	12	,	,	,
cord-254777-h8hw4m9f	91	13	showed	show	VBD
cord-254777-h8hw4m9f	91	14	no	no	DT
cord-254777-h8hw4m9f	91	15	evidence	evidence	NN
cord-254777-h8hw4m9f	91	16	of	of	IN
cord-254777-h8hw4m9f	91	17	benefit	benefit	NN
cord-254777-h8hw4m9f	91	18	for	for	IN
cord-254777-h8hw4m9f	91	19	use	use	NN
cord-254777-h8hw4m9f	91	20	of	of	IN
cord-254777-h8hw4m9f	91	21	corticosteroids	corticosteroid	NNS
cord-254777-h8hw4m9f	91	22	in	in	IN
cord-254777-h8hw4m9f	91	23	MERS	MERS	NNP
cord-254777-h8hw4m9f	91	24	,	,	,
cord-254777-h8hw4m9f	91	25	SARS	SARS	NNP
cord-254777-h8hw4m9f	91	26	,	,	,
cord-254777-h8hw4m9f	91	27	influenza	influenza	NN
cord-254777-h8hw4m9f	91	28	or	or	CC
cord-254777-h8hw4m9f	91	29	RSV	RSV	NNP
cord-254777-h8hw4m9f	91	30	.	.	.
cord-254777-h8hw4m9f	92	1	Studies	study	NNS
cord-254777-h8hw4m9f	92	2	about	about	IN
cord-254777-h8hw4m9f	92	3	steroid	steroid	NN
cord-254777-h8hw4m9f	92	4	use	use	NN
cord-254777-h8hw4m9f	92	5	in	in	IN
cord-254777-h8hw4m9f	92	6	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	92	7	infection	infection	NN
cord-254777-h8hw4m9f	92	8	are	be	VBP
cord-254777-h8hw4m9f	92	9	also	also	RB
cord-254777-h8hw4m9f	92	10	mixed	mixed	JJ
cord-254777-h8hw4m9f	92	11	.	.	.
cord-254777-h8hw4m9f	93	1	Chen	Chen	NNP
cord-254777-h8hw4m9f	93	2	et	et	NNP
cord-254777-h8hw4m9f	93	3	al	al	NNP
cord-254777-h8hw4m9f	93	4	[	[	-LRB-
cord-254777-h8hw4m9f	93	5	29	29	CD
cord-254777-h8hw4m9f	93	6	]	]	-RRB-
cord-254777-h8hw4m9f	93	7	reported	report	VBN
cord-254777-h8hw4m9f	93	8	use	use	NN
cord-254777-h8hw4m9f	93	9	of	of	IN
cord-254777-h8hw4m9f	93	10	steroids	steroid	NNS
cord-254777-h8hw4m9f	93	11	in	in	IN
cord-254777-h8hw4m9f	93	12	19	19	CD
cord-254777-h8hw4m9f	93	13	(	(	-LRB-
cord-254777-h8hw4m9f	93	14	19	19	CD
cord-254777-h8hw4m9f	93	15	%	%	NN
cord-254777-h8hw4m9f	93	16	)	)	-RRB-
cord-254777-h8hw4m9f	93	17	of	of	IN
cord-254777-h8hw4m9f	93	18	their	-PRON-	PRP$
cord-254777-h8hw4m9f	93	19	cohort	cohort	NN
cord-254777-h8hw4m9f	93	20	and	and	CC
cord-254777-h8hw4m9f	93	21	recommend	recommend	VB
cord-254777-h8hw4m9f	93	22	it	-PRON-	PRP
cord-254777-h8hw4m9f	93	23	for	for	IN
cord-254777-h8hw4m9f	93	24	patients	patient	NNS
cord-254777-h8hw4m9f	93	25	with	with	IN
cord-254777-h8hw4m9f	93	26	ARDS	ARDS	NNP
cord-254777-h8hw4m9f	93	27	for	for	IN
cord-254777-h8hw4m9f	93	28	as	as	RB
cord-254777-h8hw4m9f	93	29	short	short	JJ
cord-254777-h8hw4m9f	93	30	a	a	DT
cord-254777-h8hw4m9f	93	31	duration	duration	NN
cord-254777-h8hw4m9f	93	32	as	as	IN
cord-254777-h8hw4m9f	93	33	possible	possible	JJ
cord-254777-h8hw4m9f	93	34	.	.	.
cord-254777-h8hw4m9f	94	1	Similarly	similarly	RB
cord-254777-h8hw4m9f	94	2	,	,	,
cord-254777-h8hw4m9f	94	3	Wu	Wu	NNP
cord-254777-h8hw4m9f	94	4	et	et	NNP
cord-254777-h8hw4m9f	94	5	al	al	NNP
cord-254777-h8hw4m9f	94	6	[	[	-LRB-
cord-254777-h8hw4m9f	94	7	30	30	CD
cord-254777-h8hw4m9f	94	8	]	]	-RRB-
cord-254777-h8hw4m9f	94	9	described	describe	VBD
cord-254777-h8hw4m9f	94	10	that	that	IN
cord-254777-h8hw4m9f	94	11	the	the	DT
cord-254777-h8hw4m9f	94	12	administration	administration	NN
cord-254777-h8hw4m9f	94	13	of	of	IN
cord-254777-h8hw4m9f	94	14	methylprednisolone	methylprednisolone	NNP
cord-254777-h8hw4m9f	94	15	appears	appear	VBZ
cord-254777-h8hw4m9f	94	16	to	to	TO
cord-254777-h8hw4m9f	94	17	have	have	VB
cord-254777-h8hw4m9f	94	18	reduced	reduce	VBN
cord-254777-h8hw4m9f	94	19	the	the	DT
cord-254777-h8hw4m9f	94	20	risk	risk	NN
cord-254777-h8hw4m9f	94	21	of	of	IN
cord-254777-h8hw4m9f	94	22	death	death	NN
cord-254777-h8hw4m9f	94	23	in	in	IN
cord-254777-h8hw4m9f	94	24	patients	patient	NNS
cord-254777-h8hw4m9f	94	25	with	with	IN
cord-254777-h8hw4m9f	94	26	ARDS	ARDS	NNP
cord-254777-h8hw4m9f	94	27	(	(	-LRB-
cord-254777-h8hw4m9f	94	28	HR	HR	NNP
cord-254777-h8hw4m9f	94	29	,	,	,
cord-254777-h8hw4m9f	94	30	0.38	0.38	CD
cord-254777-h8hw4m9f	94	31	;	;	:
cord-254777-h8hw4m9f	94	32	95	95	CD
cord-254777-h8hw4m9f	94	33	%	%	NN
cord-254777-h8hw4m9f	94	34	CI	ci	NN
cord-254777-h8hw4m9f	94	35	,	,	,
cord-254777-h8hw4m9f	94	36	0.20	0.20	CD
cord-254777-h8hw4m9f	94	37	-	-	HYPH
cord-254777-h8hw4m9f	94	38	0.72	0.72	CD
cord-254777-h8hw4m9f	94	39	;	;	:
cord-254777-h8hw4m9f	94	40	P=	p=	NN
cord-254777-h8hw4m9f	94	41	.003	.003	CD
cord-254777-h8hw4m9f	94	42	)	)	-RRB-
cord-254777-h8hw4m9f	94	43	and	and	CC
cord-254777-h8hw4m9f	94	44	Wang	Wang	NNP
cord-254777-h8hw4m9f	94	45	et	et	NNP
cord-254777-h8hw4m9f	94	46	al	al	NNP
cord-254777-h8hw4m9f	94	47	[	[	-LRB-
cord-254777-h8hw4m9f	94	48	31	31	CD
cord-254777-h8hw4m9f	94	49	]	]	-RRB-
cord-254777-h8hw4m9f	94	50	reported	report	VBD
cord-254777-h8hw4m9f	94	51	that	that	IN
cord-254777-h8hw4m9f	94	52	patients	patient	NNS
cord-254777-h8hw4m9f	94	53	receiving	receive	VBG
cord-254777-h8hw4m9f	94	54	intravenous	intravenous	JJ
cord-254777-h8hw4m9f	94	55	methylprednisolone	methylprednisolone	NN
cord-254777-h8hw4m9f	94	56	at	at	IN
cord-254777-h8hw4m9f	94	57	a	a	DT
cord-254777-h8hw4m9f	94	58	dose	dose	NN
cord-254777-h8hw4m9f	94	59	of	of	IN
cord-254777-h8hw4m9f	94	60	1	1	CD
cord-254777-h8hw4m9f	94	61	-	-	HYPH
cord-254777-h8hw4m9f	94	62	2mg	2mg	NNP
cord-254777-h8hw4m9f	94	63	/	/	SYM
cord-254777-h8hw4m9f	94	64	kg	kg	NNS
cord-254777-h8hw4m9f	94	65	had	have	VBD
cord-254777-h8hw4m9f	94	66	shorter	short	JJR
cord-254777-h8hw4m9f	94	67	duration	duration	NN
cord-254777-h8hw4m9f	94	68	of	of	IN
cord-254777-h8hw4m9f	94	69	oxygen	oxygen	NN
cord-254777-h8hw4m9f	94	70	supplementation	supplementation	NN
cord-254777-h8hw4m9f	94	71	(	(	-LRB-
cord-254777-h8hw4m9f	94	72	8.2	8.2	CD
cord-254777-h8hw4m9f	94	73	days	day	NNS
cord-254777-h8hw4m9f	94	74	vs.	vs.	CC
cord-254777-h8hw4m9f	94	75	13.5	13.5	CD
cord-254777-h8hw4m9f	94	76	days	day	NNS
cord-254777-h8hw4m9f	94	77	;	;	:
cord-254777-h8hw4m9f	94	78	p	p	NN
cord-254777-h8hw4m9f	94	79	<	<	XX
cord-254777-h8hw4m9f	94	80	0.001	0.001	CD
cord-254777-h8hw4m9f	94	81	)	)	-RRB-
cord-254777-h8hw4m9f	94	82	.	.	.
cord-254777-h8hw4m9f	95	1	In	in	IN
cord-254777-h8hw4m9f	95	2	contrast	contrast	NN
cord-254777-h8hw4m9f	95	3	,	,	,
cord-254777-h8hw4m9f	95	4	Wang	Wang	NNP
cord-254777-h8hw4m9f	95	5	et	et	NNP
cord-254777-h8hw4m9f	95	6	al	al	NNP
cord-254777-h8hw4m9f	95	7	[	[	-LRB-
cord-254777-h8hw4m9f	95	8	32	32	CD
cord-254777-h8hw4m9f	95	9	]	]	-RRB-
cord-254777-h8hw4m9f	95	10	described	describe	VBD
cord-254777-h8hw4m9f	95	11	a	a	DT
cord-254777-h8hw4m9f	95	12	cohort	cohort	NN
cord-254777-h8hw4m9f	95	13	study	study	NN
cord-254777-h8hw4m9f	95	14	in	in	IN
cord-254777-h8hw4m9f	95	15	which	which	WDT
cord-254777-h8hw4m9f	95	16	the	the	DT
cord-254777-h8hw4m9f	95	17	45	45	CD
cord-254777-h8hw4m9f	95	18	%	%	NN
cord-254777-h8hw4m9f	95	19	of	of	IN
cord-254777-h8hw4m9f	95	20	patients	patient	NNS
cord-254777-h8hw4m9f	95	21	receiving	receive	VBG
cord-254777-h8hw4m9f	95	22	methylprednisolone	methylprednisolone	NN
cord-254777-h8hw4m9f	95	23	demonstrated	demonstrate	VBD
cord-254777-h8hw4m9f	95	24	"	"	``
cord-254777-h8hw4m9f	95	25	no	no	DT
cord-254777-h8hw4m9f	95	26	effective	effective	JJ
cord-254777-h8hw4m9f	95	27	outcomes	outcome	NNS
cord-254777-h8hw4m9f	95	28	"	"	''
cord-254777-h8hw4m9f	95	29	and	and	CC
cord-254777-h8hw4m9f	96	1	Zhou	Zhou	NNP
cord-254777-h8hw4m9f	96	2	et	et	NNP
cord-254777-h8hw4m9f	96	3	al	al	NNP
cord-254777-h8hw4m9f	96	4	[	[	-LRB-
cord-254777-h8hw4m9f	96	5	33	33	CD
cord-254777-h8hw4m9f	96	6	]	]	-RRB-
cord-254777-h8hw4m9f	96	7	reported	report	VBN
cord-254777-h8hw4m9f	96	8	on	on	IN
cord-254777-h8hw4m9f	96	9	15	15	CD
cord-254777-h8hw4m9f	96	10	patients	patient	NNS
cord-254777-h8hw4m9f	96	11	with	with	IN
cord-254777-h8hw4m9f	96	12	moderate	moderate	JJ
cord-254777-h8hw4m9f	96	13	-	-	HYPH
cord-254777-h8hw4m9f	96	14	severe	severe	JJ
cord-254777-h8hw4m9f	96	15	ARDS	ARDS	NNP
cord-254777-h8hw4m9f	96	16	potential	potential	JJ
cord-254777-h8hw4m9f	96	17	benefit	benefit	NN
cord-254777-h8hw4m9f	96	18	with	with	IN
cord-254777-h8hw4m9f	96	19	corticosteroids	corticosteroid	NNS
cord-254777-h8hw4m9f	96	20	but	but	CC
cord-254777-h8hw4m9f	96	21	no	no	DT
cord-254777-h8hw4m9f	96	22	improvement	improvement	NN
cord-254777-h8hw4m9f	96	23	in	in	IN
cord-254777-h8hw4m9f	96	24	overall	overall	JJ
cord-254777-h8hw4m9f	96	25	survival	survival	NN
cord-254777-h8hw4m9f	96	26	.	.	.
cord-254777-h8hw4m9f	97	1	Zhou	Zhou	NNP
cord-254777-h8hw4m9f	97	2	et	et	NNP
cord-254777-h8hw4m9f	97	3	al	al	NNP
cord-254777-h8hw4m9f	97	4	[	[	-LRB-
cord-254777-h8hw4m9f	97	5	33	33	CD
cord-254777-h8hw4m9f	97	6	]	]	-RRB-
cord-254777-h8hw4m9f	97	7	discuss	discuss	VB
cord-254777-h8hw4m9f	97	8	the	the	DT
cord-254777-h8hw4m9f	97	9	role	role	NN
cord-254777-h8hw4m9f	97	10	of	of	IN
cord-254777-h8hw4m9f	97	11	corticosteroids	corticosteroid	NNS
cord-254777-h8hw4m9f	97	12	in	in	IN
cord-254777-h8hw4m9f	97	13	severe	severe	JJ
cord-254777-h8hw4m9f	97	14	COVID-19	covid-19	JJ
cord-254777-h8hw4m9f	97	15	infection	infection	NN
cord-254777-h8hw4m9f	97	16	based	base	VBN
cord-254777-h8hw4m9f	97	17	on	on	IN
cord-254777-h8hw4m9f	97	18	observations	observation	NNS
cord-254777-h8hw4m9f	97	19	of	of	IN
cord-254777-h8hw4m9f	97	20	early	early	JJ
cord-254777-h8hw4m9f	97	21	cases	case	NNS
cord-254777-h8hw4m9f	97	22	from	from	IN
cord-254777-h8hw4m9f	97	23	Wuhan	Wuhan	NNP
cord-254777-h8hw4m9f	97	24	and	and	CC
cord-254777-h8hw4m9f	97	25	recommend	recommend	VB
cord-254777-h8hw4m9f	97	26	short	short	JJ
cord-254777-h8hw4m9f	97	27	duration	duration	NN
cord-254777-h8hw4m9f	97	28	and	and	CC
cord-254777-h8hw4m9f	97	29	lower	low	JJR
cord-254777-h8hw4m9f	97	30	dose	dose	NN
cord-254777-h8hw4m9f	97	31	treatment	treatment	NN
cord-254777-h8hw4m9f	97	32	(	(	-LRB-
cord-254777-h8hw4m9f	97	33	<	<	NNP
cord-254777-h8hw4m9f	97	34	1mg	1mg	NNP
cord-254777-h8hw4m9f	97	35	/	/	SYM
cord-254777-h8hw4m9f	97	36	kg	kg	NN
cord-254777-h8hw4m9f	97	37	body	body	NN
cord-254777-h8hw4m9f	97	38	weight	weight	NN
cord-254777-h8hw4m9f	97	39	,	,	,
cord-254777-h8hw4m9f	97	40	up	up	IN
cord-254777-h8hw4m9f	97	41	to	to	TO
cord-254777-h8hw4m9f	97	42	7	7	CD
cord-254777-h8hw4m9f	97	43	days	day	NNS
cord-254777-h8hw4m9f	97	44	)	)	-RRB-
cord-254777-h8hw4m9f	97	45	for	for	IN
cord-254777-h8hw4m9f	97	46	severely	severely	RB
cord-254777-h8hw4m9f	97	47	ill	ill	JJ
cord-254777-h8hw4m9f	97	48	patients	patient	NNS
cord-254777-h8hw4m9f	97	49	[	[	-LRB-
cord-254777-h8hw4m9f	97	50	33	33	CD
cord-254777-h8hw4m9f	97	51	]	]	-RRB-
cord-254777-h8hw4m9f	97	52	.	.	.
cord-254777-h8hw4m9f	98	1	Current	current	JJ
cord-254777-h8hw4m9f	98	2	NIH	NIH	NNP
cord-254777-h8hw4m9f	98	3	recommendations	recommendation	NNS
cord-254777-h8hw4m9f	98	4	are	be	VBP
cord-254777-h8hw4m9f	98	5	against	against	IN
cord-254777-h8hw4m9f	98	6	routine	routine	JJ
cord-254777-h8hw4m9f	98	7	use	use	NN
cord-254777-h8hw4m9f	98	8	of	of	IN
cord-254777-h8hw4m9f	98	9	systemic	systemic	JJ
cord-254777-h8hw4m9f	98	10	corticosteroids	corticosteroid	NNS
cord-254777-h8hw4m9f	98	11	in	in	IN
cord-254777-h8hw4m9f	98	12	hospitalized	hospitalize	VBN
cord-254777-h8hw4m9f	98	13	patients	patient	NNS
cord-254777-h8hw4m9f	98	14	unless	unless	IN
cord-254777-h8hw4m9f	98	15	they	-PRON-	PRP
cord-254777-h8hw4m9f	98	16	are	be	VBP
cord-254777-h8hw4m9f	98	17	in	in	IN
cord-254777-h8hw4m9f	98	18	ICU	ICU	NNP
cord-254777-h8hw4m9f	98	19	,	,	,
cord-254777-h8hw4m9f	98	20	as	as	RB
cord-254777-h8hw4m9f	98	21	well	well	RB
cord-254777-h8hw4m9f	98	22	as	as	IN
cord-254777-h8hw4m9f	98	23	against	against	IN
cord-254777-h8hw4m9f	98	24	use	use	NN
cord-254777-h8hw4m9f	98	25	in	in	IN
cord-254777-h8hw4m9f	98	26	mechanically	mechanically	RB
cord-254777-h8hw4m9f	98	27	ventilated	ventilate	VBN
cord-254777-h8hw4m9f	98	28	patients	patient	NNS
cord-254777-h8hw4m9f	98	29	without	without	IN
cord-254777-h8hw4m9f	98	30	ARDS	ARDS	NNP
cord-254777-h8hw4m9f	98	31	.	.	.
cord-254777-h8hw4m9f	99	1	For	for	IN
cord-254777-h8hw4m9f	99	2	patients	patient	NNS
cord-254777-h8hw4m9f	99	3	that	that	WDT
cord-254777-h8hw4m9f	99	4	are	be	VBP
cord-254777-h8hw4m9f	99	5	mechanically	mechanically	RB
cord-254777-h8hw4m9f	99	6	ventilated	ventilate	VBN
cord-254777-h8hw4m9f	99	7	with	with	IN
cord-254777-h8hw4m9f	99	8	ARDS	ARDS	NNP
cord-254777-h8hw4m9f	99	9	,	,	,
cord-254777-h8hw4m9f	99	10	NIH	NIH	NNP
cord-254777-h8hw4m9f	99	11	states	state	VBZ
cord-254777-h8hw4m9f	99	12	that	that	IN
cord-254777-h8hw4m9f	99	13	there	there	EX
cord-254777-h8hw4m9f	99	14	is	be	VBZ
cord-254777-h8hw4m9f	99	15	insufficient	insufficient	JJ
cord-254777-h8hw4m9f	99	16	evidence	evidence	NN
cord-254777-h8hw4m9f	99	17	for	for	IN
cord-254777-h8hw4m9f	99	18	or	or	CC
cord-254777-h8hw4m9f	99	19	against	against	IN
cord-254777-h8hw4m9f	99	20	use	use	NN
cord-254777-h8hw4m9f	99	21	of	of	IN
cord-254777-h8hw4m9f	99	22	corticosteroids	corticosteroid	NNS
cord-254777-h8hw4m9f	99	23	.	.	.
cord-254777-h8hw4m9f	100	1	The	the	DT
cord-254777-h8hw4m9f	100	2	role	role	NN
cord-254777-h8hw4m9f	100	3	of	of	IN
cord-254777-h8hw4m9f	100	4	corticosteroids	corticosteroid	NNS
cord-254777-h8hw4m9f	100	5	in	in	IN
cord-254777-h8hw4m9f	100	6	children	child	NNS
cord-254777-h8hw4m9f	100	7	with	with	IN
cord-254777-h8hw4m9f	100	8	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	100	9	or	or	CC
cord-254777-h8hw4m9f	100	10	MIS	MIS	NNP
cord-254777-h8hw4m9f	100	11	-	-	HYPH
cord-254777-h8hw4m9f	100	12	C	C	NNP
cord-254777-h8hw4m9f	100	13	has	have	VBZ
cord-254777-h8hw4m9f	100	14	yet	yet	RB
cord-254777-h8hw4m9f	100	15	to	to	TO
cord-254777-h8hw4m9f	100	16	be	be	VB
cord-254777-h8hw4m9f	100	17	fully	fully	RB
cord-254777-h8hw4m9f	100	18	elucidated	elucidate	VBN
cord-254777-h8hw4m9f	100	19	.	.	.
cord-254777-h8hw4m9f	101	1	Interleukin	interleukin	NN
cord-254777-h8hw4m9f	101	2	6	6	CD
cord-254777-h8hw4m9f	101	3	(	(	-LRB-
cord-254777-h8hw4m9f	101	4	IL-6	IL-6	NNP
cord-254777-h8hw4m9f	101	5	)	)	-RRB-
cord-254777-h8hw4m9f	101	6	is	be	VBZ
cord-254777-h8hw4m9f	101	7	a	a	DT
cord-254777-h8hw4m9f	101	8	soluble	soluble	JJ
cord-254777-h8hw4m9f	101	9	factor	factor	NN
cord-254777-h8hw4m9f	101	10	secreted	secrete	VBN
cord-254777-h8hw4m9f	101	11	by	by	IN
cord-254777-h8hw4m9f	101	12	T	T	NNP
cord-254777-h8hw4m9f	101	13	lymphocytes	lymphocyte	NNS
cord-254777-h8hw4m9f	101	14	,	,	,
cord-254777-h8hw4m9f	101	15	shown	show	VBN
cord-254777-h8hw4m9f	101	16	to	to	TO
cord-254777-h8hw4m9f	101	17	be	be	VB
cord-254777-h8hw4m9f	101	18	important	important	JJ
cord-254777-h8hw4m9f	101	19	for	for	IN
cord-254777-h8hw4m9f	101	20	antibody	antibody	NN
cord-254777-h8hw4m9f	101	21	production	production	NN
cord-254777-h8hw4m9f	101	22	by	by	IN
cord-254777-h8hw4m9f	101	23	B	b	NN
cord-254777-h8hw4m9f	101	24	cells	cell	NNS
cord-254777-h8hw4m9f	101	25	,	,	,
cord-254777-h8hw4m9f	101	26	as	as	RB
cord-254777-h8hw4m9f	101	27	well	well	RB
cord-254777-h8hw4m9f	101	28	as	as	IN
cord-254777-h8hw4m9f	101	29	activation	activation	NN
cord-254777-h8hw4m9f	101	30	of	of	IN
cord-254777-h8hw4m9f	101	31	both	both	CC
cord-254777-h8hw4m9f	101	32	local	local	JJ
cord-254777-h8hw4m9f	101	33	and	and	CC
cord-254777-h8hw4m9f	101	34	systemic	systemic	JJ
cord-254777-h8hw4m9f	101	35	inflammatory	inflammatory	JJ
cord-254777-h8hw4m9f	101	36	pathways	pathway	NNS
cord-254777-h8hw4m9f	101	37	[	[	-LRB-
cord-254777-h8hw4m9f	101	38	34	34	CD
cord-254777-h8hw4m9f	101	39	]	]	-RRB-
cord-254777-h8hw4m9f	101	40	.	.	.
cord-254777-h8hw4m9f	102	1	IL-6	IL-6	NNP
cord-254777-h8hw4m9f	102	2	binds	bind	VBZ
cord-254777-h8hw4m9f	102	3	to	to	IN
cord-254777-h8hw4m9f	102	4	a	a	DT
cord-254777-h8hw4m9f	102	5	membrane	membrane	NN
cord-254777-h8hw4m9f	102	6	receptor	receptor	NN
cord-254777-h8hw4m9f	102	7	or	or	CC
cord-254777-h8hw4m9f	102	8	a	a	DT
cord-254777-h8hw4m9f	102	9	soluble	soluble	JJ
cord-254777-h8hw4m9f	102	10	receptor	receptor	NN
cord-254777-h8hw4m9f	102	11	and	and	CC
cord-254777-h8hw4m9f	102	12	leads	lead	VBZ
cord-254777-h8hw4m9f	102	13	to	to	IN
cord-254777-h8hw4m9f	102	14	gp130	gp130	NNS
cord-254777-h8hw4m9f	102	15	dimerization	dimerization	NN
cord-254777-h8hw4m9f	102	16	,	,	,
cord-254777-h8hw4m9f	102	17	phosphorylation	phosphorylation	NN
cord-254777-h8hw4m9f	102	18	,	,	,
cord-254777-h8hw4m9f	102	19	and	and	CC
cord-254777-h8hw4m9f	102	20	activation	activation	NN
cord-254777-h8hw4m9f	102	21	of	of	IN
cord-254777-h8hw4m9f	102	22	receptor	receptor	NN
cord-254777-h8hw4m9f	102	23	-	-	HYPH
cord-254777-h8hw4m9f	102	24	associated	associate	VBN
cord-254777-h8hw4m9f	102	25	kinases	kinase	NNS
cord-254777-h8hw4m9f	102	26	[	[	-LRB-
cord-254777-h8hw4m9f	102	27	35	35	CD
cord-254777-h8hw4m9f	102	28	]	]	-RRB-
cord-254777-h8hw4m9f	102	29	.	.	.
cord-254777-h8hw4m9f	103	1	This	this	DT
cord-254777-h8hw4m9f	103	2	pathway	pathway	NN
cord-254777-h8hw4m9f	103	3	plays	play	VBZ
cord-254777-h8hw4m9f	103	4	a	a	DT
cord-254777-h8hw4m9f	103	5	role	role	NN
cord-254777-h8hw4m9f	103	6	in	in	IN
cord-254777-h8hw4m9f	103	7	the	the	DT
cord-254777-h8hw4m9f	103	8	pathogenesis	pathogenesis	NN
cord-254777-h8hw4m9f	103	9	of	of	IN
cord-254777-h8hw4m9f	103	10	several	several	JJ
cord-254777-h8hw4m9f	103	11	rheumatic	rheumatic	JJ
cord-254777-h8hw4m9f	103	12	diseases	disease	NNS
cord-254777-h8hw4m9f	103	13	,	,	,
cord-254777-h8hw4m9f	103	14	and	and	CC
cord-254777-h8hw4m9f	103	15	blockade	blockade	NN
cord-254777-h8hw4m9f	103	16	of	of	IN
cord-254777-h8hw4m9f	103	17	IL-6	IL-6	NNP
cord-254777-h8hw4m9f	103	18	has	have	VBZ
cord-254777-h8hw4m9f	103	19	proven	prove	VBN
cord-254777-h8hw4m9f	103	20	to	to	TO
cord-254777-h8hw4m9f	103	21	be	be	VB
cord-254777-h8hw4m9f	103	22	a	a	DT
cord-254777-h8hw4m9f	103	23	successful	successful	JJ
cord-254777-h8hw4m9f	103	24	therapeutic	therapeutic	JJ
cord-254777-h8hw4m9f	103	25	intervention	intervention	NN
cord-254777-h8hw4m9f	103	26	in	in	IN
cord-254777-h8hw4m9f	103	27	rheumatoid	rheumatoid	NN
cord-254777-h8hw4m9f	103	28	arthritis	arthritis	NN
cord-254777-h8hw4m9f	103	29	(	(	-LRB-
cord-254777-h8hw4m9f	103	30	RA	RA	NNP
cord-254777-h8hw4m9f	103	31	)	)	-RRB-
cord-254777-h8hw4m9f	103	32	,	,	,
cord-254777-h8hw4m9f	103	33	juvenile	juvenile	JJ
cord-254777-h8hw4m9f	103	34	idiopathy	idiopathy	JJ
cord-254777-h8hw4m9f	103	35	arthritis	arthritis	NN
cord-254777-h8hw4m9f	103	36	(	(	-LRB-
cord-254777-h8hw4m9f	103	37	JIA	JIA	NNP
cord-254777-h8hw4m9f	103	38	)	)	-RRB-
cord-254777-h8hw4m9f	103	39	,	,	,
cord-254777-h8hw4m9f	103	40	adult	adult	NN
cord-254777-h8hw4m9f	103	41	-	-	HYPH
cord-254777-h8hw4m9f	103	42	onset	onset	NN
cord-254777-h8hw4m9f	104	1	Still	still	RB
cord-254777-h8hw4m9f	104	2	's	's	POS
cord-254777-h8hw4m9f	104	3	disease	disease	NN
cord-254777-h8hw4m9f	104	4	(	(	-LRB-
cord-254777-h8hw4m9f	104	5	AoSD	AoSD	NNP
cord-254777-h8hw4m9f	104	6	)	)	-RRB-
cord-254777-h8hw4m9f	104	7	,	,	,
cord-254777-h8hw4m9f	104	8	Takayasu	Takayasu	NNP
cord-254777-h8hw4m9f	104	9	arteritis	arteritis	NN
cord-254777-h8hw4m9f	104	10	(	(	-LRB-
cord-254777-h8hw4m9f	104	11	TA	TA	NNP
cord-254777-h8hw4m9f	104	12	)	)	-RRB-
cord-254777-h8hw4m9f	104	13	as	as	RB
cord-254777-h8hw4m9f	104	14	well	well	RB
cord-254777-h8hw4m9f	104	15	as	as	IN
cord-254777-h8hw4m9f	104	16	other	other	JJ
cord-254777-h8hw4m9f	104	17	conditions	condition	NNS
cord-254777-h8hw4m9f	104	18	including	include	VBG
cord-254777-h8hw4m9f	104	19	CRS	CRS	NNP
cord-254777-h8hw4m9f	104	20	secondary	secondary	JJ
cord-254777-h8hw4m9f	104	21	to	to	IN
cord-254777-h8hw4m9f	104	22	CAR	car	NN
cord-254777-h8hw4m9f	104	23	-	-	HYPH
cord-254777-h8hw4m9f	104	24	T	t	NN
cord-254777-h8hw4m9f	104	25	cell	cell	NN
cord-254777-h8hw4m9f	104	26	therapy	therapy	NN
cord-254777-h8hw4m9f	104	27	.	.	.
cord-254777-h8hw4m9f	105	1	Multiple	multiple	JJ
cord-254777-h8hw4m9f	105	2	monoclonal	monoclonal	JJ
cord-254777-h8hw4m9f	105	3	antibodies	antibody	NNS
cord-254777-h8hw4m9f	105	4	have	have	VBP
cord-254777-h8hw4m9f	105	5	been	be	VBN
cord-254777-h8hw4m9f	105	6	developed	develop	VBN
cord-254777-h8hw4m9f	105	7	,	,	,
cord-254777-h8hw4m9f	105	8	with	with	IN
cord-254777-h8hw4m9f	105	9	those	those	DT
cord-254777-h8hw4m9f	105	10	that	that	WDT
cord-254777-h8hw4m9f	105	11	block	block	VBP
cord-254777-h8hw4m9f	105	12	the	the	DT
cord-254777-h8hw4m9f	105	13	IL-6	IL-6	NNP
cord-254777-h8hw4m9f	105	14	receptor	receptor	NN
cord-254777-h8hw4m9f	105	15	(	(	-LRB-
cord-254777-h8hw4m9f	105	16	tocilizumab	tocilizumab	NNP
cord-254777-h8hw4m9f	105	17	,	,	,
cord-254777-h8hw4m9f	105	18	sarilumab	sarilumab	NNP
cord-254777-h8hw4m9f	105	19	)	)	-RRB-
cord-254777-h8hw4m9f	105	20	most	most	RBS
cord-254777-h8hw4m9f	105	21	frequently	frequently	RB
cord-254777-h8hw4m9f	105	22	studied	study	VBN
cord-254777-h8hw4m9f	105	23	in	in	IN
cord-254777-h8hw4m9f	105	24	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	105	25	.	.	.
cord-254777-h8hw4m9f	106	1	Most	Most	JJS
cord-254777-h8hw4m9f	106	2	safety	safety	NN
cord-254777-h8hw4m9f	106	3	concerns	concern	NNS
cord-254777-h8hw4m9f	106	4	with	with	IN
cord-254777-h8hw4m9f	106	5	IL-6	IL-6	NNP
cord-254777-h8hw4m9f	106	6	receptor	receptor	NN
cord-254777-h8hw4m9f	106	7	blocker	blocker	NNP
cord-254777-h8hw4m9f	106	8	show	show	VBP
cord-254777-h8hw4m9f	106	9	reversible	reversible	JJ
cord-254777-h8hw4m9f	106	10	elevation	elevation	NN
cord-254777-h8hw4m9f	106	11	of	of	IN
cord-254777-h8hw4m9f	106	12	liver	liver	NN
cord-254777-h8hw4m9f	106	13	enzymes	enzyme	NNS
cord-254777-h8hw4m9f	106	14	,	,	,
cord-254777-h8hw4m9f	106	15	pancreatitis	pancreatitis	NN
cord-254777-h8hw4m9f	106	16	,	,	,
cord-254777-h8hw4m9f	106	17	risk	risk	NN
cord-254777-h8hw4m9f	106	18	for	for	IN
cord-254777-h8hw4m9f	106	19	GI	GI	NNP
cord-254777-h8hw4m9f	106	20	perforation	perforation	NN
cord-254777-h8hw4m9f	106	21	and	and	CC
cord-254777-h8hw4m9f	106	22	risk	risk	NN
cord-254777-h8hw4m9f	106	23	for	for	IN
cord-254777-h8hw4m9f	106	24	serious	serious	JJ
cord-254777-h8hw4m9f	106	25	bacterial	bacterial	JJ
cord-254777-h8hw4m9f	106	26	or	or	CC
cord-254777-h8hw4m9f	106	27	fungal	fungal	JJ
cord-254777-h8hw4m9f	106	28	infections	infection	NNS
cord-254777-h8hw4m9f	106	29	.	.	.
cord-254777-h8hw4m9f	107	1	The	the	DT
cord-254777-h8hw4m9f	107	2	rationale	rationale	NN
cord-254777-h8hw4m9f	107	3	for	for	IN
cord-254777-h8hw4m9f	107	4	use	use	NN
cord-254777-h8hw4m9f	107	5	of	of	IN
cord-254777-h8hw4m9f	107	6	IL-6	IL-6	NNP
cord-254777-h8hw4m9f	107	7	blockade	blockade	NN
cord-254777-h8hw4m9f	107	8	in	in	IN
cord-254777-h8hw4m9f	107	9	serious	serious	JJ
cord-254777-h8hw4m9f	107	10	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	107	11	infections	infection	NNS
cord-254777-h8hw4m9f	107	12	is	be	VBZ
cord-254777-h8hw4m9f	107	13	based	base	VBN
cord-254777-h8hw4m9f	107	14	on	on	IN
cord-254777-h8hw4m9f	107	15	the	the	DT
cord-254777-h8hw4m9f	107	16	observation	observation	NN
cord-254777-h8hw4m9f	107	17	that	that	IN
cord-254777-h8hw4m9f	107	18	for	for	IN
cord-254777-h8hw4m9f	107	19	the	the	DT
cord-254777-h8hw4m9f	107	20	subset	subset	NN
cord-254777-h8hw4m9f	107	21	of	of	IN
cord-254777-h8hw4m9f	107	22	patients	patient	NNS
cord-254777-h8hw4m9f	107	23	with	with	IN
cord-254777-h8hw4m9f	107	24	severe	severe	JJ
cord-254777-h8hw4m9f	107	25	manifestations	manifestation	NNS
cord-254777-h8hw4m9f	107	26	,	,	,
cord-254777-h8hw4m9f	107	27	IL-6	IL-6	NNP
cord-254777-h8hw4m9f	107	28	is	be	VBZ
cord-254777-h8hw4m9f	107	29	most	most	RBS
cord-254777-h8hw4m9f	107	30	likely	likely	JJ
cord-254777-h8hw4m9f	107	31	one	one	CD
cord-254777-h8hw4m9f	107	32	of	of	IN
cord-254777-h8hw4m9f	107	33	the	the	DT
cord-254777-h8hw4m9f	107	34	drivers	driver	NNS
cord-254777-h8hw4m9f	107	35	of	of	IN
cord-254777-h8hw4m9f	107	36	the	the	DT
cord-254777-h8hw4m9f	107	37	cytokine	cytokine	NN
cord-254777-h8hw4m9f	107	38	storm	storm	NN
cord-254777-h8hw4m9f	107	39	,	,	,
cord-254777-h8hw4m9f	107	40	and	and	CC
cord-254777-h8hw4m9f	107	41	elevated	elevated	JJ
cord-254777-h8hw4m9f	107	42	levels	level	NNS
cord-254777-h8hw4m9f	107	43	of	of	IN
cord-254777-h8hw4m9f	107	44	IL-6	IL-6	NNP
cord-254777-h8hw4m9f	107	45	have	have	VBP
cord-254777-h8hw4m9f	107	46	been	be	VBN
cord-254777-h8hw4m9f	107	47	consistently	consistently	RB
cord-254777-h8hw4m9f	107	48	shown	show	VBN
cord-254777-h8hw4m9f	107	49	[	[	-LRB-
cord-254777-h8hw4m9f	107	50	14	14	CD
cord-254777-h8hw4m9f	107	51	]	]	-RRB-
cord-254777-h8hw4m9f	107	52	.	.	.
cord-254777-h8hw4m9f	108	1	Tocilizumab	Tocilizumab	NNP
cord-254777-h8hw4m9f	108	2	was	be	VBD
cord-254777-h8hw4m9f	108	3	one	one	CD
cord-254777-h8hw4m9f	108	4	of	of	IN
cord-254777-h8hw4m9f	108	5	the	the	DT
cord-254777-h8hw4m9f	108	6	first	first	JJ
cord-254777-h8hw4m9f	108	7	anti	anti	JJ
cord-254777-h8hw4m9f	108	8	-	-	JJ
cord-254777-h8hw4m9f	108	9	inflammatory	inflammatory	JJ
cord-254777-h8hw4m9f	108	10	agents	agent	NNS
cord-254777-h8hw4m9f	108	11	trialed	triale	VBN
cord-254777-h8hw4m9f	108	12	and	and	CC
cord-254777-h8hw4m9f	108	13	multiple	multiple	JJ
cord-254777-h8hw4m9f	108	14	clinical	clinical	JJ
cord-254777-h8hw4m9f	108	15	trials	trial	NNS
cord-254777-h8hw4m9f	108	16	in	in	IN
cord-254777-h8hw4m9f	108	17	IL-6	IL-6	NNP
cord-254777-h8hw4m9f	108	18	blockade	blockade	NN
cord-254777-h8hw4m9f	108	19	are	be	VBP
cord-254777-h8hw4m9f	108	20	ongoing	ongoing	JJ
cord-254777-h8hw4m9f	108	21	globally	globally	RB
cord-254777-h8hw4m9f	108	22	.	.	.
cord-254777-h8hw4m9f	109	1	Current	current	JJ
cord-254777-h8hw4m9f	109	2	data	datum	NNS
cord-254777-h8hw4m9f	109	3	for	for	IN
cord-254777-h8hw4m9f	109	4	IL-6	IL-6	NNP
cord-254777-h8hw4m9f	109	5	blockade	blockade	NN
cord-254777-h8hw4m9f	109	6	in	in	IN
cord-254777-h8hw4m9f	109	7	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	109	8	is	be	VBZ
cord-254777-h8hw4m9f	109	9	limited	limit	VBN
cord-254777-h8hw4m9f	109	10	to	to	IN
cord-254777-h8hw4m9f	109	11	adults	adult	NNS
cord-254777-h8hw4m9f	109	12	but	but	CC
cord-254777-h8hw4m9f	109	13	has	have	VBZ
cord-254777-h8hw4m9f	109	14	overall	overall	RB
cord-254777-h8hw4m9f	109	15	been	be	VBN
cord-254777-h8hw4m9f	109	16	promising	promise	VBG
cord-254777-h8hw4m9f	109	17	.	.	.
cord-254777-h8hw4m9f	110	1	In	in	IN
cord-254777-h8hw4m9f	110	2	the	the	DT
cord-254777-h8hw4m9f	110	3	earliest	early	JJS
cord-254777-h8hw4m9f	110	4	tocilizumab	tocilizumab	JJ
cord-254777-h8hw4m9f	110	5	study	study	NN
cord-254777-h8hw4m9f	110	6	,	,	,
cord-254777-h8hw4m9f	110	7	Xu	Xu	NNP
cord-254777-h8hw4m9f	110	8	et	et	NNP
cord-254777-h8hw4m9f	110	9	al	al	NNP
cord-254777-h8hw4m9f	110	10	reported	report	VBD
cord-254777-h8hw4m9f	110	11	improvement	improvement	NN
cord-254777-h8hw4m9f	110	12	in	in	IN
cord-254777-h8hw4m9f	110	13	all	all	DT
cord-254777-h8hw4m9f	110	14	21	21	CD
cord-254777-h8hw4m9f	110	15	patients	patient	NNS
cord-254777-h8hw4m9f	110	16	receiving	receive	VBG
cord-254777-h8hw4m9f	110	17	tocilizumab	tocilizumab	NN
cord-254777-h8hw4m9f	110	18	,	,	,
cord-254777-h8hw4m9f	110	19	however	however	RB
cord-254777-h8hw4m9f	110	20	this	this	DT
cord-254777-h8hw4m9f	110	21	was	be	VBD
cord-254777-h8hw4m9f	110	22	a	a	DT
cord-254777-h8hw4m9f	110	23	small	small	JJ
cord-254777-h8hw4m9f	110	24	single	single	JJ
cord-254777-h8hw4m9f	110	25	arm	arm	NN
cord-254777-h8hw4m9f	110	26	study	study	NN
cord-254777-h8hw4m9f	110	27	with	with	IN
cord-254777-h8hw4m9f	110	28	no	no	DT
cord-254777-h8hw4m9f	110	29	control	control	NN
cord-254777-h8hw4m9f	110	30	group	group	NN
cord-254777-h8hw4m9f	110	31	[	[	-LRB-
cord-254777-h8hw4m9f	110	32	36	36	CD
cord-254777-h8hw4m9f	110	33	]	]	-RRB-
cord-254777-h8hw4m9f	110	34	.	.	.
cord-254777-h8hw4m9f	111	1	Two	two	CD
cord-254777-h8hw4m9f	111	2	additional	additional	JJ
cord-254777-h8hw4m9f	111	3	studies	study	NNS
cord-254777-h8hw4m9f	111	4	from	from	IN
cord-254777-h8hw4m9f	111	5	France	France	NNP
cord-254777-h8hw4m9f	111	6	showed	show	VBD
cord-254777-h8hw4m9f	111	7	significant	significant	JJ
cord-254777-h8hw4m9f	111	8	improvement	improvement	NN
cord-254777-h8hw4m9f	111	9	in	in	IN
cord-254777-h8hw4m9f	111	10	patients	patient	NNS
cord-254777-h8hw4m9f	111	11	treated	treat	VBN
cord-254777-h8hw4m9f	111	12	with	with	IN
cord-254777-h8hw4m9f	111	13	tocilizumab	tocilizumab	NNS
cord-254777-h8hw4m9f	111	14	with	with	IN
cord-254777-h8hw4m9f	111	15	reduced	reduced	JJ
cord-254777-h8hw4m9f	111	16	rate	rate	NN
cord-254777-h8hw4m9f	111	17	of	of	IN
cord-254777-h8hw4m9f	111	18	ICU	ICU	NNP
cord-254777-h8hw4m9f	111	19	admission	admission	NN
cord-254777-h8hw4m9f	111	20	and	and	CC
cord-254777-h8hw4m9f	111	21	risk	risk	NN
cord-254777-h8hw4m9f	111	22	for	for	IN
cord-254777-h8hw4m9f	111	23	mechanical	mechanical	JJ
cord-254777-h8hw4m9f	111	24	ventilation	ventilation	NN
cord-254777-h8hw4m9f	111	25	,	,	,
cord-254777-h8hw4m9f	111	26	however	however	WRB
cord-254777-h8hw4m9f	111	27	there	there	EX
cord-254777-h8hw4m9f	111	28	was	be	VBD
cord-254777-h8hw4m9f	111	29	no	no	DT
cord-254777-h8hw4m9f	111	30	significant	significant	JJ
cord-254777-h8hw4m9f	111	31	reduction	reduction	NN
cord-254777-h8hw4m9f	111	32	in	in	IN
cord-254777-h8hw4m9f	111	33	mortality	mortality	NN
cord-254777-h8hw4m9f	111	34	[	[	-LRB-
cord-254777-h8hw4m9f	111	35	37	37	CD
cord-254777-h8hw4m9f	111	36	,	,	,
cord-254777-h8hw4m9f	111	37	38	38	CD
cord-254777-h8hw4m9f	111	38	]	]	-RRB-
cord-254777-h8hw4m9f	111	39	.	.	.
cord-254777-h8hw4m9f	112	1	Additional	additional	JJ
cord-254777-h8hw4m9f	112	2	studies	study	NNS
cord-254777-h8hw4m9f	112	3	have	have	VBP
cord-254777-h8hw4m9f	112	4	shown	show	VBN
cord-254777-h8hw4m9f	112	5	mixed	mixed	JJ
cord-254777-h8hw4m9f	112	6	results	result	NNS
cord-254777-h8hw4m9f	112	7	(	(	-LRB-
cord-254777-h8hw4m9f	112	8	Table	table	NN
cord-254777-h8hw4m9f	112	9	2	2	CD
cord-254777-h8hw4m9f	112	10	)	)	-RRB-
cord-254777-h8hw4m9f	112	11	[	[	-LRB-
cord-254777-h8hw4m9f	112	12	39	39	CD
cord-254777-h8hw4m9f	112	13	]	]	-RRB-
cord-254777-h8hw4m9f	112	14	[	[	-LRB-
cord-254777-h8hw4m9f	112	15	40	40	CD
cord-254777-h8hw4m9f	112	16	]	]	-RRB-
cord-254777-h8hw4m9f	112	17	[	[	-LRB-
cord-254777-h8hw4m9f	112	18	41	41	CD
cord-254777-h8hw4m9f	112	19	]	]	-RRB-
cord-254777-h8hw4m9f	112	20	[	[	-LRB-
cord-254777-h8hw4m9f	112	21	42	42	CD
cord-254777-h8hw4m9f	112	22	]	]	-RRB-
cord-254777-h8hw4m9f	112	23	.	.	.
cord-254777-h8hw4m9f	113	1	At	at	IN
cord-254777-h8hw4m9f	113	2	the	the	DT
cord-254777-h8hw4m9f	113	3	time	time	NN
cord-254777-h8hw4m9f	113	4	of	of	IN
cord-254777-h8hw4m9f	113	5	this	this	DT
cord-254777-h8hw4m9f	113	6	review	review	NN
cord-254777-h8hw4m9f	113	7	,	,	,
cord-254777-h8hw4m9f	113	8	the	the	DT
cord-254777-h8hw4m9f	113	9	largest	large	JJS
cord-254777-h8hw4m9f	113	10	trial	trial	NN
cord-254777-h8hw4m9f	113	11	to	to	IN
cord-254777-h8hw4m9f	113	12	date	date	NN
cord-254777-h8hw4m9f	113	13	is	be	VBZ
cord-254777-h8hw4m9f	113	14	the	the	DT
cord-254777-h8hw4m9f	113	15	Sanofi	Sanofi	NNP
cord-254777-h8hw4m9f	113	16	/	/	SYM
cord-254777-h8hw4m9f	113	17	Regeneron	Regeneron	NNP
cord-254777-h8hw4m9f	113	18	phase	phase	NN
cord-254777-h8hw4m9f	113	19	2/3	2/3	CD
cord-254777-h8hw4m9f	113	20	Sarilumab	Sarilumab	NNP
cord-254777-h8hw4m9f	113	21	trial	trial	NN
cord-254777-h8hw4m9f	113	22	.	.	.
cord-254777-h8hw4m9f	114	1	In	in	IN
cord-254777-h8hw4m9f	114	2	this	this	DT
cord-254777-h8hw4m9f	114	3	trial	trial	NN
cord-254777-h8hw4m9f	114	4	,	,	,
cord-254777-h8hw4m9f	114	5	457	457	CD
cord-254777-h8hw4m9f	114	6	hospitalized	hospitalize	VBN
cord-254777-h8hw4m9f	114	7	patients	patient	NNS
cord-254777-h8hw4m9f	114	8	were	be	VBD
cord-254777-h8hw4m9f	114	9	categorized	categorize	VBN
cord-254777-h8hw4m9f	114	10	as	as	IN
cord-254777-h8hw4m9f	114	11	having	have	VBG
cord-254777-h8hw4m9f	114	12	either	either	CC
cord-254777-h8hw4m9f	114	13	"	"	``
cord-254777-h8hw4m9f	114	14	severe	severe	JJ
cord-254777-h8hw4m9f	114	15	"	"	''
cord-254777-h8hw4m9f	114	16	illness	illness	NN
cord-254777-h8hw4m9f	114	17	(	(	-LRB-
cord-254777-h8hw4m9f	114	18	28	28	CD
cord-254777-h8hw4m9f	114	19	%	%	NN
cord-254777-h8hw4m9f	114	20	)	)	-RRB-
cord-254777-h8hw4m9f	114	21	,	,	,
cord-254777-h8hw4m9f	114	22	"	"	``
cord-254777-h8hw4m9f	114	23	critical	critical	JJ
cord-254777-h8hw4m9f	114	24	"	"	''
cord-254777-h8hw4m9f	114	25	illness	illness	NN
cord-254777-h8hw4m9f	114	26	(	(	-LRB-
cord-254777-h8hw4m9f	114	27	49	49	CD
cord-254777-h8hw4m9f	114	28	%	%	NN
cord-254777-h8hw4m9f	114	29	)	)	-RRB-
cord-254777-h8hw4m9f	114	30	or	or	CC
cord-254777-h8hw4m9f	114	31	"	"	``
cord-254777-h8hw4m9f	114	32	multisystem	multisystem	JJ
cord-254777-h8hw4m9f	114	33	organ	organ	NN
cord-254777-h8hw4m9f	114	34	dysfunction	dysfunction	NN
cord-254777-h8hw4m9f	114	35	"	"	''
cord-254777-h8hw4m9f	114	36	(	(	-LRB-
cord-254777-h8hw4m9f	114	37	MSOD	MSOD	NNP
cord-254777-h8hw4m9f	114	38	)	)	-RRB-
cord-254777-h8hw4m9f	114	39	(	(	-LRB-
cord-254777-h8hw4m9f	114	40	23	23	CD
cord-254777-h8hw4m9f	114	41	%	%	NN
cord-254777-h8hw4m9f	114	42	)	)	-RRB-
cord-254777-h8hw4m9f	115	1	[	[	-LRB-
cord-254777-h8hw4m9f	115	2	43	43	CD
cord-254777-h8hw4m9f	115	3	]	]	-RRB-
cord-254777-h8hw4m9f	115	4	.	.	.
cord-254777-h8hw4m9f	116	1	Patients	patient	NNS
cord-254777-h8hw4m9f	116	2	were	be	VBD
cord-254777-h8hw4m9f	116	3	classified	classify	VBN
cord-254777-h8hw4m9f	116	4	as	as	IN
cord-254777-h8hw4m9f	116	5	"	"	``
cord-254777-h8hw4m9f	116	6	severe	severe	JJ
cord-254777-h8hw4m9f	116	7	"	"	''
cord-254777-h8hw4m9f	116	8	if	if	IN
cord-254777-h8hw4m9f	116	9	they	-PRON-	PRP
cord-254777-h8hw4m9f	116	10	required	require	VBD
cord-254777-h8hw4m9f	116	11	oxygen	oxygen	NN
cord-254777-h8hw4m9f	116	12	supplementation	supplementation	NN
cord-254777-h8hw4m9f	116	13	without	without	IN
cord-254777-h8hw4m9f	116	14	mechanical	mechanical	JJ
cord-254777-h8hw4m9f	116	15	or	or	CC
cord-254777-h8hw4m9f	116	16	high	high	JJ
cord-254777-h8hw4m9f	116	17	-	-	HYPH
cord-254777-h8hw4m9f	116	18	flow	flow	NN
cord-254777-h8hw4m9f	116	19	oxygenation	oxygenation	NN
cord-254777-h8hw4m9f	116	20	;	;	:
cord-254777-h8hw4m9f	116	21	or	or	CC
cord-254777-h8hw4m9f	116	22	"	"	``
cord-254777-h8hw4m9f	116	23	critical	critical	JJ
cord-254777-h8hw4m9f	116	24	"	"	''
cord-254777-h8hw4m9f	116	25	if	if	IN
cord-254777-h8hw4m9f	116	26	they	-PRON-	PRP
cord-254777-h8hw4m9f	116	27	required	require	VBD
cord-254777-h8hw4m9f	116	28	mechanical	mechanical	JJ
cord-254777-h8hw4m9f	116	29	ventilation	ventilation	NN
cord-254777-h8hw4m9f	116	30	or	or	CC
cord-254777-h8hw4m9f	116	31	high	high	JJ
cord-254777-h8hw4m9f	116	32	-	-	HYPH
cord-254777-h8hw4m9f	116	33	flow	flow	NN
cord-254777-h8hw4m9f	116	34	oxygenation	oxygenation	NN
cord-254777-h8hw4m9f	116	35	or	or	CC
cord-254777-h8hw4m9f	116	36	required	require	VBN
cord-254777-h8hw4m9f	116	37	treatment	treatment	NN
cord-254777-h8hw4m9f	116	38	in	in	IN
cord-254777-h8hw4m9f	116	39	an	an	DT
cord-254777-h8hw4m9f	116	40	intensive	intensive	JJ
cord-254777-h8hw4m9f	116	41	care	care	NN
cord-254777-h8hw4m9f	116	42	unit	unit	NN
cord-254777-h8hw4m9f	116	43	.	.	.
cord-254777-h8hw4m9f	117	1	The	the	DT
cord-254777-h8hw4m9f	117	2	trial	trial	NN
cord-254777-h8hw4m9f	117	3	met	meet	VBD
cord-254777-h8hw4m9f	117	4	its	-PRON-	PRP$
cord-254777-h8hw4m9f	117	5	primary	primary	JJ
cord-254777-h8hw4m9f	117	6	endpoint	endpoint	NN
cord-254777-h8hw4m9f	117	7	of	of	IN
cord-254777-h8hw4m9f	117	8	CRP	CRP	NNP
cord-254777-h8hw4m9f	117	9	reduction	reduction	NN
cord-254777-h8hw4m9f	117	10	and	and	CC
cord-254777-h8hw4m9f	117	11	demonstrated	demonstrate	VBD
cord-254777-h8hw4m9f	117	12	no	no	DT
cord-254777-h8hw4m9f	117	13	new	new	JJ
cord-254777-h8hw4m9f	117	14	safety	safety	NN
cord-254777-h8hw4m9f	117	15	concerns	concern	NNS
cord-254777-h8hw4m9f	117	16	.	.	.
cord-254777-h8hw4m9f	118	1	There	there	EX
cord-254777-h8hw4m9f	118	2	is	be	VBZ
cord-254777-h8hw4m9f	118	3	caution	caution	NN
cord-254777-h8hw4m9f	118	4	not	not	RB
cord-254777-h8hw4m9f	118	5	to	to	TO
cord-254777-h8hw4m9f	118	6	overinterpret	overinterpret	VB
cord-254777-h8hw4m9f	118	7	the	the	DT
cord-254777-h8hw4m9f	118	8	results	result	NNS
cord-254777-h8hw4m9f	118	9	of	of	IN
cord-254777-h8hw4m9f	118	10	this	this	DT
cord-254777-h8hw4m9f	118	11	trial	trial	NN
cord-254777-h8hw4m9f	118	12	,	,	,
cord-254777-h8hw4m9f	118	13	in	in	IN
cord-254777-h8hw4m9f	118	14	that	that	DT
cord-254777-h8hw4m9f	118	15	,	,	,
cord-254777-h8hw4m9f	118	16	reduction	reduction	NN
cord-254777-h8hw4m9f	118	17	in	in	IN
cord-254777-h8hw4m9f	118	18	CRP	CRP	NNP
cord-254777-h8hw4m9f	118	19	is	be	VBZ
cord-254777-h8hw4m9f	118	20	an	an	DT
cord-254777-h8hw4m9f	118	21	expected	expect	VBN
cord-254777-h8hw4m9f	118	22	outcome	outcome	NN
cord-254777-h8hw4m9f	118	23	of	of	IN
cord-254777-h8hw4m9f	118	24	treatment	treatment	NN
cord-254777-h8hw4m9f	118	25	with	with	IN
cord-254777-h8hw4m9f	118	26	IL-6	IL-6	NNP
cord-254777-h8hw4m9f	118	27	blockade	blockade	NN
cord-254777-h8hw4m9f	118	28	and	and	CC
cord-254777-h8hw4m9f	118	29	thus	thus	RB
cord-254777-h8hw4m9f	118	30	may	may	MD
cord-254777-h8hw4m9f	118	31	have	have	VB
cord-254777-h8hw4m9f	118	32	not	not	RB
cord-254777-h8hw4m9f	118	33	been	be	VBN
cord-254777-h8hw4m9f	118	34	an	an	DT
cord-254777-h8hw4m9f	118	35	ideal	ideal	JJ
cord-254777-h8hw4m9f	118	36	primary	primary	JJ
cord-254777-h8hw4m9f	118	37	endpoint	endpoint	NN
cord-254777-h8hw4m9f	118	38	.	.	.
cord-254777-h8hw4m9f	119	1	An	an	DT
cord-254777-h8hw4m9f	119	2	exploratory	exploratory	JJ
cord-254777-h8hw4m9f	119	3	analysis	analysis	NN
cord-254777-h8hw4m9f	119	4	of	of	IN
cord-254777-h8hw4m9f	119	5	outcome	outcome	NN
cord-254777-h8hw4m9f	119	6	(	(	-LRB-
cord-254777-h8hw4m9f	119	7	clinical	clinical	JJ
cord-254777-h8hw4m9f	119	8	status	status	NN
cord-254777-h8hw4m9f	119	9	,	,	,
cord-254777-h8hw4m9f	119	10	mortality	mortality	NN
cord-254777-h8hw4m9f	119	11	,	,	,
cord-254777-h8hw4m9f	119	12	discharge	discharge	NN
cord-254777-h8hw4m9f	119	13	)	)	-RRB-
cord-254777-h8hw4m9f	119	14	,	,	,
cord-254777-h8hw4m9f	119	15	showed	show	VBD
cord-254777-h8hw4m9f	119	16	negative	negative	JJ
cord-254777-h8hw4m9f	119	17	trends	trend	NNS
cord-254777-h8hw4m9f	119	18	for	for	IN
cord-254777-h8hw4m9f	119	19	outcomes	outcome	NNS
cord-254777-h8hw4m9f	119	20	in	in	IN
cord-254777-h8hw4m9f	119	21	"	"	``
cord-254777-h8hw4m9f	119	22	severe	severe	JJ
cord-254777-h8hw4m9f	119	23	"	"	''
cord-254777-h8hw4m9f	119	24	group	group	NN
cord-254777-h8hw4m9f	119	25	,	,	,
cord-254777-h8hw4m9f	119	26	and	and	CC
cord-254777-h8hw4m9f	119	27	positive	positive	JJ
cord-254777-h8hw4m9f	119	28	trends	trend	NNS
cord-254777-h8hw4m9f	119	29	for	for	IN
cord-254777-h8hw4m9f	119	30	outcome	outcome	NN
cord-254777-h8hw4m9f	119	31	in	in	IN
cord-254777-h8hw4m9f	119	32	"	"	``
cord-254777-h8hw4m9f	119	33	critical	critical	JJ
cord-254777-h8hw4m9f	119	34	"	"	''
cord-254777-h8hw4m9f	119	35	group	group	NN
cord-254777-h8hw4m9f	119	36	.	.	.
cord-254777-h8hw4m9f	120	1	Ongoing	ongoing	JJ
cord-254777-h8hw4m9f	120	2	phase	phase	NN
cord-254777-h8hw4m9f	120	3	3	3	CD
cord-254777-h8hw4m9f	120	4	trial	trial	NN
cord-254777-h8hw4m9f	120	5	is	be	VBZ
cord-254777-h8hw4m9f	120	6	currently	currently	RB
cord-254777-h8hw4m9f	120	7	enrolling	enrol	VBG
cord-254777-h8hw4m9f	120	8	internationally	internationally	RB
cord-254777-h8hw4m9f	120	9	.	.	.
cord-254777-h8hw4m9f	121	1	Interleukin	interleukin	NN
cord-254777-h8hw4m9f	121	2	1	1	CD
cord-254777-h8hw4m9f	121	3	is	be	VBZ
cord-254777-h8hw4m9f	121	4	one	one	CD
cord-254777-h8hw4m9f	121	5	of	of	IN
cord-254777-h8hw4m9f	121	6	the	the	DT
cord-254777-h8hw4m9f	121	7	primary	primary	JJ
cord-254777-h8hw4m9f	121	8	cytokines	cytokine	NNS
cord-254777-h8hw4m9f	121	9	involved	involve	VBN
cord-254777-h8hw4m9f	121	10	in	in	IN
cord-254777-h8hw4m9f	121	11	hyperinflammation	hyperinflammation	NN
cord-254777-h8hw4m9f	121	12	and	and	CC
cord-254777-h8hw4m9f	121	13	has	have	VBZ
cord-254777-h8hw4m9f	121	14	a	a	DT
cord-254777-h8hw4m9f	121	15	fundamental	fundamental	JJ
cord-254777-h8hw4m9f	121	16	role	role	NN
cord-254777-h8hw4m9f	121	17	in	in	IN
cord-254777-h8hw4m9f	121	18	the	the	DT
cord-254777-h8hw4m9f	121	19	development	development	NN
cord-254777-h8hw4m9f	121	20	of	of	IN
cord-254777-h8hw4m9f	121	21	cytokine	cytokine	NN
cord-254777-h8hw4m9f	121	22	storm	storm	NN
cord-254777-h8hw4m9f	121	23	in	in	IN
cord-254777-h8hw4m9f	121	24	sHLH	sHLH	NNP
cord-254777-h8hw4m9f	121	25	.	.	.
cord-254777-h8hw4m9f	122	1	Anakinra	Anakinra	NNP
cord-254777-h8hw4m9f	122	2	is	be	VBZ
cord-254777-h8hw4m9f	122	3	a	a	DT
cord-254777-h8hw4m9f	122	4	recombinant	recombinant	JJ
cord-254777-h8hw4m9f	122	5	IL-1	IL-1	NNP
cord-254777-h8hw4m9f	122	6	receptor	receptor	NN
cord-254777-h8hw4m9f	122	7	antagonist	antagonist	NN
cord-254777-h8hw4m9f	122	8	originally	originally	RB
cord-254777-h8hw4m9f	122	9	developed	develop	VBD
cord-254777-h8hw4m9f	122	10	to	to	TO
cord-254777-h8hw4m9f	122	11	control	control	VB
cord-254777-h8hw4m9f	122	12	sepsis	sepsis	NN
cord-254777-h8hw4m9f	122	13	-	-	HYPH
cord-254777-h8hw4m9f	122	14	induced	induce	VBN
cord-254777-h8hw4m9f	122	15	cytokine	cytokine	NN
cord-254777-h8hw4m9f	122	16	storm	storm	NN
cord-254777-h8hw4m9f	122	17	and	and	CC
cord-254777-h8hw4m9f	122	18	subsequently	subsequently	RB
cord-254777-h8hw4m9f	122	19	used	use	VBN
cord-254777-h8hw4m9f	122	20	in	in	IN
cord-254777-h8hw4m9f	122	21	cytokine	cytokine	NN
cord-254777-h8hw4m9f	122	22	storm	storm	NN
cord-254777-h8hw4m9f	122	23	induced	induce	VBN
cord-254777-h8hw4m9f	122	24	by	by	IN
cord-254777-h8hw4m9f	122	25	a	a	DT
cord-254777-h8hw4m9f	122	26	variety	variety	NN
cord-254777-h8hw4m9f	122	27	of	of	IN
cord-254777-h8hw4m9f	122	28	conditions	condition	NNS
cord-254777-h8hw4m9f	122	29	.	.	.
cord-254777-h8hw4m9f	123	1	It	-PRON-	PRP
cord-254777-h8hw4m9f	123	2	is	be	VBZ
cord-254777-h8hw4m9f	123	3	currently	currently	RB
cord-254777-h8hw4m9f	123	4	FDA	FDA	NNP
cord-254777-h8hw4m9f	123	5	approved	approve	VBN
cord-254777-h8hw4m9f	123	6	for	for	IN
cord-254777-h8hw4m9f	123	7	treatment	treatment	NN
cord-254777-h8hw4m9f	123	8	of	of	IN
cord-254777-h8hw4m9f	123	9	RA	RA	NNP
cord-254777-h8hw4m9f	123	10	,	,	,
cord-254777-h8hw4m9f	123	11	Systemic	Systemic	NNP
cord-254777-h8hw4m9f	123	12	JIA	JIA	NNP
cord-254777-h8hw4m9f	123	13	,	,	,
cord-254777-h8hw4m9f	123	14	Still	still	RB
cord-254777-h8hw4m9f	123	15	's	's	POS
cord-254777-h8hw4m9f	123	16	disease	disease	NN
cord-254777-h8hw4m9f	123	17	and	and	CC
cord-254777-h8hw4m9f	123	18	cryopyrin	cryopyrin	NN
cord-254777-h8hw4m9f	123	19	-	-	HYPH
cord-254777-h8hw4m9f	123	20	associated	associate	VBN
cord-254777-h8hw4m9f	123	21	periodic	periodic	JJ
cord-254777-h8hw4m9f	123	22	syndromes	syndrome	NNS
cord-254777-h8hw4m9f	123	23	and	and	CC
cord-254777-h8hw4m9f	123	24	used	use	VBN
cord-254777-h8hw4m9f	123	25	off	off	IN
cord-254777-h8hw4m9f	123	26	-	-	HYPH
cord-254777-h8hw4m9f	123	27	label	label	NN
cord-254777-h8hw4m9f	123	28	for	for	IN
cord-254777-h8hw4m9f	123	29	cytokine	cytokine	NN
cord-254777-h8hw4m9f	123	30	storm	storm	NN
cord-254777-h8hw4m9f	123	31	syndromes	syndrome	NNS
cord-254777-h8hw4m9f	123	32	with	with	IN
cord-254777-h8hw4m9f	123	33	accumulating	accumulate	VBG
cord-254777-h8hw4m9f	123	34	evidence	evidence	NN
cord-254777-h8hw4m9f	123	35	of	of	IN
cord-254777-h8hw4m9f	123	36	its	-PRON-	PRP$
cord-254777-h8hw4m9f	123	37	benefit	benefit	NN
cord-254777-h8hw4m9f	123	38	in	in	IN
cord-254777-h8hw4m9f	123	39	controlling	control	VBG
cord-254777-h8hw4m9f	123	40	hyperinflammation	hyperinflammation	NN
cord-254777-h8hw4m9f	123	41	[	[	-LRB-
cord-254777-h8hw4m9f	123	42	44	44	CD
cord-254777-h8hw4m9f	123	43	]	]	-RRB-
cord-254777-h8hw4m9f	123	44	.	.	.
cord-254777-h8hw4m9f	124	1	A	a	DT
cord-254777-h8hw4m9f	124	2	perceived	perceive	VBN
cord-254777-h8hw4m9f	124	3	advantage	advantage	NN
cord-254777-h8hw4m9f	124	4	of	of	IN
cord-254777-h8hw4m9f	124	5	using	use	VBG
cord-254777-h8hw4m9f	124	6	anakinra	anakinra	NNP
cord-254777-h8hw4m9f	124	7	for	for	IN
cord-254777-h8hw4m9f	124	8	IL-1	IL-1	NNP
cord-254777-h8hw4m9f	124	9	blockade	blockade	NN
cord-254777-h8hw4m9f	124	10	is	be	VBZ
cord-254777-h8hw4m9f	124	11	its	-PRON-	PRP$
cord-254777-h8hw4m9f	124	12	short	short	JJ
cord-254777-h8hw4m9f	124	13	half	half	JJ
cord-254777-h8hw4m9f	124	14	-	-	HYPH
cord-254777-h8hw4m9f	124	15	life	life	NN
cord-254777-h8hw4m9f	124	16	,	,	,
cord-254777-h8hw4m9f	124	17	with	with	IN
cord-254777-h8hw4m9f	124	18	high	high	JJ
cord-254777-h8hw4m9f	124	19	dose	dose	NN
cord-254777-h8hw4m9f	124	20	regimens	regimen	NNS
cord-254777-h8hw4m9f	124	21	shown	show	VBN
cord-254777-h8hw4m9f	124	22	to	to	TO
cord-254777-h8hw4m9f	124	23	be	be	VB
cord-254777-h8hw4m9f	124	24	safe	safe	JJ
cord-254777-h8hw4m9f	124	25	,	,	,
cord-254777-h8hw4m9f	124	26	even	even	RB
cord-254777-h8hw4m9f	124	27	in	in	IN
cord-254777-h8hw4m9f	124	28	context	context	NN
cord-254777-h8hw4m9f	124	29	of	of	IN
cord-254777-h8hw4m9f	124	30	sepsis	sepsis	NN
cord-254777-h8hw4m9f	124	31	[	[	-LRB-
cord-254777-h8hw4m9f	124	32	3	3	CD
cord-254777-h8hw4m9f	124	33	,	,	,
cord-254777-h8hw4m9f	124	34	45	45	CD
cord-254777-h8hw4m9f	124	35	]	]	-RRB-
cord-254777-h8hw4m9f	124	36	.	.	.
cord-254777-h8hw4m9f	125	1	In	in	IN
cord-254777-h8hw4m9f	125	2	COVID-19	covid-19	JJ
cord-254777-h8hw4m9f	125	3	infection	infection	NN
cord-254777-h8hw4m9f	125	4	,	,	,
cord-254777-h8hw4m9f	125	5	IL-1	IL-1	NNP
cord-254777-h8hw4m9f	125	6	blockade	blockade	NN
cord-254777-h8hw4m9f	125	7	has	have	VBZ
cord-254777-h8hw4m9f	125	8	been	be	VBN
cord-254777-h8hw4m9f	125	9	hypothesized	hypothesize	VBN
cord-254777-h8hw4m9f	125	10	to	to	TO
cord-254777-h8hw4m9f	125	11	play	play	VB
cord-254777-h8hw4m9f	125	12	a	a	DT
cord-254777-h8hw4m9f	125	13	significant	significant	JJ
cord-254777-h8hw4m9f	125	14	role	role	NN
cord-254777-h8hw4m9f	125	15	in	in	IN
cord-254777-h8hw4m9f	125	16	controlling	control	VBG
cord-254777-h8hw4m9f	125	17	hyperinflammation	hyperinflammation	NN
cord-254777-h8hw4m9f	125	18	[	[	-LRB-
cord-254777-h8hw4m9f	125	19	2	2	CD
cord-254777-h8hw4m9f	125	20	,	,	,
cord-254777-h8hw4m9f	125	21	46	46	CD
cord-254777-h8hw4m9f	125	22	,	,	,
cord-254777-h8hw4m9f	125	23	47	47	CD
cord-254777-h8hw4m9f	125	24	]	]	-RRB-
cord-254777-h8hw4m9f	125	25	.	.	.
cord-254777-h8hw4m9f	126	1	IL-1α	IL-1α	NNP
cord-254777-h8hw4m9f	126	2	is	be	VBZ
cord-254777-h8hw4m9f	126	3	released	release	VBN
cord-254777-h8hw4m9f	126	4	by	by	IN
cord-254777-h8hw4m9f	126	5	dying	die	VBG
cord-254777-h8hw4m9f	126	6	epithelial	epithelial	JJ
cord-254777-h8hw4m9f	126	7	and	and	CC
cord-254777-h8hw4m9f	126	8	endothelial	endothelial	JJ
cord-254777-h8hw4m9f	126	9	cells	cell	NNS
cord-254777-h8hw4m9f	126	10	,	,	,
cord-254777-h8hw4m9f	126	11	whereas	whereas	IN
cord-254777-h8hw4m9f	126	12	IL-1β	il-1β	NN
cord-254777-h8hw4m9f	126	13	is	be	VBZ
cord-254777-h8hw4m9f	126	14	produced	produce	VBN
cord-254777-h8hw4m9f	126	15	by	by	IN
cord-254777-h8hw4m9f	126	16	infiltrating	infiltrate	VBG
cord-254777-h8hw4m9f	126	17	monocytes	monocyte	NNS
cord-254777-h8hw4m9f	126	18	,	,	,
cord-254777-h8hw4m9f	126	19	macrophages	macrophage	NNS
cord-254777-h8hw4m9f	126	20	,	,	,
cord-254777-h8hw4m9f	126	21	and	and	CC
cord-254777-h8hw4m9f	126	22	neutrophils	neutrophil	NNS
cord-254777-h8hw4m9f	126	23	[	[	-LRB-
cord-254777-h8hw4m9f	126	24	46	46	CD
cord-254777-h8hw4m9f	126	25	]	]	-RRB-
cord-254777-h8hw4m9f	126	26	;	;	:
cord-254777-h8hw4m9f	127	1	both	both	DT
cord-254777-h8hw4m9f	127	2	major	major	JJ
cord-254777-h8hw4m9f	127	3	factors	factor	NNS
cord-254777-h8hw4m9f	127	4	contributing	contribute	VBG
cord-254777-h8hw4m9f	127	5	to	to	IN
cord-254777-h8hw4m9f	127	6	hyperinflammation	hyperinflammation	NN
cord-254777-h8hw4m9f	127	7	.	.	.
cord-254777-h8hw4m9f	128	1	To	to	IN
cord-254777-h8hw4m9f	128	2	date	date	NN
cord-254777-h8hw4m9f	128	3	,	,	,
cord-254777-h8hw4m9f	128	4	the	the	DT
cord-254777-h8hw4m9f	128	5	data	datum	NNS
cord-254777-h8hw4m9f	128	6	on	on	IN
cord-254777-h8hw4m9f	128	7	IL-1	IL-1	NNP
cord-254777-h8hw4m9f	128	8	blockade	blockade	NN
cord-254777-h8hw4m9f	128	9	in	in	IN
cord-254777-h8hw4m9f	128	10	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	128	11	infection	infection	NN
cord-254777-h8hw4m9f	128	12	is	be	VBZ
cord-254777-h8hw4m9f	128	13	scarce	scarce	JJ
cord-254777-h8hw4m9f	128	14	but	but	CC
cord-254777-h8hw4m9f	128	15	encouraging	encouraging	JJ
cord-254777-h8hw4m9f	128	16	,	,	,
cord-254777-h8hw4m9f	128	17	with	with	IN
cord-254777-h8hw4m9f	128	18	multiple	multiple	JJ
cord-254777-h8hw4m9f	128	19	clinical	clinical	JJ
cord-254777-h8hw4m9f	128	20	trials	trial	NNS
cord-254777-h8hw4m9f	128	21	currently	currently	RB
cord-254777-h8hw4m9f	128	22	in	in	IN
cord-254777-h8hw4m9f	128	23	progress	progress	NN
cord-254777-h8hw4m9f	128	24	.	.	.
cord-254777-h8hw4m9f	129	1	Cavalli	Cavalli	NNP
cord-254777-h8hw4m9f	129	2	et	et	FW
cord-254777-h8hw4m9f	129	3	al	al	NNP
cord-254777-h8hw4m9f	129	4	[	[	-LRB-
cord-254777-h8hw4m9f	129	5	46	46	CD
cord-254777-h8hw4m9f	129	6	]	]	-RRB-
cord-254777-h8hw4m9f	129	7	describe	describe	VB
cord-254777-h8hw4m9f	129	8	a	a	DT
cord-254777-h8hw4m9f	129	9	retrospective	retrospective	JJ
cord-254777-h8hw4m9f	129	10	cohort	cohort	NN
cord-254777-h8hw4m9f	129	11	study	study	NN
cord-254777-h8hw4m9f	129	12	of	of	IN
cord-254777-h8hw4m9f	129	13	36	36	CD
cord-254777-h8hw4m9f	129	14	adult	adult	NN
cord-254777-h8hw4m9f	129	15	patients	patient	NNS
cord-254777-h8hw4m9f	129	16	treated	treat	VBN
cord-254777-h8hw4m9f	129	17	with	with	IN
cord-254777-h8hw4m9f	129	18	anakinra	anakinra	NNP
cord-254777-h8hw4m9f	129	19	(	(	-LRB-
cord-254777-h8hw4m9f	129	20	7	7	CD
cord-254777-h8hw4m9f	129	21	patients	patient	NNS
cord-254777-h8hw4m9f	129	22	received	receive	VBD
cord-254777-h8hw4m9f	129	23	'	'	``
cord-254777-h8hw4m9f	129	24	low	low	JJ
cord-254777-h8hw4m9f	129	25	-	-	HYPH
cord-254777-h8hw4m9f	129	26	dose	dose	NN
cord-254777-h8hw4m9f	129	27	'	'	''
cord-254777-h8hw4m9f	129	28	100	100	CD
cord-254777-h8hw4m9f	129	29	mg	mg	NNS
cord-254777-h8hw4m9f	129	30	subcutaneously	subcutaneously	RB
cord-254777-h8hw4m9f	129	31	BID	BID	VBD
cord-254777-h8hw4m9f	129	32	and	and	CC
cord-254777-h8hw4m9f	129	33	29	29	CD
cord-254777-h8hw4m9f	129	34	patients	patient	NNS
cord-254777-h8hw4m9f	129	35	received	receive	VBD
cord-254777-h8hw4m9f	129	36	'	'	``
cord-254777-h8hw4m9f	129	37	high	high	JJ
cord-254777-h8hw4m9f	129	38	-	-	HYPH
cord-254777-h8hw4m9f	129	39	dose	dose	NN
cord-254777-h8hw4m9f	129	40	'	'	''
cord-254777-h8hw4m9f	129	41	5	5	CD
cord-254777-h8hw4m9f	129	42	mg	mg	NNP
cord-254777-h8hw4m9f	129	43	/	/	SYM
cord-254777-h8hw4m9f	129	44	kg	kg	XX
cord-254777-h8hw4m9f	129	45	intravenously	intravenously	RB
cord-254777-h8hw4m9f	129	46	BID	BID	VBD
cord-254777-h8hw4m9f	129	47	)	)	-RRB-
cord-254777-h8hw4m9f	129	48	.	.	.
cord-254777-h8hw4m9f	130	1	The	the	DT
cord-254777-h8hw4m9f	130	2	authors	author	NNS
cord-254777-h8hw4m9f	130	3	report	report	VBP
cord-254777-h8hw4m9f	130	4	that	that	IN
cord-254777-h8hw4m9f	130	5	treatment	treatment	NN
cord-254777-h8hw4m9f	130	6	with	with	IN
cord-254777-h8hw4m9f	130	7	low	low	JJ
cord-254777-h8hw4m9f	130	8	-	-	HYPH
cord-254777-h8hw4m9f	130	9	dose	dose	NN
cord-254777-h8hw4m9f	130	10	anakinra	anakinra	NN
cord-254777-h8hw4m9f	130	11	demonstrated	demonstrate	VBD
cord-254777-h8hw4m9f	130	12	no	no	DT
cord-254777-h8hw4m9f	130	13	benefit	benefit	NN
cord-254777-h8hw4m9f	130	14	at	at	IN
cord-254777-h8hw4m9f	130	15	7	7	CD
cord-254777-h8hw4m9f	130	16	days	day	NNS
cord-254777-h8hw4m9f	130	17	and	and	CC
cord-254777-h8hw4m9f	130	18	was	be	VBD
cord-254777-h8hw4m9f	130	19	discontinued	discontinue	VBN
cord-254777-h8hw4m9f	130	20	,	,	,
cord-254777-h8hw4m9f	130	21	however	however	RB
cord-254777-h8hw4m9f	130	22	treatment	treatment	NN
cord-254777-h8hw4m9f	130	23	with	with	IN
cord-254777-h8hw4m9f	130	24	high	high	JJ
cord-254777-h8hw4m9f	130	25	-	-	HYPH
cord-254777-h8hw4m9f	130	26	dose	dose	NN
cord-254777-h8hw4m9f	130	27	anakinra	anakinra	NN
cord-254777-h8hw4m9f	130	28	resulted	result	VBD
cord-254777-h8hw4m9f	130	29	in	in	IN
cord-254777-h8hw4m9f	130	30	higher	high	JJR
cord-254777-h8hw4m9f	130	31	survival	survival	NN
cord-254777-h8hw4m9f	130	32	rate	rate	NN
cord-254777-h8hw4m9f	130	33	at	at	IN
cord-254777-h8hw4m9f	130	34	21	21	CD
cord-254777-h8hw4m9f	130	35	days	day	NNS
cord-254777-h8hw4m9f	130	36	(	(	-LRB-
cord-254777-h8hw4m9f	130	37	cumulative	cumulative	JJ
cord-254777-h8hw4m9f	130	38	survival	survival	NN
cord-254777-h8hw4m9f	130	39	of	of	IN
cord-254777-h8hw4m9f	130	40	90	90	CD
cord-254777-h8hw4m9f	130	41	%	%	NN
cord-254777-h8hw4m9f	130	42	in	in	IN
cord-254777-h8hw4m9f	130	43	the	the	DT
cord-254777-h8hw4m9f	130	44	anakinra	anakinra	NNP
cord-254777-h8hw4m9f	130	45	group	group	NN
cord-254777-h8hw4m9f	130	46	versus	versus	IN
cord-254777-h8hw4m9f	130	47	56	56	CD
cord-254777-h8hw4m9f	130	48	%	%	NN
cord-254777-h8hw4m9f	130	49	in	in	IN
cord-254777-h8hw4m9f	130	50	the	the	DT
cord-254777-h8hw4m9f	130	51	standard	standard	JJ
cord-254777-h8hw4m9f	130	52	treatment	treatment	NN
cord-254777-h8hw4m9f	130	53	group	group	NN
cord-254777-h8hw4m9f	130	54	(	(	-LRB-
cord-254777-h8hw4m9f	130	55	p=0.009	p=0.009	NN
cord-254777-h8hw4m9f	130	56	)	)	-RRB-
cord-254777-h8hw4m9f	130	57	)	)	-RRB-
cord-254777-h8hw4m9f	130	58	.	.	.
cord-254777-h8hw4m9f	131	1	Pontali	Pontali	NNP
cord-254777-h8hw4m9f	131	2	et	et	NNP
cord-254777-h8hw4m9f	131	3	al	al	NNP
cord-254777-h8hw4m9f	131	4	[	[	-LRB-
cord-254777-h8hw4m9f	131	5	48	48	CD
cord-254777-h8hw4m9f	131	6	]	]	-RRB-
cord-254777-h8hw4m9f	131	7	also	also	RB
cord-254777-h8hw4m9f	131	8	described	describe	VBN
cord-254777-h8hw4m9f	131	9	early	early	JJ
cord-254777-h8hw4m9f	131	10	treatment	treatment	NN
cord-254777-h8hw4m9f	131	11	with	with	IN
cord-254777-h8hw4m9f	131	12	high	high	JJ
cord-254777-h8hw4m9f	131	13	dose	dose	NN
cord-254777-h8hw4m9f	131	14	IV	IV	NNP
cord-254777-h8hw4m9f	131	15	anakinra	anakinra	NNP
cord-254777-h8hw4m9f	131	16	(	(	-LRB-
cord-254777-h8hw4m9f	131	17	100	100	CD
cord-254777-h8hw4m9f	131	18	mg	mg	NNP
cord-254777-h8hw4m9f	131	19	IV	IV	NNP
cord-254777-h8hw4m9f	131	20	every	every	DT
cord-254777-h8hw4m9f	131	21	8	8	CD
cord-254777-h8hw4m9f	131	22	hours	hour	NNS
cord-254777-h8hw4m9f	131	23	)	)	-RRB-
cord-254777-h8hw4m9f	131	24	for	for	IN
cord-254777-h8hw4m9f	131	25	5	5	CD
cord-254777-h8hw4m9f	131	26	patients	patient	NNS
cord-254777-h8hw4m9f	131	27	with	with	IN
cord-254777-h8hw4m9f	131	28	COVID-19	covid-19	JJ
cord-254777-h8hw4m9f	131	29	and	and	CC
cord-254777-h8hw4m9f	131	30	severe	severe	JJ
cord-254777-h8hw4m9f	131	31	lung	lung	NN
cord-254777-h8hw4m9f	131	32	involvement	involvement	NN
cord-254777-h8hw4m9f	131	33	.	.	.
cord-254777-h8hw4m9f	132	1	All	all	DT
cord-254777-h8hw4m9f	132	2	five	five	CD
cord-254777-h8hw4m9f	132	3	patients	patient	NNS
cord-254777-h8hw4m9f	132	4	had	have	VBD
cord-254777-h8hw4m9f	132	5	rapid	rapid	JJ
cord-254777-h8hw4m9f	132	6	resolution	resolution	NN
cord-254777-h8hw4m9f	132	7	of	of	IN
cord-254777-h8hw4m9f	132	8	systemic	systemic	JJ
cord-254777-h8hw4m9f	132	9	inflammation	inflammation	NN
cord-254777-h8hw4m9f	132	10	and	and	CC
cord-254777-h8hw4m9f	132	11	remarkable	remarkable	JJ
cord-254777-h8hw4m9f	132	12	improvement	improvement	NN
cord-254777-h8hw4m9f	132	13	in	in	IN
cord-254777-h8hw4m9f	132	14	respiratory	respiratory	JJ
cord-254777-h8hw4m9f	132	15	status	status	NN
cord-254777-h8hw4m9f	132	16	,	,	,
cord-254777-h8hw4m9f	132	17	with	with	IN
cord-254777-h8hw4m9f	132	18	no	no	DT
cord-254777-h8hw4m9f	132	19	adverse	adverse	JJ
cord-254777-h8hw4m9f	132	20	effects	effect	NNS
cord-254777-h8hw4m9f	132	21	seen	see	VBN
cord-254777-h8hw4m9f	132	22	.	.	.
cord-254777-h8hw4m9f	133	1	Use	use	NN
cord-254777-h8hw4m9f	133	2	of	of	IN
cord-254777-h8hw4m9f	133	3	immunoglobulins	immunoglobulin	NNS
cord-254777-h8hw4m9f	133	4	is	be	VBZ
cord-254777-h8hw4m9f	133	5	another	another	DT
cord-254777-h8hw4m9f	133	6	potential	potential	JJ
cord-254777-h8hw4m9f	133	7	adjunctive	adjunctive	JJ
cord-254777-h8hw4m9f	133	8	therapy	therapy	NN
cord-254777-h8hw4m9f	133	9	for	for	IN
cord-254777-h8hw4m9f	133	10	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	133	11	.	.	.
cord-254777-h8hw4m9f	134	1	The	the	DT
cord-254777-h8hw4m9f	134	2	rationale	rationale	NN
cord-254777-h8hw4m9f	134	3	for	for	IN
cord-254777-h8hw4m9f	134	4	use	use	NN
cord-254777-h8hw4m9f	134	5	of	of	IN
cord-254777-h8hw4m9f	134	6	hyperimmune	hyperimmune	NN
cord-254777-h8hw4m9f	134	7	immunoglobulins	immunoglobulin	NNS
cord-254777-h8hw4m9f	134	8	or	or	CC
cord-254777-h8hw4m9f	134	9	intravenous	intravenous	JJ
cord-254777-h8hw4m9f	134	10	immunoglobulins	immunoglobulin	NNS
cord-254777-h8hw4m9f	134	11	(	(	-LRB-
cord-254777-h8hw4m9f	134	12	IVIG	IVIG	NNP
cord-254777-h8hw4m9f	134	13	)	)	-RRB-
cord-254777-h8hw4m9f	134	14	is	be	VBZ
cord-254777-h8hw4m9f	134	15	that	that	IN
cord-254777-h8hw4m9f	134	16	the	the	DT
cord-254777-h8hw4m9f	134	17	high	high	JJ
cord-254777-h8hw4m9f	134	18	IgG	igg	NN
cord-254777-h8hw4m9f	134	19	levels	level	NNS
cord-254777-h8hw4m9f	134	20	in	in	IN
cord-254777-h8hw4m9f	134	21	serum	serum	NN
cord-254777-h8hw4m9f	134	22	help	help	NN
cord-254777-h8hw4m9f	134	23	block	block	VB
cord-254777-h8hw4m9f	134	24	Fcγ	Fcγ	NNP
cord-254777-h8hw4m9f	134	25	receptors	receptor	NNS
cord-254777-h8hw4m9f	134	26	,	,	,
cord-254777-h8hw4m9f	134	27	neutralize	neutralize	VB
cord-254777-h8hw4m9f	134	28	pathogens	pathogen	NNS
cord-254777-h8hw4m9f	134	29	in	in	IN
cord-254777-h8hw4m9f	134	30	respiratory	respiratory	JJ
cord-254777-h8hw4m9f	134	31	tract	tract	NN
cord-254777-h8hw4m9f	134	32	,	,	,
cord-254777-h8hw4m9f	134	33	block	block	NN
cord-254777-h8hw4m9f	134	34	receptors	receptor	NNS
cord-254777-h8hw4m9f	134	35	associate	associate	VBP
cord-254777-h8hw4m9f	134	36	with	with	IN
cord-254777-h8hw4m9f	134	37	target	target	NN
cord-254777-h8hw4m9f	134	38	cells	cell	NNS
cord-254777-h8hw4m9f	134	39	,	,	,
cord-254777-h8hw4m9f	134	40	as	as	RB
cord-254777-h8hw4m9f	134	41	well	well	RB
cord-254777-h8hw4m9f	134	42	as	as	IN
cord-254777-h8hw4m9f	134	43	influence	influence	NN
cord-254777-h8hw4m9f	134	44	lymphocyte	lymphocyte	NN
cord-254777-h8hw4m9f	134	45	differentiation	differentiation	NN
cord-254777-h8hw4m9f	134	46	and	and	CC
cord-254777-h8hw4m9f	134	47	maturation	maturation	NN
cord-254777-h8hw4m9f	134	48	[	[	-LRB-
cord-254777-h8hw4m9f	134	49	2	2	CD
cord-254777-h8hw4m9f	134	50	,	,	,
cord-254777-h8hw4m9f	134	51	49	49	CD
cord-254777-h8hw4m9f	134	52	]	]	-RRB-
cord-254777-h8hw4m9f	134	53	.	.	.
cord-254777-h8hw4m9f	135	1	In	in	IN
cord-254777-h8hw4m9f	135	2	addition	addition	NN
cord-254777-h8hw4m9f	135	3	,	,	,
cord-254777-h8hw4m9f	135	4	IVIG	IVIG	NNP
cord-254777-h8hw4m9f	135	5	has	have	VBZ
cord-254777-h8hw4m9f	135	6	been	be	VBN
cord-254777-h8hw4m9f	135	7	proposed	propose	VBN
cord-254777-h8hw4m9f	135	8	to	to	TO
cord-254777-h8hw4m9f	135	9	inhibit	inhibit	VB
cord-254777-h8hw4m9f	135	10	cytokine	cytokine	JJ
cord-254777-h8hw4m9f	135	11	production	production	NN
cord-254777-h8hw4m9f	135	12	and	and	CC
cord-254777-h8hw4m9f	135	13	function	function	NN
cord-254777-h8hw4m9f	135	14	(	(	-LRB-
cord-254777-h8hw4m9f	135	15	particularly	particularly	RB
cord-254777-h8hw4m9f	135	16	IL-1	IL-1	NNP
cord-254777-h8hw4m9f	135	17	and	and	CC
cord-254777-h8hw4m9f	135	18	IL-6	IL-6	NNP
cord-254777-h8hw4m9f	135	19	)	)	-RRB-
cord-254777-h8hw4m9f	135	20	.	.	.
cord-254777-h8hw4m9f	136	1	This	this	DT
cord-254777-h8hw4m9f	136	2	treatment	treatment	NN
cord-254777-h8hw4m9f	136	3	has	have	VBZ
cord-254777-h8hw4m9f	136	4	been	be	VBN
cord-254777-h8hw4m9f	136	5	studied	study	VBN
cord-254777-h8hw4m9f	136	6	in	in	IN
cord-254777-h8hw4m9f	136	7	other	other	JJ
cord-254777-h8hw4m9f	136	8	viral	viral	JJ
cord-254777-h8hw4m9f	136	9	infections	infection	NNS
cord-254777-h8hw4m9f	136	10	,	,	,
cord-254777-h8hw4m9f	136	11	including	include	VBG
cord-254777-h8hw4m9f	136	12	influenza	influenza	NN
cord-254777-h8hw4m9f	136	13	,	,	,
cord-254777-h8hw4m9f	136	14	SARS	SARS	NNP
cord-254777-h8hw4m9f	136	15	and	and	CC
cord-254777-h8hw4m9f	136	16	MERS	MERS	NNP
cord-254777-h8hw4m9f	136	17	,	,	,
cord-254777-h8hw4m9f	136	18	with	with	IN
cord-254777-h8hw4m9f	136	19	reported	report	VBN
cord-254777-h8hw4m9f	136	20	reduction	reduction	NN
cord-254777-h8hw4m9f	136	21	in	in	IN
cord-254777-h8hw4m9f	136	22	mortality	mortality	NN
cord-254777-h8hw4m9f	136	23	,	,	,
cord-254777-h8hw4m9f	136	24	however	however	RB
cord-254777-h8hw4m9f	136	25	study	study	NN
cord-254777-h8hw4m9f	136	26	quality	quality	NN
cord-254777-h8hw4m9f	136	27	was	be	VBD
cord-254777-h8hw4m9f	136	28	low	low	JJ
cord-254777-h8hw4m9f	136	29	with	with	IN
cord-254777-h8hw4m9f	136	30	risk	risk	NN
cord-254777-h8hw4m9f	136	31	for	for	IN
cord-254777-h8hw4m9f	136	32	bias	bias	NN
cord-254777-h8hw4m9f	136	33	[	[	-LRB-
cord-254777-h8hw4m9f	136	34	50	50	CD
cord-254777-h8hw4m9f	136	35	]	]	-RRB-
cord-254777-h8hw4m9f	136	36	.	.	.
cord-254777-h8hw4m9f	137	1	Data	datum	NNS
cord-254777-h8hw4m9f	137	2	in	in	IN
cord-254777-h8hw4m9f	137	3	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	137	4	is	be	VBZ
cord-254777-h8hw4m9f	137	5	limited	limit	VBN
cord-254777-h8hw4m9f	137	6	.	.	.
cord-254777-h8hw4m9f	138	1	Xie	Xie	NNP
cord-254777-h8hw4m9f	138	2	et	et	FW
cord-254777-h8hw4m9f	138	3	al	al	NNP
cord-254777-h8hw4m9f	138	4	describe	describe	VB
cord-254777-h8hw4m9f	138	5	a	a	DT
cord-254777-h8hw4m9f	138	6	retrospective	retrospective	JJ
cord-254777-h8hw4m9f	138	7	study	study	NN
cord-254777-h8hw4m9f	138	8	of	of	IN
cord-254777-h8hw4m9f	138	9	58	58	CD
cord-254777-h8hw4m9f	138	10	cases	case	NNS
cord-254777-h8hw4m9f	138	11	of	of	IN
cord-254777-h8hw4m9f	138	12	severe	severe	JJ
cord-254777-h8hw4m9f	138	13	or	or	CC
cord-254777-h8hw4m9f	138	14	critical	critical	JJ
cord-254777-h8hw4m9f	138	15	patients	patient	NNS
cord-254777-h8hw4m9f	138	16	treated	treat	VBN
cord-254777-h8hw4m9f	138	17	with	with	IN
cord-254777-h8hw4m9f	138	18	IVIG	IVIG	NNP
cord-254777-h8hw4m9f	138	19	(	(	-LRB-
cord-254777-h8hw4m9f	138	20	in	in	IN
cord-254777-h8hw4m9f	138	21	addition	addition	NN
cord-254777-h8hw4m9f	138	22	to	to	IN
cord-254777-h8hw4m9f	138	23	standard	standard	JJ
cord-254777-h8hw4m9f	138	24	therapy	therapy	NN
cord-254777-h8hw4m9f	138	25	)	)	-RRB-
cord-254777-h8hw4m9f	138	26	either	either	CC
cord-254777-h8hw4m9f	138	27	within	within	IN
cord-254777-h8hw4m9f	138	28	48	48	CD
cord-254777-h8hw4m9f	138	29	hours	hour	NNS
cord-254777-h8hw4m9f	138	30	from	from	IN
cord-254777-h8hw4m9f	138	31	admission	admission	NN
cord-254777-h8hw4m9f	138	32	or	or	CC
cord-254777-h8hw4m9f	138	33	after	after	IN
cord-254777-h8hw4m9f	138	34	48	48	CD
cord-254777-h8hw4m9f	138	35	hours	hour	NNS
cord-254777-h8hw4m9f	138	36	[	[	-LRB-
cord-254777-h8hw4m9f	138	37	49	49	CD
cord-254777-h8hw4m9f	138	38	]	]	-RRB-
cord-254777-h8hw4m9f	138	39	.	.	.
cord-254777-h8hw4m9f	139	1	Patients	patient	NNS
cord-254777-h8hw4m9f	139	2	in	in	IN
cord-254777-h8hw4m9f	139	3	the	the	DT
cord-254777-h8hw4m9f	139	4	early	early	JJ
cord-254777-h8hw4m9f	139	5	treatment	treatment	NN
cord-254777-h8hw4m9f	139	6	group	group	NN
cord-254777-h8hw4m9f	139	7	were	be	VBD
cord-254777-h8hw4m9f	139	8	found	find	VBN
cord-254777-h8hw4m9f	139	9	to	to	TO
cord-254777-h8hw4m9f	139	10	have	have	VB
cord-254777-h8hw4m9f	139	11	significant	significant	JJ
cord-254777-h8hw4m9f	139	12	improvement	improvement	NN
cord-254777-h8hw4m9f	139	13	in	in	IN
cord-254777-h8hw4m9f	139	14	28	28	CD
cord-254777-h8hw4m9f	139	15	days	day	NNS
cord-254777-h8hw4m9f	139	16	mortality	mortality	NN
cord-254777-h8hw4m9f	139	17	(	(	-LRB-
cord-254777-h8hw4m9f	139	18	P=0.009	p=0.009	NN
cord-254777-h8hw4m9f	139	19	)	)	-RRB-
cord-254777-h8hw4m9f	139	20	,	,	,
cord-254777-h8hw4m9f	139	21	decreased	decrease	VBD
cord-254777-h8hw4m9f	139	22	length	length	NN
cord-254777-h8hw4m9f	139	23	of	of	IN
cord-254777-h8hw4m9f	139	24	stay	stay	NN
cord-254777-h8hw4m9f	139	25	(	(	-LRB-
cord-254777-h8hw4m9f	139	26	p=0.0055	p=0.0055	NNP
cord-254777-h8hw4m9f	139	27	)	)	-RRB-
cord-254777-h8hw4m9f	139	28	,	,	,
cord-254777-h8hw4m9f	139	29	length	length	NN
cord-254777-h8hw4m9f	139	30	of	of	IN
cord-254777-h8hw4m9f	139	31	stay	stay	NN
cord-254777-h8hw4m9f	139	32	in	in	IN
cord-254777-h8hw4m9f	139	33	ICU	ICU	NNP
cord-254777-h8hw4m9f	139	34	(	(	-LRB-
cord-254777-h8hw4m9f	139	35	p=0.0453	p=0.0453	NNP
cord-254777-h8hw4m9f	139	36	)	)	-RRB-
cord-254777-h8hw4m9f	139	37	and	and	CC
cord-254777-h8hw4m9f	139	38	need	need	VB
cord-254777-h8hw4m9f	139	39	for	for	IN
cord-254777-h8hw4m9f	139	40	mechanical	mechanical	JJ
cord-254777-h8hw4m9f	139	41	ventilation	ventilation	NN
cord-254777-h8hw4m9f	139	42	(	(	-LRB-
cord-254777-h8hw4m9f	139	43	p=0.016	p=0.016	RB
cord-254777-h8hw4m9f	139	44	)	)	-RRB-
cord-254777-h8hw4m9f	139	45	.	.	.
cord-254777-h8hw4m9f	140	1	IVIG	IVIG	NNP
cord-254777-h8hw4m9f	140	2	has	have	VBZ
cord-254777-h8hw4m9f	140	3	been	be	VBN
cord-254777-h8hw4m9f	140	4	considered	consider	VBN
cord-254777-h8hw4m9f	140	5	for	for	IN
cord-254777-h8hw4m9f	140	6	the	the	DT
cord-254777-h8hw4m9f	140	7	treatment	treatment	NN
cord-254777-h8hw4m9f	140	8	MIS	MIS	NNP
cord-254777-h8hw4m9f	140	9	-	-	HYPH
cord-254777-h8hw4m9f	140	10	C	C	NNP
cord-254777-h8hw4m9f	140	11	given	give	VBD
cord-254777-h8hw4m9f	140	12	the	the	DT
cord-254777-h8hw4m9f	140	13	similarity	similarity	NN
cord-254777-h8hw4m9f	140	14	in	in	IN
cord-254777-h8hw4m9f	140	15	features	feature	NNS
cord-254777-h8hw4m9f	140	16	with	with	IN
cord-254777-h8hw4m9f	140	17	Kawasaki	Kawasaki	NNP
cord-254777-h8hw4m9f	140	18	disease	disease	NN
cord-254777-h8hw4m9f	140	19	(	(	-LRB-
cord-254777-h8hw4m9f	140	20	KD	KD	NNP
cord-254777-h8hw4m9f	140	21	)	)	-RRB-
cord-254777-h8hw4m9f	140	22	.	.	.
cord-254777-h8hw4m9f	141	1	Since	since	IN
cord-254777-h8hw4m9f	141	2	IVIG	IVIG	NNP
cord-254777-h8hw4m9f	141	3	is	be	VBZ
cord-254777-h8hw4m9f	141	4	standard	standard	JJ
cord-254777-h8hw4m9f	141	5	treatment	treatment	NN
cord-254777-h8hw4m9f	141	6	for	for	IN
cord-254777-h8hw4m9f	141	7	KD	KD	NNP
cord-254777-h8hw4m9f	141	8	,	,	,
cord-254777-h8hw4m9f	141	9	IVIG	IVIG	NNP
cord-254777-h8hw4m9f	141	10	has	have	VBZ
cord-254777-h8hw4m9f	141	11	been	be	VBN
cord-254777-h8hw4m9f	141	12	used	use	VBN
cord-254777-h8hw4m9f	141	13	for	for	IN
cord-254777-h8hw4m9f	141	14	treatment	treatment	NN
cord-254777-h8hw4m9f	141	15	of	of	IN
cord-254777-h8hw4m9f	141	16	MIS	MIS	NNP
cord-254777-h8hw4m9f	141	17	-	-	HYPH
cord-254777-h8hw4m9f	141	18	C	C	NNP
cord-254777-h8hw4m9f	141	19	in	in	IN
cord-254777-h8hw4m9f	141	20	most	most	JJS
cord-254777-h8hw4m9f	141	21	reports	report	NNS
cord-254777-h8hw4m9f	141	22	to	to	IN
cord-254777-h8hw4m9f	141	23	date	date	NN
cord-254777-h8hw4m9f	141	24	,	,	,
cord-254777-h8hw4m9f	141	25	in	in	IN
cord-254777-h8hw4m9f	141	26	combination	combination	NN
cord-254777-h8hw4m9f	141	27	with	with	IN
cord-254777-h8hw4m9f	141	28	other	other	JJ
cord-254777-h8hw4m9f	141	29	agents	agent	NNS
cord-254777-h8hw4m9f	141	30	such	such	JJ
cord-254777-h8hw4m9f	141	31	as	as	IN
cord-254777-h8hw4m9f	141	32	corticosteroids	corticosteroid	NNS
cord-254777-h8hw4m9f	141	33	and	and	CC
cord-254777-h8hw4m9f	141	34	aspirin	aspirin	NN
cord-254777-h8hw4m9f	141	35	(	(	-LRB-
cord-254777-h8hw4m9f	141	36	Table	table	NN
cord-254777-h8hw4m9f	141	37	1	1	CD
cord-254777-h8hw4m9f	141	38	)	)	-RRB-
cord-254777-h8hw4m9f	141	39	.	.	.
cord-254777-h8hw4m9f	142	1	Passive	passive	JJ
cord-254777-h8hw4m9f	142	2	immunization	immunization	NN
cord-254777-h8hw4m9f	142	3	can	can	MD
cord-254777-h8hw4m9f	142	4	also	also	RB
cord-254777-h8hw4m9f	142	5	be	be	VB
cord-254777-h8hw4m9f	142	6	applied	apply	VBN
cord-254777-h8hw4m9f	142	7	through	through	IN
cord-254777-h8hw4m9f	142	8	use	use	NN
cord-254777-h8hw4m9f	142	9	of	of	IN
cord-254777-h8hw4m9f	142	10	convalescent	convalescent	JJ
cord-254777-h8hw4m9f	142	11	plasma	plasma	NN
cord-254777-h8hw4m9f	142	12	.	.	.
cord-254777-h8hw4m9f	143	1	This	this	DT
cord-254777-h8hw4m9f	143	2	treatment	treatment	NN
cord-254777-h8hw4m9f	143	3	modality	modality	NN
cord-254777-h8hw4m9f	143	4	has	have	VBZ
cord-254777-h8hw4m9f	143	5	been	be	VBN
cord-254777-h8hw4m9f	143	6	trialed	triale	VBN
cord-254777-h8hw4m9f	143	7	since	since	IN
cord-254777-h8hw4m9f	143	8	early	early	JJ
cord-254777-h8hw4m9f	143	9	20	20	CD
cord-254777-h8hw4m9f	143	10	th	th	XX
cord-254777-h8hw4m9f	143	11	century	century	NN
cord-254777-h8hw4m9f	143	12	for	for	IN
cord-254777-h8hw4m9f	143	13	infections	infection	NNS
cord-254777-h8hw4m9f	143	14	with	with	IN
cord-254777-h8hw4m9f	143	15	'	'	``
cord-254777-h8hw4m9f	143	16	Spanish	spanish	JJ
cord-254777-h8hw4m9f	143	17	flu	flu	NN
cord-254777-h8hw4m9f	143	18	'	'	''
cord-254777-h8hw4m9f	143	19	Influenza	Influenza	NNP
cord-254777-h8hw4m9f	143	20	A	A	NNP
cord-254777-h8hw4m9f	143	21	(	(	-LRB-
cord-254777-h8hw4m9f	143	22	H1N1	H1N1	NNP
cord-254777-h8hw4m9f	143	23	)	)	-RRB-
cord-254777-h8hw4m9f	143	24	,	,	,
cord-254777-h8hw4m9f	143	25	SARS	SARS	NNP
cord-254777-h8hw4m9f	143	26	-	-	HYPH
cord-254777-h8hw4m9f	143	27	CoV	CoV	NNP
cord-254777-h8hw4m9f	143	28	,	,	,
cord-254777-h8hw4m9f	143	29	West	West	NNP
cord-254777-h8hw4m9f	143	30	Nile	Nile	NNP
cord-254777-h8hw4m9f	143	31	virus	virus	NN
cord-254777-h8hw4m9f	143	32	and	and	CC
cord-254777-h8hw4m9f	143	33	Ebola	Ebola	NNP
cord-254777-h8hw4m9f	143	34	,	,	,
cord-254777-h8hw4m9f	143	35	with	with	IN
cord-254777-h8hw4m9f	143	36	mixed	mixed	JJ
cord-254777-h8hw4m9f	143	37	effect	effect	NN
cord-254777-h8hw4m9f	143	38	.	.	.
cord-254777-h8hw4m9f	144	1	Some	some	DT
cord-254777-h8hw4m9f	144	2	studies	study	NNS
cord-254777-h8hw4m9f	144	3	found	find	VBD
cord-254777-h8hw4m9f	144	4	benefit	benefit	NN
cord-254777-h8hw4m9f	144	5	in	in	IN
cord-254777-h8hw4m9f	144	6	influenza	influenza	NN
cord-254777-h8hw4m9f	144	7	and	and	CC
cord-254777-h8hw4m9f	144	8	SARS	SARS	NNP
cord-254777-h8hw4m9f	144	9	infection	infection	NN
cord-254777-h8hw4m9f	144	10	when	when	WRB
cord-254777-h8hw4m9f	144	11	administered	administer	VBN
cord-254777-h8hw4m9f	144	12	early	early	RB
cord-254777-h8hw4m9f	144	13	in	in	IN
cord-254777-h8hw4m9f	144	14	the	the	DT
cord-254777-h8hw4m9f	144	15	course	course	NN
cord-254777-h8hw4m9f	144	16	of	of	IN
cord-254777-h8hw4m9f	144	17	the	the	DT
cord-254777-h8hw4m9f	144	18	disease	disease	NN
cord-254777-h8hw4m9f	144	19	,	,	,
cord-254777-h8hw4m9f	144	20	however	however	RB
cord-254777-h8hw4m9f	144	21	no	no	DT
cord-254777-h8hw4m9f	144	22	similar	similar	JJ
cord-254777-h8hw4m9f	144	23	response	response	NN
cord-254777-h8hw4m9f	144	24	was	be	VBD
cord-254777-h8hw4m9f	144	25	found	find	VBN
cord-254777-h8hw4m9f	144	26	in	in	IN
cord-254777-h8hw4m9f	144	27	Ebola	Ebola	NNP
cord-254777-h8hw4m9f	144	28	virus	virus	NN
cord-254777-h8hw4m9f	144	29	disease	disease	NN
cord-254777-h8hw4m9f	144	30	[	[	-LRB-
cord-254777-h8hw4m9f	144	31	51	51	CD
cord-254777-h8hw4m9f	144	32	]	]	-RRB-
cord-254777-h8hw4m9f	144	33	.	.	.
cord-254777-h8hw4m9f	145	1	Importantly	importantly	RB
cord-254777-h8hw4m9f	145	2	,	,	,
cord-254777-h8hw4m9f	145	3	convalescent	convalescent	JJ
cord-254777-h8hw4m9f	145	4	plasma	plasma	NN
cord-254777-h8hw4m9f	145	5	has	have	VBZ
cord-254777-h8hw4m9f	145	6	been	be	VBN
cord-254777-h8hw4m9f	145	7	shown	show	VBN
cord-254777-h8hw4m9f	145	8	to	to	TO
cord-254777-h8hw4m9f	145	9	be	be	VB
cord-254777-h8hw4m9f	145	10	safe	safe	JJ
cord-254777-h8hw4m9f	145	11	when	when	WRB
cord-254777-h8hw4m9f	145	12	administered	administer	VBN
cord-254777-h8hw4m9f	145	13	in	in	IN
cord-254777-h8hw4m9f	145	14	infection	infection	NN
cord-254777-h8hw4m9f	145	15	with	with	IN
cord-254777-h8hw4m9f	145	16	multiple	multiple	JJ
cord-254777-h8hw4m9f	145	17	viruses	virus	NNS
cord-254777-h8hw4m9f	145	18	including	include	VBG
cord-254777-h8hw4m9f	145	19	influenza	influenza	NN
cord-254777-h8hw4m9f	145	20	,	,	,
cord-254777-h8hw4m9f	145	21	SARS	SARS	NNP
cord-254777-h8hw4m9f	145	22	,	,	,
cord-254777-h8hw4m9f	145	23	MERS	MERS	NNP
cord-254777-h8hw4m9f	145	24	,	,	,
cord-254777-h8hw4m9f	145	25	Ebola	Ebola	NNP
cord-254777-h8hw4m9f	145	26	and	and	CC
cord-254777-h8hw4m9f	145	27	SARS	SARS	NNP
cord-254777-h8hw4m9f	145	28	-	-	HYPH
cord-254777-h8hw4m9f	145	29	CoV-2	CoV-2	NNP
cord-254777-h8hw4m9f	145	30	[	[	-LRB-
cord-254777-h8hw4m9f	145	31	51	51	CD
cord-254777-h8hw4m9f	145	32	]	]	-RRB-
cord-254777-h8hw4m9f	145	33	.	.	.
cord-254777-h8hw4m9f	146	1	Convalescent	convalescent	JJ
cord-254777-h8hw4m9f	146	2	plasma	plasma	NN
cord-254777-h8hw4m9f	146	3	contains	contain	VBZ
cord-254777-h8hw4m9f	146	4	both	both	DT
cord-254777-h8hw4m9f	146	5	neutralizing	neutralize	VBG
cord-254777-h8hw4m9f	146	6	antibodies	antibody	NNS
cord-254777-h8hw4m9f	146	7	to	to	IN
cord-254777-h8hw4m9f	146	8	the	the	DT
cord-254777-h8hw4m9f	146	9	viral	viral	JJ
cord-254777-h8hw4m9f	146	10	infection	infection	NN
cord-254777-h8hw4m9f	146	11	as	as	RB
cord-254777-h8hw4m9f	146	12	well	well	RB
cord-254777-h8hw4m9f	146	13	as	as	IN
cord-254777-h8hw4m9f	146	14	other	other	JJ
cord-254777-h8hw4m9f	146	15	protective	protective	JJ
cord-254777-h8hw4m9f	146	16	antibodies	antibody	NNS
cord-254777-h8hw4m9f	146	17	including	include	VBG
cord-254777-h8hw4m9f	146	18	IgG	IgG	NNP
cord-254777-h8hw4m9f	146	19	,	,	,
cord-254777-h8hw4m9f	146	20	IgM	IgM	NNP
cord-254777-h8hw4m9f	146	21	,	,	,
cord-254777-h8hw4m9f	146	22	anti	anti	JJ
cord-254777-h8hw4m9f	146	23	-	-	JJ
cord-254777-h8hw4m9f	146	24	inflammatory	inflammatory	JJ
cord-254777-h8hw4m9f	146	25	cytokines	cytokine	NNS
cord-254777-h8hw4m9f	146	26	;	;	:
cord-254777-h8hw4m9f	146	27	it	-PRON-	PRP
cord-254777-h8hw4m9f	146	28	plays	play	VBZ
cord-254777-h8hw4m9f	146	29	a	a	DT
cord-254777-h8hw4m9f	146	30	role	role	NN
cord-254777-h8hw4m9f	146	31	in	in	IN
cord-254777-h8hw4m9f	146	32	both	both	CC
cord-254777-h8hw4m9f	146	33	anti	anti	JJ
cord-254777-h8hw4m9f	146	34	-	-	JJ
cord-254777-h8hw4m9f	146	35	viral	viral	JJ
cord-254777-h8hw4m9f	146	36	mechanisms	mechanism	NNS
cord-254777-h8hw4m9f	146	37	as	as	RB
cord-254777-h8hw4m9f	146	38	well	well	RB
cord-254777-h8hw4m9f	146	39	as	as	IN
cord-254777-h8hw4m9f	146	40	multiple	multiple	JJ
cord-254777-h8hw4m9f	146	41	mechanisms	mechanism	NNS
cord-254777-h8hw4m9f	146	42	of	of	IN
cord-254777-h8hw4m9f	146	43	immunomodulation	immunomodulation	NN
cord-254777-h8hw4m9f	146	44	.	.	.
cord-254777-h8hw4m9f	147	1	Multiple	multiple	JJ
cord-254777-h8hw4m9f	147	2	convalescent	convalescent	JJ
cord-254777-h8hw4m9f	147	3	plasma	plasma	NN
cord-254777-h8hw4m9f	147	4	trials	trial	NNS
cord-254777-h8hw4m9f	147	5	in	in	IN
cord-254777-h8hw4m9f	147	6	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	147	7	are	be	VBP
cord-254777-h8hw4m9f	147	8	currently	currently	RB
cord-254777-h8hw4m9f	147	9	ongoing	ongoing	JJ
cord-254777-h8hw4m9f	147	10	.	.	.
cord-254777-h8hw4m9f	148	1	The	the	DT
cord-254777-h8hw4m9f	148	2	JAK	JAK	NNP
cord-254777-h8hw4m9f	148	3	/	/	SYM
cord-254777-h8hw4m9f	148	4	STAT	stat	NN
cord-254777-h8hw4m9f	148	5	pathway	pathway	NN
cord-254777-h8hw4m9f	148	6	is	be	VBZ
cord-254777-h8hw4m9f	148	7	the	the	DT
cord-254777-h8hw4m9f	148	8	principal	principal	JJ
cord-254777-h8hw4m9f	148	9	signaling	signal	VBG
cord-254777-h8hw4m9f	148	10	mechanism	mechanism	NN
cord-254777-h8hw4m9f	148	11	for	for	IN
cord-254777-h8hw4m9f	148	12	a	a	DT
cord-254777-h8hw4m9f	148	13	wide	wide	JJ
cord-254777-h8hw4m9f	148	14	array	array	NN
cord-254777-h8hw4m9f	148	15	of	of	IN
cord-254777-h8hw4m9f	148	16	cytokine	cytokine	NN
cord-254777-h8hw4m9f	148	17	and	and	CC
cord-254777-h8hw4m9f	148	18	growth	growth	NN
cord-254777-h8hw4m9f	148	19	factors	factor	NNS
cord-254777-h8hw4m9f	148	20	,	,	,
cord-254777-h8hw4m9f	148	21	and	and	CC
cord-254777-h8hw4m9f	148	22	JAK	JAK	NNP
cord-254777-h8hw4m9f	148	23	activation	activation	NN
cord-254777-h8hw4m9f	148	24	stimulates	stimulate	VBZ
cord-254777-h8hw4m9f	148	25	cell	cell	NN
cord-254777-h8hw4m9f	148	26	proliferation	proliferation	NN
cord-254777-h8hw4m9f	148	27	,	,	,
cord-254777-h8hw4m9f	148	28	differentiation	differentiation	NN
cord-254777-h8hw4m9f	148	29	,	,	,
cord-254777-h8hw4m9f	148	30	migration	migration	NN
cord-254777-h8hw4m9f	148	31	and	and	CC
cord-254777-h8hw4m9f	148	32	apoptosis	apoptosis	NN
cord-254777-h8hw4m9f	148	33	[	[	-LRB-
cord-254777-h8hw4m9f	148	34	52	52	CD
cord-254777-h8hw4m9f	148	35	]	]	-RRB-
cord-254777-h8hw4m9f	148	36	.	.	.
cord-254777-h8hw4m9f	149	1	This	this	DT
cord-254777-h8hw4m9f	149	2	pathway	pathway	NN
cord-254777-h8hw4m9f	149	3	is	be	VBZ
cord-254777-h8hw4m9f	149	4	thought	think	VBN
cord-254777-h8hw4m9f	149	5	to	to	TO
cord-254777-h8hw4m9f	149	6	be	be	VB
cord-254777-h8hw4m9f	149	7	used	use	VBN
cord-254777-h8hw4m9f	149	8	by	by	IN
cord-254777-h8hw4m9f	149	9	SARS	SARS	NNP
cord-254777-h8hw4m9f	149	10	-	-	HYPH
cord-254777-h8hw4m9f	149	11	CoV-2	CoV-2	NNP
cord-254777-h8hw4m9f	149	12	host	host	NN
cord-254777-h8hw4m9f	149	13	cells	cell	NNS
cord-254777-h8hw4m9f	149	14	,	,	,
cord-254777-h8hw4m9f	149	15	mainly	mainly	RB
cord-254777-h8hw4m9f	149	16	lung	lung	NN
cord-254777-h8hw4m9f	149	17	cells	cell	NNS
cord-254777-h8hw4m9f	149	18	which	which	WDT
cord-254777-h8hw4m9f	149	19	express	express	VBP
cord-254777-h8hw4m9f	149	20	ACE2	ACE2	NNP
cord-254777-h8hw4m9f	149	21	and	and	CC
cord-254777-h8hw4m9f	149	22	AP2-associated	ap2-associated	JJ
cord-254777-h8hw4m9f	149	23	protein	protein	NN
cord-254777-h8hw4m9f	149	24	kinase	kinase	NN
cord-254777-h8hw4m9f	149	25	1	1	CD
cord-254777-h8hw4m9f	149	26	(	(	-LRB-
cord-254777-h8hw4m9f	149	27	AAK1	AAK1	NNP
cord-254777-h8hw4m9f	149	28	)	)	-RRB-
cord-254777-h8hw4m9f	150	1	(	(	-LRB-
cord-254777-h8hw4m9f	150	2	a	a	DT
cord-254777-h8hw4m9f	150	3	regulator	regulator	NN
cord-254777-h8hw4m9f	150	4	of	of	IN
cord-254777-h8hw4m9f	150	5	endocytosis	endocytosis	NN
cord-254777-h8hw4m9f	150	6	)	)	-RRB-
cord-254777-h8hw4m9f	150	7	.	.	.
cord-254777-h8hw4m9f	151	1	Reports	report	NNS
cord-254777-h8hw4m9f	151	2	suggest	suggest	VBP
cord-254777-h8hw4m9f	151	3	that	that	IN
cord-254777-h8hw4m9f	151	4	blocking	block	VBG
cord-254777-h8hw4m9f	151	5	AAK1	AAK1	NNP
cord-254777-h8hw4m9f	151	6	may	may	MD
cord-254777-h8hw4m9f	151	7	interrupt	interrupt	VB
cord-254777-h8hw4m9f	151	8	viral	viral	JJ
cord-254777-h8hw4m9f	151	9	entry	entry	NN
cord-254777-h8hw4m9f	151	10	into	into	IN
cord-254777-h8hw4m9f	151	11	cells	cell	NNS
cord-254777-h8hw4m9f	151	12	and	and	CC
cord-254777-h8hw4m9f	151	13	thus	thus	RB
cord-254777-h8hw4m9f	151	14	decrease	decrease	VB
cord-254777-h8hw4m9f	151	15	the	the	DT
cord-254777-h8hw4m9f	151	16	viral	viral	JJ
cord-254777-h8hw4m9f	151	17	proliferation	proliferation	NN
cord-254777-h8hw4m9f	151	18	phase	phase	NN
cord-254777-h8hw4m9f	151	19	[	[	-LRB-
cord-254777-h8hw4m9f	151	20	53	53	CD
cord-254777-h8hw4m9f	151	21	]	]	-RRB-
cord-254777-h8hw4m9f	151	22	.	.	.
cord-254777-h8hw4m9f	152	1	A	a	DT
cord-254777-h8hw4m9f	152	2	second	second	JJ
cord-254777-h8hw4m9f	152	3	mechanism	mechanism	NN
cord-254777-h8hw4m9f	152	4	by	by	IN
cord-254777-h8hw4m9f	152	5	which	which	WDT
cord-254777-h8hw4m9f	152	6	the	the	DT
cord-254777-h8hw4m9f	152	7	JAK	JAK	NNP
cord-254777-h8hw4m9f	152	8	/	/	SYM
cord-254777-h8hw4m9f	152	9	STAT	stat	NN
cord-254777-h8hw4m9f	152	10	pathway	pathway	NN
cord-254777-h8hw4m9f	152	11	contributes	contribute	VBZ
cord-254777-h8hw4m9f	152	12	to	to	IN
cord-254777-h8hw4m9f	153	1	COVID-19	covid-19	JJ
cord-254777-h8hw4m9f	153	2	pathogenesis	pathogenesis	NN
cord-254777-h8hw4m9f	153	3	is	be	VBZ
cord-254777-h8hw4m9f	153	4	through	through	IN
cord-254777-h8hw4m9f	153	5	cytokine	cytokine	NN
cord-254777-h8hw4m9f	153	6	release	release	NN
cord-254777-h8hw4m9f	153	7	.	.	.
cord-254777-h8hw4m9f	154	1	Interferons	interferons	NN
cord-254777-h8hw4m9f	154	2	α	α	NN
cord-254777-h8hw4m9f	154	3	and	and	CC
cord-254777-h8hw4m9f	154	4	β	β	NN
cord-254777-h8hw4m9f	154	5	and	and	CC
cord-254777-h8hw4m9f	154	6	IL-6	IL-6	NNP
cord-254777-h8hw4m9f	154	7	all	all	DT
cord-254777-h8hw4m9f	154	8	signal	signal	VBP
cord-254777-h8hw4m9f	154	9	through	through	IN
cord-254777-h8hw4m9f	154	10	the	the	DT
cord-254777-h8hw4m9f	154	11	JAK	JAK	NNP
cord-254777-h8hw4m9f	154	12	/	/	SYM
cord-254777-h8hw4m9f	154	13	STAT	STAT	NNP
cord-254777-h8hw4m9f	154	14	pathway	pathway	NN
cord-254777-h8hw4m9f	154	15	,	,	,
cord-254777-h8hw4m9f	154	16	thus	thus	RB
cord-254777-h8hw4m9f	154	17	inhibiting	inhibit	VBG
cord-254777-h8hw4m9f	154	18	JAK	JAK	NNP
cord-254777-h8hw4m9f	154	19	/	/	SYM
cord-254777-h8hw4m9f	154	20	STAT	stat	NN
cord-254777-h8hw4m9f	154	21	activation	activation	NN
cord-254777-h8hw4m9f	154	22	could	could	MD
cord-254777-h8hw4m9f	154	23	lead	lead	VB
cord-254777-h8hw4m9f	154	24	to	to	IN
cord-254777-h8hw4m9f	154	25	dampening	dampening	NN
cord-254777-h8hw4m9f	154	26	of	of	IN
cord-254777-h8hw4m9f	154	27	the	the	DT
cord-254777-h8hw4m9f	154	28	cytokine	cytokine	NN
cord-254777-h8hw4m9f	154	29	storm	storm	NN
cord-254777-h8hw4m9f	154	30	.	.	.
cord-254777-h8hw4m9f	155	1	JAK	JAK	NNP
cord-254777-h8hw4m9f	155	2	inhibitors	inhibitor	NNS
cord-254777-h8hw4m9f	155	3	have	have	VBP
cord-254777-h8hw4m9f	155	4	been	be	VBN
cord-254777-h8hw4m9f	155	5	suggested	suggest	VBN
cord-254777-h8hw4m9f	155	6	for	for	IN
cord-254777-h8hw4m9f	155	7	treatment	treatment	NN
cord-254777-h8hw4m9f	155	8	of	of	IN
cord-254777-h8hw4m9f	155	9	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	155	10	[	[	-LRB-
cord-254777-h8hw4m9f	155	11	54	54	CD
cord-254777-h8hw4m9f	155	12	,	,	,
cord-254777-h8hw4m9f	155	13	55	55	CD
cord-254777-h8hw4m9f	155	14	]	]	-RRB-
cord-254777-h8hw4m9f	155	15	,	,	,
cord-254777-h8hw4m9f	155	16	although	although	IN
cord-254777-h8hw4m9f	155	17	some	some	DT
cord-254777-h8hw4m9f	155	18	authors	author	NNS
cord-254777-h8hw4m9f	155	19	caution	caution	VBP
cord-254777-h8hw4m9f	155	20	against	against	IN
cord-254777-h8hw4m9f	155	21	its	-PRON-	PRP$
cord-254777-h8hw4m9f	155	22	use	use	NN
cord-254777-h8hw4m9f	155	23	.	.	.
cord-254777-h8hw4m9f	156	1	Concerns	concern	NNS
cord-254777-h8hw4m9f	156	2	regarding	regard	VBG
cord-254777-h8hw4m9f	156	3	the	the	DT
cord-254777-h8hw4m9f	156	4	use	use	NN
cord-254777-h8hw4m9f	156	5	of	of	IN
cord-254777-h8hw4m9f	156	6	JAK	JAK	NNP
cord-254777-h8hw4m9f	156	7	inhibitors	inhibitor	NNS
cord-254777-h8hw4m9f	156	8	include	include	VBP
cord-254777-h8hw4m9f	156	9	cytopenias	cytopenia	NNS
cord-254777-h8hw4m9f	156	10	,	,	,
cord-254777-h8hw4m9f	156	11	elevation	elevation	NN
cord-254777-h8hw4m9f	156	12	of	of	IN
cord-254777-h8hw4m9f	156	13	creatine	creatine	NN
cord-254777-h8hw4m9f	156	14	kinase	kinase	NN
cord-254777-h8hw4m9f	156	15	,	,	,
cord-254777-h8hw4m9f	156	16	risk	risk	NN
cord-254777-h8hw4m9f	156	17	for	for	IN
cord-254777-h8hw4m9f	156	18	infection	infection	NN
cord-254777-h8hw4m9f	156	19	[	[	-LRB-
cord-254777-h8hw4m9f	156	20	56	56	CD
cord-254777-h8hw4m9f	156	21	]	]	-RRB-
cord-254777-h8hw4m9f	156	22	,	,	,
cord-254777-h8hw4m9f	156	23	risk	risk	NN
cord-254777-h8hw4m9f	156	24	for	for	IN
cord-254777-h8hw4m9f	156	25	thrombosis	thrombosis	NN
cord-254777-h8hw4m9f	156	26	and	and	CC
cord-254777-h8hw4m9f	156	27	the	the	DT
cord-254777-h8hw4m9f	156	28	fear	fear	NN
cord-254777-h8hw4m9f	156	29	of	of	IN
cord-254777-h8hw4m9f	156	30	inhibiting	inhibit	VBG
cord-254777-h8hw4m9f	156	31	interferon	interferon	NN
cord-254777-h8hw4m9f	156	32	-	-	HYPH
cord-254777-h8hw4m9f	156	33	mediated	mediate	VBN
cord-254777-h8hw4m9f	156	34	anti	anti	JJ
cord-254777-h8hw4m9f	156	35	-	-	JJ
cord-254777-h8hw4m9f	156	36	viral	viral	JJ
cord-254777-h8hw4m9f	156	37	response	response	NN
cord-254777-h8hw4m9f	156	38	,	,	,
cord-254777-h8hw4m9f	156	39	with	with	IN
cord-254777-h8hw4m9f	156	40	potential	potential	JJ
cord-254777-h8hw4m9f	156	41	facilitating	facilitate	VBG
cord-254777-h8hw4m9f	156	42	effect	effect	NN
cord-254777-h8hw4m9f	156	43	on	on	IN
cord-254777-h8hw4m9f	156	44	COVID-19	covid-19	JJ
cord-254777-h8hw4m9f	156	45	infection	infection	NN
cord-254777-h8hw4m9f	156	46	[	[	-LRB-
cord-254777-h8hw4m9f	156	47	57	57	CD
cord-254777-h8hw4m9f	156	48	]	]	-RRB-
cord-254777-h8hw4m9f	156	49	.	.	.
cord-254777-h8hw4m9f	157	1	There	there	EX
cord-254777-h8hw4m9f	157	2	are	be	VBP
cord-254777-h8hw4m9f	157	3	a	a	DT
cord-254777-h8hw4m9f	157	4	number	number	NN
cord-254777-h8hw4m9f	157	5	of	of	IN
cord-254777-h8hw4m9f	157	6	JAK	JAK	NNP
cord-254777-h8hw4m9f	157	7	inhibitors	inhibitor	NNS
cord-254777-h8hw4m9f	157	8	currently	currently	RB
cord-254777-h8hw4m9f	157	9	in	in	IN
cord-254777-h8hw4m9f	157	10	use	use	NN
cord-254777-h8hw4m9f	157	11	,	,	,
cord-254777-h8hw4m9f	157	12	mostly	mostly	RB
cord-254777-h8hw4m9f	157	13	in	in	IN
cord-254777-h8hw4m9f	157	14	rheumatic	rheumatic	JJ
cord-254777-h8hw4m9f	157	15	and	and	CC
cord-254777-h8hw4m9f	157	16	dermatologic	dermatologic	JJ
cord-254777-h8hw4m9f	157	17	conditions	condition	NNS
cord-254777-h8hw4m9f	157	18	.	.	.
cord-254777-h8hw4m9f	158	1	Baricitinib	Baricitinib	NNP
cord-254777-h8hw4m9f	158	2	is	be	VBZ
cord-254777-h8hw4m9f	158	3	an	an	DT
cord-254777-h8hw4m9f	158	4	oral	oral	JJ
cord-254777-h8hw4m9f	158	5	selective	selective	JJ
cord-254777-h8hw4m9f	158	6	JAK	JAK	NNP
cord-254777-h8hw4m9f	158	7	1	1	CD
cord-254777-h8hw4m9f	158	8	and	and	CC
cord-254777-h8hw4m9f	158	9	2	2	CD
cord-254777-h8hw4m9f	158	10	inhibitor	inhibitor	NN
cord-254777-h8hw4m9f	158	11	which	which	WDT
cord-254777-h8hw4m9f	158	12	is	be	VBZ
cord-254777-h8hw4m9f	158	13	FDA	FDA	NNP
cord-254777-h8hw4m9f	158	14	approved	approve	VBN
cord-254777-h8hw4m9f	158	15	for	for	IN
cord-254777-h8hw4m9f	158	16	RA	RA	NNP
cord-254777-h8hw4m9f	158	17	and	and	CC
cord-254777-h8hw4m9f	158	18	has	have	VBZ
cord-254777-h8hw4m9f	158	19	also	also	RB
cord-254777-h8hw4m9f	158	20	been	be	VBN
cord-254777-h8hw4m9f	158	21	used	use	VBN
cord-254777-h8hw4m9f	158	22	in	in	IN
cord-254777-h8hw4m9f	158	23	interferonopathies	interferonopathie	NNS
cord-254777-h8hw4m9f	158	24	.	.	.
cord-254777-h8hw4m9f	159	1	A	a	DT
cord-254777-h8hw4m9f	159	2	small	small	JJ
cord-254777-h8hw4m9f	159	3	pilot	pilot	NN
cord-254777-h8hw4m9f	159	4	study	study	NN
cord-254777-h8hw4m9f	159	5	from	from	IN
cord-254777-h8hw4m9f	159	6	Italy	Italy	NNP
cord-254777-h8hw4m9f	159	7	[	[	-LRB-
cord-254777-h8hw4m9f	159	8	58	58	CD
cord-254777-h8hw4m9f	159	9	]	]	-RRB-
cord-254777-h8hw4m9f	159	10	showed	show	VBD
cord-254777-h8hw4m9f	159	11	that	that	IN
cord-254777-h8hw4m9f	159	12	baricitinib	baricitinib	NN
cord-254777-h8hw4m9f	159	13	at	at	IN
cord-254777-h8hw4m9f	159	14	4	4	CD
cord-254777-h8hw4m9f	159	15	mg	mg	NNP
cord-254777-h8hw4m9f	159	16	/	/	SYM
cord-254777-h8hw4m9f	159	17	day	day	NN
cord-254777-h8hw4m9f	159	18	/	/	,
cord-254777-h8hw4m9f	159	19	orally	orally	RB
cord-254777-h8hw4m9f	159	20	(	(	-LRB-
cord-254777-h8hw4m9f	159	21	combined	combine	VBN
cord-254777-h8hw4m9f	159	22	with	with	IN
cord-254777-h8hw4m9f	159	23	lopinavir	lopinavir	NNS
cord-254777-h8hw4m9f	159	24	-	-	HYPH
cord-254777-h8hw4m9f	159	25	ritonavir	ritonavir	NNP
cord-254777-h8hw4m9f	159	26	)	)	-RRB-
cord-254777-h8hw4m9f	159	27	was	be	VBD
cord-254777-h8hw4m9f	159	28	safe	safe	JJ
cord-254777-h8hw4m9f	159	29	in	in	IN
cord-254777-h8hw4m9f	159	30	12	12	CD
cord-254777-h8hw4m9f	159	31	patients	patient	NNS
cord-254777-h8hw4m9f	159	32	with	with	IN
cord-254777-h8hw4m9f	159	33	moderate	moderate	JJ
cord-254777-h8hw4m9f	159	34	COVID-19	covid-19	JJ
cord-254777-h8hw4m9f	159	35	pneumonia	pneumonia	NN
cord-254777-h8hw4m9f	159	36	,	,	,
cord-254777-h8hw4m9f	159	37	with	with	IN
cord-254777-h8hw4m9f	159	38	significant	significant	JJ
cord-254777-h8hw4m9f	159	39	improvement	improvement	NN
cord-254777-h8hw4m9f	159	40	in	in	IN
cord-254777-h8hw4m9f	159	41	clinical	clinical	JJ
cord-254777-h8hw4m9f	159	42	and	and	CC
cord-254777-h8hw4m9f	159	43	respiratory	respiratory	JJ
cord-254777-h8hw4m9f	159	44	parameters	parameter	NNS
cord-254777-h8hw4m9f	159	45	at	at	IN
cord-254777-h8hw4m9f	159	46	2	2	CD
cord-254777-h8hw4m9f	159	47	weeks	week	NNS
cord-254777-h8hw4m9f	159	48	.	.	.
cord-254777-h8hw4m9f	160	1	Ruxolitinib	Ruxolitinib	NNP
cord-254777-h8hw4m9f	160	2	,	,	,
cord-254777-h8hw4m9f	160	3	another	another	DT
cord-254777-h8hw4m9f	160	4	JAK	JAK	NNP
cord-254777-h8hw4m9f	160	5	1	1	CD
cord-254777-h8hw4m9f	160	6	and	and	CC
cord-254777-h8hw4m9f	160	7	2	2	CD
cord-254777-h8hw4m9f	160	8	inhibitor	inhibitor	NN
cord-254777-h8hw4m9f	160	9	,	,	,
cord-254777-h8hw4m9f	160	10	was	be	VBD
cord-254777-h8hw4m9f	160	11	recently	recently	RB
cord-254777-h8hw4m9f	160	12	reported	report	VBN
cord-254777-h8hw4m9f	160	13	to	to	TO
cord-254777-h8hw4m9f	160	14	be	be	VB
cord-254777-h8hw4m9f	160	15	safe	safe	JJ
cord-254777-h8hw4m9f	160	16	and	and	CC
cord-254777-h8hw4m9f	160	17	show	show	VB
cord-254777-h8hw4m9f	160	18	a	a	DT
cord-254777-h8hw4m9f	160	19	numerically	numerically	RB
cord-254777-h8hw4m9f	160	20	faster	fast	JJR
cord-254777-h8hw4m9f	160	21	improvement	improvement	NN
cord-254777-h8hw4m9f	160	22	in	in	IN
cord-254777-h8hw4m9f	160	23	clinical	clinical	JJ
cord-254777-h8hw4m9f	160	24	symptoms	symptom	NNS
cord-254777-h8hw4m9f	160	25	in	in	IN
cord-254777-h8hw4m9f	160	26	20	20	CD
cord-254777-h8hw4m9f	160	27	patients	patient	NNS
cord-254777-h8hw4m9f	160	28	with	with	IN
cord-254777-h8hw4m9f	160	29	severe	severe	JJ
cord-254777-h8hw4m9f	160	30	COVID-19	covid-19	NN
cord-254777-h8hw4m9f	160	31	,	,	,
cord-254777-h8hw4m9f	160	32	although	although	IN
cord-254777-h8hw4m9f	160	33	this	this	DT
cord-254777-h8hw4m9f	160	34	was	be	VBD
cord-254777-h8hw4m9f	160	35	not	not	RB
cord-254777-h8hw4m9f	160	36	statistically	statistically	RB
cord-254777-h8hw4m9f	160	37	significant	significant	JJ
cord-254777-h8hw4m9f	160	38	[	[	-LRB-
cord-254777-h8hw4m9f	160	39	59	59	CD
cord-254777-h8hw4m9f	160	40	]	]	-RRB-
cord-254777-h8hw4m9f	160	41	.	.	.
cord-254777-h8hw4m9f	161	1	Other	other	JJ
cord-254777-h8hw4m9f	161	2	agents	agent	NNS
cord-254777-h8hw4m9f	161	3	currently	currently	RB
cord-254777-h8hw4m9f	161	4	under	under	IN
cord-254777-h8hw4m9f	161	5	investigation	investigation	NN
cord-254777-h8hw4m9f	161	6	for	for	IN
cord-254777-h8hw4m9f	161	7	their	-PRON-	PRP$
cord-254777-h8hw4m9f	161	8	role	role	NN
cord-254777-h8hw4m9f	161	9	in	in	IN
cord-254777-h8hw4m9f	161	10	treating	treat	VBG
cord-254777-h8hw4m9f	161	11	COVID-19	covid-19	JJ
cord-254777-h8hw4m9f	161	12	associated	associated	JJ
cord-254777-h8hw4m9f	161	13	hyperinflammation	hyperinflammation	NN
cord-254777-h8hw4m9f	161	14	are	be	VBP
cord-254777-h8hw4m9f	161	15	emapalumab	emapalumab	JJ
cord-254777-h8hw4m9f	161	16	(	(	-LRB-
cord-254777-h8hw4m9f	161	17	an	an	DT
cord-254777-h8hw4m9f	161	18	Anti	Anti	NNP
cord-254777-h8hw4m9f	161	19	-	-	NNS
cord-254777-h8hw4m9f	161	20	IFNγ	IFNγ	NNS
cord-254777-h8hw4m9f	161	21	Monoclonal	Monoclonal	NNP
cord-254777-h8hw4m9f	161	22	Antibody	Antibody	NNP
cord-254777-h8hw4m9f	161	23	)	)	-RRB-
cord-254777-h8hw4m9f	161	24	,	,	,
cord-254777-h8hw4m9f	161	25	colchicine	colchicine	NNP
cord-254777-h8hw4m9f	161	26	,	,	,
cord-254777-h8hw4m9f	161	27	complement	complement	VBP
cord-254777-h8hw4m9f	161	28	C3	C3	NNP
cord-254777-h8hw4m9f	161	29	inhibitor	inhibitor	NN
cord-254777-h8hw4m9f	162	1	AMY-101	AMY-101	NNP
cord-254777-h8hw4m9f	162	2	.	.	.
cord-254777-h8hw4m9f	163	1	Infection	infection	NN
cord-254777-h8hw4m9f	163	2	with	with	IN
cord-254777-h8hw4m9f	163	3	the	the	DT
cord-254777-h8hw4m9f	163	4	novel	novel	JJ
cord-254777-h8hw4m9f	163	5	coronavirus	coronavirus	NN
cord-254777-h8hw4m9f	163	6	SARS	SARS	NNP
cord-254777-h8hw4m9f	163	7	-	-	HYPH
cord-254777-h8hw4m9f	163	8	C0V-2	C0V-2	NNP
cord-254777-h8hw4m9f	163	9	represents	represent	VBZ
cord-254777-h8hw4m9f	163	10	the	the	DT
cord-254777-h8hw4m9f	163	11	greatest	great	JJS
cord-254777-h8hw4m9f	163	12	public	public	JJ
cord-254777-h8hw4m9f	163	13	health	health	NN
cord-254777-h8hw4m9f	163	14	crisis	crisis	NN
cord-254777-h8hw4m9f	163	15	of	of	IN
cord-254777-h8hw4m9f	163	16	our	-PRON-	PRP$
cord-254777-h8hw4m9f	163	17	generation	generation	NN
cord-254777-h8hw4m9f	163	18	.	.	.
cord-254777-h8hw4m9f	164	1	This	this	DT
cord-254777-h8hw4m9f	164	2	is	be	VBZ
cord-254777-h8hw4m9f	164	3	due	due	JJ
cord-254777-h8hw4m9f	164	4	to	to	IN
cord-254777-h8hw4m9f	164	5	the	the	DT
cord-254777-h8hw4m9f	164	6	fact	fact	NN
cord-254777-h8hw4m9f	164	7	that	that	IN
cord-254777-h8hw4m9f	164	8	there	there	EX
cord-254777-h8hw4m9f	164	9	is	be	VBZ
cord-254777-h8hw4m9f	164	10	no	no	DT
cord-254777-h8hw4m9f	164	11	existing	exist	VBG
cord-254777-h8hw4m9f	164	12	immunity	immunity	NN
cord-254777-h8hw4m9f	164	13	and	and	CC
cord-254777-h8hw4m9f	164	14	a	a	DT
cord-254777-h8hw4m9f	164	15	significant	significant	JJ
cord-254777-h8hw4m9f	164	16	proportion	proportion	NN
cord-254777-h8hw4m9f	164	17	of	of	IN
cord-254777-h8hw4m9f	164	18	the	the	DT
cord-254777-h8hw4m9f	164	19	population	population	NN
cord-254777-h8hw4m9f	164	20	develops	develop	VBZ
cord-254777-h8hw4m9f	164	21	severe	severe	JJ
cord-254777-h8hw4m9f	164	22	disease	disease	NN
cord-254777-h8hw4m9f	164	23	.	.	.
cord-254777-h8hw4m9f	165	1	The	the	DT
cord-254777-h8hw4m9f	165	2	virus	virus	NN
cord-254777-h8hw4m9f	165	3	seems	seem	VBZ
cord-254777-h8hw4m9f	165	4	to	to	TO
cord-254777-h8hw4m9f	165	5	behave	behave	VB
cord-254777-h8hw4m9f	165	6	in	in	IN
cord-254777-h8hw4m9f	165	7	new	new	JJ
cord-254777-h8hw4m9f	165	8	and	and	CC
cord-254777-h8hw4m9f	165	9	unexpected	unexpected	JJ
cord-254777-h8hw4m9f	165	10	ways	way	NNS
cord-254777-h8hw4m9f	165	11	,	,	,
cord-254777-h8hw4m9f	165	12	as	as	IN
cord-254777-h8hw4m9f	165	13	evidenced	evidence	VBN
cord-254777-h8hw4m9f	165	14	by	by	IN
cord-254777-h8hw4m9f	165	15	the	the	DT
cord-254777-h8hw4m9f	165	16	presentation	presentation	NN
cord-254777-h8hw4m9f	165	17	of	of	IN
cord-254777-h8hw4m9f	165	18	MIS	MIS	NNP
cord-254777-h8hw4m9f	165	19	-	-	HYPH
cord-254777-h8hw4m9f	165	20	C	C	NNP
cord-254777-h8hw4m9f	165	21	,	,	,
cord-254777-h8hw4m9f	165	22	which	which	WDT
cord-254777-h8hw4m9f	165	23	has	have	VBZ
cord-254777-h8hw4m9f	165	24	not	not	RB
cord-254777-h8hw4m9f	165	25	been	be	VBN
cord-254777-h8hw4m9f	165	26	previously	previously	RB
cord-254777-h8hw4m9f	165	27	described	describe	VBN
cord-254777-h8hw4m9f	165	28	with	with	IN
cord-254777-h8hw4m9f	165	29	other	other	JJ
cord-254777-h8hw4m9f	165	30	coronavirus	coronavirus	NN
cord-254777-h8hw4m9f	165	31	infections	infection	NNS
cord-254777-h8hw4m9f	165	32	.	.	.
cord-254777-h8hw4m9f	166	1	Much	much	JJ
cord-254777-h8hw4m9f	166	2	work	work	NN
cord-254777-h8hw4m9f	166	3	is	be	VBZ
cord-254777-h8hw4m9f	166	4	needed	need	VBN
cord-254777-h8hw4m9f	166	5	to	to	TO
cord-254777-h8hw4m9f	166	6	develop	develop	VB
cord-254777-h8hw4m9f	166	7	evidence	evidence	NN
cord-254777-h8hw4m9f	166	8	-	-	HYPH
cord-254777-h8hw4m9f	166	9	based	base	VBN
cord-254777-h8hw4m9f	166	10	,	,	,
cord-254777-h8hw4m9f	166	11	therapeutic	therapeutic	JJ
cord-254777-h8hw4m9f	166	12	manipulation	manipulation	NN
cord-254777-h8hw4m9f	166	13	of	of	IN
cord-254777-h8hw4m9f	166	14	the	the	DT
cord-254777-h8hw4m9f	166	15	inflammatory	inflammatory	JJ
cord-254777-h8hw4m9f	166	16	response	response	NN
cord-254777-h8hw4m9f	166	17	resulting	result	VBG
cord-254777-h8hw4m9f	166	18	from	from	IN
cord-254777-h8hw4m9f	166	19	severe	severe	JJ
cord-254777-h8hw4m9f	166	20	infection	infection	NN
cord-254777-h8hw4m9f	166	21	with	with	IN
cord-254777-h8hw4m9f	166	22	SARS	SARS	NNP
cord-254777-h8hw4m9f	166	23	-	-	HYPH
cord-254777-h8hw4m9f	166	24	CoV-2	CoV-2	NNP
cord-254777-h8hw4m9f	166	25	.	.	.
cord-254777-h8hw4m9f	167	1	This	this	DT
cord-254777-h8hw4m9f	167	2	is	be	VBZ
cord-254777-h8hw4m9f	167	3	desperately	desperately	RB
cord-254777-h8hw4m9f	167	4	needed	need	VBN
cord-254777-h8hw4m9f	167	5	now	now	RB
cord-254777-h8hw4m9f	167	6	,	,	,
cord-254777-h8hw4m9f	167	7	in	in	IN
cord-254777-h8hw4m9f	167	8	the	the	DT
cord-254777-h8hw4m9f	167	9	period	period	NN
cord-254777-h8hw4m9f	167	10	before	before	IN
cord-254777-h8hw4m9f	167	11	a	a	DT
cord-254777-h8hw4m9f	167	12	safe	safe	JJ
cord-254777-h8hw4m9f	167	13	and	and	CC
cord-254777-h8hw4m9f	167	14	efficacious	efficacious	JJ
cord-254777-h8hw4m9f	167	15	vaccine	vaccine	NN
cord-254777-h8hw4m9f	167	16	can	can	MD
cord-254777-h8hw4m9f	167	17	be	be	VB
cord-254777-h8hw4m9f	167	18	developed	develop	VBN
cord-254777-h8hw4m9f	167	19	.	.	.
cord-254777-h8hw4m9f	167	20	 	 	_SP
cord-254777-h8hw4m9f	168	1	COVID-19	covid-19	JJ
cord-254777-h8hw4m9f	168	2	illness	illness	NN
cord-254777-h8hw4m9f	168	3	in	in	IN
cord-254777-h8hw4m9f	168	4	native	native	JJ
cord-254777-h8hw4m9f	168	5	and	and	CC
cord-254777-h8hw4m9f	168	6	immunosuppressed	immunosuppressed	JJ
cord-254777-h8hw4m9f	168	7	states	state	NNS
cord-254777-h8hw4m9f	168	8	:	:	:
cord-254777-h8hw4m9f	168	9	A	a	DT
cord-254777-h8hw4m9f	168	10	clinical	clinical	JJ
cord-254777-h8hw4m9f	168	11	-	-	HYPH
cord-254777-h8hw4m9f	168	12	therapeutic	therapeutic	JJ
cord-254777-h8hw4m9f	168	13	staging	staging	NN
cord-254777-h8hw4m9f	168	14	proposal	proposal	NN
cord-254777-h8hw4m9f	168	15	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	168	16	:	:	:
cord-254777-h8hw4m9f	168	17	Immunology	immunology	NN
cord-254777-h8hw4m9f	168	18	and	and	CC
cord-254777-h8hw4m9f	168	19	treatment	treatment	NN
cord-254777-h8hw4m9f	168	20	options	option	NNS
cord-254777-h8hw4m9f	168	21	On	on	IN
cord-254777-h8hw4m9f	168	22	the	the	DT
cord-254777-h8hw4m9f	168	23	Alert	Alert	NNP
cord-254777-h8hw4m9f	168	24	for	for	IN
cord-254777-h8hw4m9f	168	25	Cytokine	Cytokine	NNP
cord-254777-h8hw4m9f	168	26	Storm	Storm	NNP
cord-254777-h8hw4m9f	168	27	:	:	:
cord-254777-h8hw4m9f	169	1	Immunopathology	immunopathology	NN
cord-254777-h8hw4m9f	169	2	in	in	IN
cord-254777-h8hw4m9f	169	3	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	169	4	Is	be	VBZ
cord-254777-h8hw4m9f	169	5	the	the	DT
cord-254777-h8hw4m9f	169	6	HScore	HScore	NNP
cord-254777-h8hw4m9f	169	7	useful	useful	JJ
cord-254777-h8hw4m9f	169	8	in	in	IN
cord-254777-h8hw4m9f	169	9	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	169	10	?	?	.
cord-254777-h8hw4m9f	170	1	The	the	DT
cord-254777-h8hw4m9f	170	2	Lancet	Lancet	NNP
cord-254777-h8hw4m9f	170	3	Is	be	VBZ
cord-254777-h8hw4m9f	170	4	antibody	antibody	NN
cord-254777-h8hw4m9f	170	5	-	-	HYPH
cord-254777-h8hw4m9f	170	6	dependent	dependent	JJ
cord-254777-h8hw4m9f	170	7	enhancement	enhancement	NN
cord-254777-h8hw4m9f	170	8	playing	play	VBG
cord-254777-h8hw4m9f	170	9	a	a	DT
cord-254777-h8hw4m9f	170	10	role	role	NN
cord-254777-h8hw4m9f	170	11	in	in	IN
cord-254777-h8hw4m9f	170	12	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	170	13	pathogenesis	pathogenesis	NN
cord-254777-h8hw4m9f	171	1	The	the	DT
cord-254777-h8hw4m9f	171	2	use	use	NN
cord-254777-h8hw4m9f	171	3	of	of	IN
cord-254777-h8hw4m9f	171	4	anti	anti	JJ
cord-254777-h8hw4m9f	171	5	-	-	JJ
cord-254777-h8hw4m9f	171	6	inflammatory	inflammatory	JJ
cord-254777-h8hw4m9f	171	7	drugs	drug	NNS
cord-254777-h8hw4m9f	171	8	in	in	IN
cord-254777-h8hw4m9f	171	9	the	the	DT
cord-254777-h8hw4m9f	171	10	treatment	treatment	NN
cord-254777-h8hw4m9f	171	11	of	of	IN
cord-254777-h8hw4m9f	171	12	people	people	NNS
cord-254777-h8hw4m9f	171	13	with	with	IN
cord-254777-h8hw4m9f	171	14	severe	severe	JJ
cord-254777-h8hw4m9f	171	15	coronavirus	coronavirus	NN
cord-254777-h8hw4m9f	171	16	disease	disease	NN
cord-254777-h8hw4m9f	171	17	2019	2019	CD
cord-254777-h8hw4m9f	171	18	(	(	-LRB-
cord-254777-h8hw4m9f	171	19	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	171	20	)	)	-RRB-
cord-254777-h8hw4m9f	171	21	:	:	:
cord-254777-h8hw4m9f	171	22	The	the	DT
cord-254777-h8hw4m9f	171	23	Perspectives	perspective	NNS
cord-254777-h8hw4m9f	171	24	of	of	IN
cord-254777-h8hw4m9f	171	25	clinical	clinical	JJ
cord-254777-h8hw4m9f	171	26	immunologists	immunologist	NNS
cord-254777-h8hw4m9f	171	27	from	from	IN
cord-254777-h8hw4m9f	171	28	China	China	NNP
cord-254777-h8hw4m9f	171	29	Characteristics	Characteristics	NNP
cord-254777-h8hw4m9f	171	30	of	of	IN
cord-254777-h8hw4m9f	171	31	and	and	CC
cord-254777-h8hw4m9f	171	32	Important	important	JJ
cord-254777-h8hw4m9f	171	33	Lessons	lesson	NNS
cord-254777-h8hw4m9f	171	34	From	from	IN
cord-254777-h8hw4m9f	171	35	the	the	DT
cord-254777-h8hw4m9f	171	36	Coronavirus	Coronavirus	NNP
cord-254777-h8hw4m9f	171	37	Disease	Disease	NNP
cord-254777-h8hw4m9f	171	38	2019	2019	CD
cord-254777-h8hw4m9f	172	1	(	(	-LRB-
cord-254777-h8hw4m9f	172	2	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	172	3	)	)	-RRB-
cord-254777-h8hw4m9f	172	4	Outbreak	outbreak	NN
cord-254777-h8hw4m9f	172	5	in	in	IN
cord-254777-h8hw4m9f	172	6	China	China	NNP
cord-254777-h8hw4m9f	172	7	:	:	:
cord-254777-h8hw4m9f	173	1	Summary	summary	NN
cord-254777-h8hw4m9f	173	2	of	of	IN
cord-254777-h8hw4m9f	173	3	a	a	DT
cord-254777-h8hw4m9f	173	4	Report	Report	NNP
cord-254777-h8hw4m9f	173	5	of	of	IN
cord-254777-h8hw4m9f	173	6	72	72	CD
cord-254777-h8hw4m9f	173	7	314	314	CD
cord-254777-h8hw4m9f	173	8	Cases	case	NNS
cord-254777-h8hw4m9f	173	9	From	from	IN
cord-254777-h8hw4m9f	173	10	the	the	DT
cord-254777-h8hw4m9f	173	11	Chinese	Chinese	NNP
cord-254777-h8hw4m9f	173	12	Center	Center	NNP
cord-254777-h8hw4m9f	173	13	for	for	IN
cord-254777-h8hw4m9f	173	14	Disease	Disease	NNP
cord-254777-h8hw4m9f	173	15	Control	Control	NNP
cord-254777-h8hw4m9f	173	16	and	and	CC
cord-254777-h8hw4m9f	173	17	Prevention	Prevention	NNP
cord-254777-h8hw4m9f	173	18	Clinical	Clinical	NNP
cord-254777-h8hw4m9f	173	19	features	feature	NNS
cord-254777-h8hw4m9f	173	20	of	of	IN
cord-254777-h8hw4m9f	173	21	patients	patient	NNS
cord-254777-h8hw4m9f	173	22	infected	infect	VBN
cord-254777-h8hw4m9f	173	23	with	with	IN
cord-254777-h8hw4m9f	173	24	2019	2019	CD
cord-254777-h8hw4m9f	173	25	novel	novel	JJ
cord-254777-h8hw4m9f	173	26	coronavirus	coronavirus	NN
cord-254777-h8hw4m9f	173	27	in	in	IN
cord-254777-h8hw4m9f	173	28	Wuhan	Wuhan	NNP
cord-254777-h8hw4m9f	173	29	,	,	,
cord-254777-h8hw4m9f	173	30	China	China	NNP
cord-254777-h8hw4m9f	173	31	.	.	.
cord-254777-h8hw4m9f	174	1	The	the	DT
cord-254777-h8hw4m9f	174	2	Lancet	Lancet	NNP
cord-254777-h8hw4m9f	174	3	Clinical	clinical	JJ
cord-254777-h8hw4m9f	174	4	Characteristics	characteristic	NNS
cord-254777-h8hw4m9f	174	5	of	of	IN
cord-254777-h8hw4m9f	174	6	Coronavirus	Coronavirus	NNP
cord-254777-h8hw4m9f	174	7	Disease	Disease	NNP
cord-254777-h8hw4m9f	174	8	2019	2019	CD
cord-254777-h8hw4m9f	174	9	in	in	IN
cord-254777-h8hw4m9f	174	10	China	China	NNP
cord-254777-h8hw4m9f	174	11	Epidemiology	Epidemiology	NNP
cord-254777-h8hw4m9f	174	12	,	,	,
cord-254777-h8hw4m9f	174	13	clinical	clinical	JJ
cord-254777-h8hw4m9f	174	14	course	course	NN
cord-254777-h8hw4m9f	174	15	,	,	,
cord-254777-h8hw4m9f	174	16	and	and	CC
cord-254777-h8hw4m9f	174	17	outcomes	outcome	NNS
cord-254777-h8hw4m9f	174	18	of	of	IN
cord-254777-h8hw4m9f	174	19	critically	critically	RB
cord-254777-h8hw4m9f	174	20	ill	ill	JJ
cord-254777-h8hw4m9f	174	21	adults	adult	NNS
cord-254777-h8hw4m9f	174	22	with	with	IN
cord-254777-h8hw4m9f	174	23	COVID-19	covid-19	CD
cord-254777-h8hw4m9f	174	24	in	in	IN
cord-254777-h8hw4m9f	174	25	New	New	NNP
cord-254777-h8hw4m9f	174	26	York	York	NNP
cord-254777-h8hw4m9f	174	27	City	City	NNP
cord-254777-h8hw4m9f	174	28	:	:	:
cord-254777-h8hw4m9f	174	29	a	a	DT
cord-254777-h8hw4m9f	174	30	prospective	prospective	JJ
cord-254777-h8hw4m9f	174	31	cohort	cohort	NN
cord-254777-h8hw4m9f	174	32	study	study	NN
cord-254777-h8hw4m9f	174	33	.	.	.
cord-254777-h8hw4m9f	175	1	The	the	DT
cord-254777-h8hw4m9f	175	2	Lancet	Lancet	NNP
cord-254777-h8hw4m9f	175	3	Clinical	clinical	JJ
cord-254777-h8hw4m9f	175	4	course	course	NN
cord-254777-h8hw4m9f	175	5	and	and	CC
cord-254777-h8hw4m9f	175	6	risk	risk	NN
cord-254777-h8hw4m9f	175	7	factors	factor	NNS
cord-254777-h8hw4m9f	175	8	for	for	IN
cord-254777-h8hw4m9f	175	9	mortality	mortality	NN
cord-254777-h8hw4m9f	175	10	of	of	IN
cord-254777-h8hw4m9f	175	11	adult	adult	NN
cord-254777-h8hw4m9f	175	12	inpatients	inpatient	NNS
cord-254777-h8hw4m9f	175	13	with	with	IN
cord-254777-h8hw4m9f	175	14	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	175	15	in	in	IN
cord-254777-h8hw4m9f	175	16	Wuhan	Wuhan	NNP
cord-254777-h8hw4m9f	175	17	,	,	,
cord-254777-h8hw4m9f	175	18	China	China	NNP
cord-254777-h8hw4m9f	175	19	:	:	:
cord-254777-h8hw4m9f	175	20	a	a	DT
cord-254777-h8hw4m9f	175	21	retrospective	retrospective	JJ
cord-254777-h8hw4m9f	175	22	cohort	cohort	NN
cord-254777-h8hw4m9f	175	23	study	study	NN
cord-254777-h8hw4m9f	175	24	.	.	.
cord-254777-h8hw4m9f	176	1	The	the	DT
cord-254777-h8hw4m9f	176	2	Lancet	Lancet	NNP
cord-254777-h8hw4m9f	176	3	Dysregulation	Dysregulation	NNP
cord-254777-h8hw4m9f	176	4	of	of	IN
cord-254777-h8hw4m9f	176	5	immune	immune	JJ
cord-254777-h8hw4m9f	176	6	response	response	NN
cord-254777-h8hw4m9f	176	7	in	in	IN
cord-254777-h8hw4m9f	176	8	patients	patient	NNS
cord-254777-h8hw4m9f	176	9	with	with	IN
cord-254777-h8hw4m9f	176	10	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	176	11	in	in	IN
cord-254777-h8hw4m9f	176	12	Wuhan	Wuhan	NNP
cord-254777-h8hw4m9f	176	13	,	,	,
cord-254777-h8hw4m9f	176	14	China	China	NNP
cord-254777-h8hw4m9f	176	15	Clinical	clinical	JJ
cord-254777-h8hw4m9f	176	16	and	and	CC
cord-254777-h8hw4m9f	176	17	immunological	immunological	JJ
cord-254777-h8hw4m9f	176	18	features	feature	NNS
cord-254777-h8hw4m9f	176	19	of	of	IN
cord-254777-h8hw4m9f	176	20	severe	severe	JJ
cord-254777-h8hw4m9f	176	21	and	and	CC
cord-254777-h8hw4m9f	176	22	moderate	moderate	JJ
cord-254777-h8hw4m9f	176	23	coronavirus	coronavirus	NN
cord-254777-h8hw4m9f	176	24	disease	disease	NN
cord-254777-h8hw4m9f	176	25	2019	2019	CD
cord-254777-h8hw4m9f	176	26	Clinical	Clinical	NNP
cord-254777-h8hw4m9f	176	27	Laboratory	Laboratory	NNP
cord-254777-h8hw4m9f	176	28	Parameters	Parameters	NNP
cord-254777-h8hw4m9f	176	29	Associated	Associated	NNP
cord-254777-h8hw4m9f	176	30	with	with	IN
cord-254777-h8hw4m9f	176	31	Severe	severe	JJ
cord-254777-h8hw4m9f	176	32	or	or	CC
cord-254777-h8hw4m9f	176	33	Critical	critical	JJ
cord-254777-h8hw4m9f	176	34	Novel	Novel	NNP
cord-254777-h8hw4m9f	176	35	Coronavirus	Coronavirus	NNP
cord-254777-h8hw4m9f	176	36	Disease	Disease	NNP
cord-254777-h8hw4m9f	176	37	2019	2019	CD
cord-254777-h8hw4m9f	176	38	(	(	-LRB-
cord-254777-h8hw4m9f	176	39	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	176	40	)	)	-RRB-
cord-254777-h8hw4m9f	176	41	:	:	:
cord-254777-h8hw4m9f	177	1	A	a	DT
cord-254777-h8hw4m9f	177	2	Systematic	Systematic	NNP
cord-254777-h8hw4m9f	177	3	Review	Review	NNP
cord-254777-h8hw4m9f	177	4	and	and	CC
cord-254777-h8hw4m9f	177	5	Meta	Meta	NNP
cord-254777-h8hw4m9f	177	6	-	-	HYPH
cord-254777-h8hw4m9f	177	7	analysis	analysis	NN
cord-254777-h8hw4m9f	177	8	Risk	risk	NN
cord-254777-h8hw4m9f	177	9	factors	factor	NNS
cord-254777-h8hw4m9f	177	10	for	for	IN
cord-254777-h8hw4m9f	177	11	severe	severe	JJ
cord-254777-h8hw4m9f	177	12	corona	corona	NN
cord-254777-h8hw4m9f	177	13	virus	virus	NN
cord-254777-h8hw4m9f	177	14	disease	disease	NNP
cord-254777-h8hw4m9f	177	15	2019	2019	CD
cord-254777-h8hw4m9f	177	16	(	(	-LRB-
cord-254777-h8hw4m9f	177	17	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	177	18	)	)	-RRB-
cord-254777-h8hw4m9f	177	19	patients	patient	NNS
cord-254777-h8hw4m9f	177	20	:	:	:
cord-254777-h8hw4m9f	177	21	a	a	DT
cord-254777-h8hw4m9f	177	22	systematic	systematic	JJ
cord-254777-h8hw4m9f	177	23	review	review	NN
cord-254777-h8hw4m9f	177	24	and	and	CC
cord-254777-h8hw4m9f	177	25	meta	meta	NNP
cord-254777-h8hw4m9f	177	26	analysis	analysis	NN
cord-254777-h8hw4m9f	177	27	.	.	.
cord-254777-h8hw4m9f	178	1	medRxiv	medRxiv	NNS
cord-254777-h8hw4m9f	178	2	,	,	,
cord-254777-h8hw4m9f	178	3	2020	2020	CD
cord-254777-h8hw4m9f	178	4	:	:	:
cord-254777-h8hw4m9f	179	1	p.	p.	NN
cord-254777-h8hw4m9f	179	2	2020.03.30.20047415	2020.03.30.20047415	CD
cord-254777-h8hw4m9f	179	3	.	.	.
cord-254777-h8hw4m9f	180	1	16	16	CD
cord-254777-h8hw4m9f	180	2	.	.	.
cord-254777-h8hw4m9f	181	1	Castagnoli	Castagnoli	NNP
cord-254777-h8hw4m9f	181	2	,	,	,
cord-254777-h8hw4m9f	181	3	Severe	severe	JJ
cord-254777-h8hw4m9f	181	4	Acute	acute	JJ
cord-254777-h8hw4m9f	181	5	Respiratory	Respiratory	NNP
cord-254777-h8hw4m9f	181	6	Syndrome	Syndrome	NNP
cord-254777-h8hw4m9f	181	7	Coronavirus	Coronavirus	NNP
cord-254777-h8hw4m9f	181	8	2	2	CD
cord-254777-h8hw4m9f	182	1	(	(	-LRB-
cord-254777-h8hw4m9f	182	2	SARS	SARS	NNP
cord-254777-h8hw4m9f	182	3	-	-	HYPH
cord-254777-h8hw4m9f	182	4	CoV-2	CoV-2	NNP
cord-254777-h8hw4m9f	182	5	)	)	-RRB-
cord-254777-h8hw4m9f	182	6	Infection	infection	NN
cord-254777-h8hw4m9f	182	7	in	in	IN
cord-254777-h8hw4m9f	182	8	Children	Children	NNPS
cord-254777-h8hw4m9f	182	9	and	and	CC
cord-254777-h8hw4m9f	182	10	Adolescents	Adolescents	NNPS
cord-254777-h8hw4m9f	183	1	A	a	DT
cord-254777-h8hw4m9f	183	2	Systematic	systematic	JJ
cord-254777-h8hw4m9f	183	3	Review	Review	NNP
cord-254777-h8hw4m9f	183	4	Epidemiology	Epidemiology	NNP
cord-254777-h8hw4m9f	183	5	of	of	IN
cord-254777-h8hw4m9f	183	6	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	183	7	Among	among	IN
cord-254777-h8hw4m9f	183	8	Children	Children	NNP
cord-254777-h8hw4m9f	183	9	in	in	IN
cord-254777-h8hw4m9f	183	10	China	China	NNP
cord-254777-h8hw4m9f	183	11	Chilblains	Chilblains	NNP
cord-254777-h8hw4m9f	183	12	-	-	HYPH
cord-254777-h8hw4m9f	183	13	like	like	JJ
cord-254777-h8hw4m9f	183	14	lesions	lesion	NNS
cord-254777-h8hw4m9f	183	15	in	in	IN
cord-254777-h8hw4m9f	183	16	children	child	NNS
cord-254777-h8hw4m9f	183	17	following	follow	VBG
cord-254777-h8hw4m9f	183	18	suspected	suspect	VBN
cord-254777-h8hw4m9f	183	19	Covid-19	covid-19	NN
cord-254777-h8hw4m9f	183	20	infection	infection	NN
cord-254777-h8hw4m9f	183	21	Clustered	Clustered	NNP
cord-254777-h8hw4m9f	183	22	Cases	case	NNS
cord-254777-h8hw4m9f	183	23	of	of	IN
cord-254777-h8hw4m9f	183	24	Acral	Acral	NNP
cord-254777-h8hw4m9f	183	25	Perniosis	Perniosis	NNP
cord-254777-h8hw4m9f	183	26	:	:	:
cord-254777-h8hw4m9f	183	27	Clinical	Clinical	NNP
cord-254777-h8hw4m9f	183	28	Features	Features	NNPS
cord-254777-h8hw4m9f	183	29	,	,	,
cord-254777-h8hw4m9f	183	30	Histopathology	Histopathology	NNP
cord-254777-h8hw4m9f	183	31	and	and	CC
cord-254777-h8hw4m9f	183	32	Relationship	Relationship	NNP
cord-254777-h8hw4m9f	183	33	to	to	TO
cord-254777-h8hw4m9f	183	34	COVID-19	covid-19	VB
cord-254777-h8hw4m9f	183	35	Clinical	Clinical	NNP
cord-254777-h8hw4m9f	183	36	Characteristics	Characteristics	NNPS
cord-254777-h8hw4m9f	183	37	and	and	CC
cord-254777-h8hw4m9f	183	38	Outcomes	Outcomes	NNPS
cord-254777-h8hw4m9f	183	39	of	of	IN
cord-254777-h8hw4m9f	183	40	Hospitalized	Hospitalized	NNP
cord-254777-h8hw4m9f	183	41	and	and	CC
cord-254777-h8hw4m9f	183	42	Critically	critically	RB
cord-254777-h8hw4m9f	183	43	Ill	Ill	NNP
cord-254777-h8hw4m9f	183	44	Children	Children	NNPS
cord-254777-h8hw4m9f	183	45	and	and	CC
cord-254777-h8hw4m9f	183	46	Adolescents	Adolescents	NNPS
cord-254777-h8hw4m9f	183	47	with	with	IN
cord-254777-h8hw4m9f	183	48	Coronavirus	Coronavirus	NNP
cord-254777-h8hw4m9f	183	49	Disease	Disease	NNP
cord-254777-h8hw4m9f	183	50	2019	2019	CD
cord-254777-h8hw4m9f	184	1	(	(	-LRB-
cord-254777-h8hw4m9f	184	2	COVID-19	covid-19	VB
cord-254777-h8hw4m9f	184	3	)	)	-RRB-
cord-254777-h8hw4m9f	184	4	at	at	IN
cord-254777-h8hw4m9f	184	5	a	a	DT
cord-254777-h8hw4m9f	184	6	Tertiary	Tertiary	NNP
cord-254777-h8hw4m9f	184	7	Care	Care	NNP
cord-254777-h8hw4m9f	184	8	Medical	Medical	NNP
cord-254777-h8hw4m9f	184	9	Center	Center	NNP
cord-254777-h8hw4m9f	184	10	Severe	Severe	NNP
cord-254777-h8hw4m9f	184	11	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	184	12	in	in	IN
cord-254777-h8hw4m9f	184	13	Children	Children	NNP
cord-254777-h8hw4m9f	184	14	and	and	CC
cord-254777-h8hw4m9f	184	15	Young	Young	NNP
cord-254777-h8hw4m9f	184	16	Adults	Adults	NNPS
cord-254777-h8hw4m9f	184	17	in	in	IN
cord-254777-h8hw4m9f	184	18	the	the	DT
cord-254777-h8hw4m9f	184	19	Washington	Washington	NNP
cord-254777-h8hw4m9f	184	20	,	,	,
cord-254777-h8hw4m9f	184	21	DC	DC	NNP
cord-254777-h8hw4m9f	184	22	Metropolitan	Metropolitan	NNP
cord-254777-h8hw4m9f	184	23	Region	Region	NNP
cord-254777-h8hw4m9f	184	24	Hyperinflammatory	Hyperinflammatory	NNP
cord-254777-h8hw4m9f	184	25	shock	shock	NN
cord-254777-h8hw4m9f	184	26	in	in	IN
cord-254777-h8hw4m9f	184	27	children	child	NNS
cord-254777-h8hw4m9f	184	28	during	during	IN
cord-254777-h8hw4m9f	184	29	COVID-19	covid-19	CD
cord-254777-h8hw4m9f	184	30	pandemic	pandemic	NN
cord-254777-h8hw4m9f	184	31	.	.	.
cord-254777-h8hw4m9f	185	1	The	the	DT
cord-254777-h8hw4m9f	185	2	Lancet	Lancet	NNP
cord-254777-h8hw4m9f	185	3	An	an	DT
cord-254777-h8hw4m9f	185	4	outbreak	outbreak	NN
cord-254777-h8hw4m9f	185	5	of	of	IN
cord-254777-h8hw4m9f	185	6	severe	severe	JJ
cord-254777-h8hw4m9f	185	7	Kawasaki	Kawasaki	NNP
cord-254777-h8hw4m9f	185	8	-	-	HYPH
cord-254777-h8hw4m9f	185	9	like	like	JJ
cord-254777-h8hw4m9f	185	10	disease	disease	NN
cord-254777-h8hw4m9f	185	11	at	at	IN
cord-254777-h8hw4m9f	185	12	the	the	DT
cord-254777-h8hw4m9f	185	13	Italian	italian	JJ
cord-254777-h8hw4m9f	185	14	epicentre	epicentre	NN
cord-254777-h8hw4m9f	185	15	of	of	IN
cord-254777-h8hw4m9f	185	16	the	the	DT
cord-254777-h8hw4m9f	185	17	SARS	SARS	NNP
cord-254777-h8hw4m9f	185	18	-	-	HYPH
cord-254777-h8hw4m9f	185	19	CoV-2	CoV-2	NNP
cord-254777-h8hw4m9f	185	20	epidemic	epidemic	NN
cord-254777-h8hw4m9f	185	21	:	:	:
cord-254777-h8hw4m9f	185	22	an	an	DT
cord-254777-h8hw4m9f	185	23	observational	observational	JJ
cord-254777-h8hw4m9f	185	24	cohort	cohort	NN
cord-254777-h8hw4m9f	185	25	study	study	NN
cord-254777-h8hw4m9f	185	26	.	.	.
cord-254777-h8hw4m9f	186	1	The	the	DT
cord-254777-h8hw4m9f	186	2	Lancet	Lancet	NNP
cord-254777-h8hw4m9f	186	3	Acute	acute	JJ
cord-254777-h8hw4m9f	186	4	heart	heart	NN
cord-254777-h8hw4m9f	186	5	failure	failure	NN
cord-254777-h8hw4m9f	186	6	in	in	IN
cord-254777-h8hw4m9f	186	7	multisystem	multisystem	JJ
cord-254777-h8hw4m9f	186	8	inflammatory	inflammatory	JJ
cord-254777-h8hw4m9f	186	9	syndrome	syndrome	NN
cord-254777-h8hw4m9f	186	10	in	in	IN
cord-254777-h8hw4m9f	186	11	children	child	NNS
cord-254777-h8hw4m9f	186	12	(	(	-LRB-
cord-254777-h8hw4m9f	186	13	MIS	MIS	NNP
cord-254777-h8hw4m9f	186	14	-	-	HYPH
cord-254777-h8hw4m9f	186	15	C	C	NNP
cord-254777-h8hw4m9f	186	16	)	)	-RRB-
cord-254777-h8hw4m9f	186	17	in	in	IN
cord-254777-h8hw4m9f	186	18	the	the	DT
cord-254777-h8hw4m9f	186	19	context	context	NN
cord-254777-h8hw4m9f	186	20	of	of	IN
cord-254777-h8hw4m9f	186	21	global	global	JJ
cord-254777-h8hw4m9f	186	22	SARS	SARS	NNP
cord-254777-h8hw4m9f	186	23	-	-	HYPH
cord-254777-h8hw4m9f	186	24	CoV-2	CoV-2	NNP
cord-254777-h8hw4m9f	186	25	pandemic	pandemic	NN
cord-254777-h8hw4m9f	186	26	Outbreak	outbreak	NN
cord-254777-h8hw4m9f	186	27	of	of	IN
cord-254777-h8hw4m9f	186	28	Kawasaki	Kawasaki	NNP
cord-254777-h8hw4m9f	186	29	disease	disease	NN
cord-254777-h8hw4m9f	186	30	in	in	IN
cord-254777-h8hw4m9f	186	31	children	child	NNS
cord-254777-h8hw4m9f	186	32	during	during	IN
cord-254777-h8hw4m9f	186	33	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	186	34	pandemic	pandemic	NN
cord-254777-h8hw4m9f	186	35	:	:	:
cord-254777-h8hw4m9f	186	36	a	a	DT
cord-254777-h8hw4m9f	186	37	prospective	prospective	JJ
cord-254777-h8hw4m9f	186	38	observational	observational	JJ
cord-254777-h8hw4m9f	186	39	Guidelines	Guidelines	NNPS
cord-254777-h8hw4m9f	186	40	for	for	IN
cord-254777-h8hw4m9f	186	41	the	the	DT
cord-254777-h8hw4m9f	186	42	Diagnosis	Diagnosis	NNP
cord-254777-h8hw4m9f	186	43	and	and	CC
cord-254777-h8hw4m9f	186	44	Management	Management	NNP
cord-254777-h8hw4m9f	186	45	of	of	IN
cord-254777-h8hw4m9f	186	46	Critical	Critical	NNP
cord-254777-h8hw4m9f	186	47	Illness	Illness	NNP
cord-254777-h8hw4m9f	186	48	-	-	HYPH
cord-254777-h8hw4m9f	186	49	Related	relate	VBN
cord-254777-h8hw4m9f	186	50	Corticosteroid	Corticosteroid	NNP
cord-254777-h8hw4m9f	186	51	Insufficiency	Insufficiency	NNP
cord-254777-h8hw4m9f	186	52	(	(	-LRB-
cord-254777-h8hw4m9f	186	53	CIRCI	CIRCI	NNP
cord-254777-h8hw4m9f	186	54	)	)	-RRB-
cord-254777-h8hw4m9f	186	55	in	in	IN
cord-254777-h8hw4m9f	186	56	Critically	Critically	NNP
cord-254777-h8hw4m9f	186	57	Ill	Ill	NNP
cord-254777-h8hw4m9f	186	58	Patients	Patients	NNP
cord-254777-h8hw4m9f	186	59	(	(	-LRB-
cord-254777-h8hw4m9f	186	60	Part	part	NN
cord-254777-h8hw4m9f	186	61	I	i	NN
cord-254777-h8hw4m9f	186	62	)	)	-RRB-
cord-254777-h8hw4m9f	186	63	:	:	:
cord-254777-h8hw4m9f	187	1	Society	Society	NNP
cord-254777-h8hw4m9f	187	2	of	of	IN
cord-254777-h8hw4m9f	187	3	Critical	Critical	NNP
cord-254777-h8hw4m9f	187	4	Care	Care	NNP
cord-254777-h8hw4m9f	187	5	Medicine	Medicine	NNP
cord-254777-h8hw4m9f	187	6	(	(	-LRB-
cord-254777-h8hw4m9f	187	7	SCCM	SCCM	NNP
cord-254777-h8hw4m9f	187	8	)	)	-RRB-
cord-254777-h8hw4m9f	187	9	and	and	CC
cord-254777-h8hw4m9f	187	10	European	European	NNP
cord-254777-h8hw4m9f	187	11	Society	Society	NNP
cord-254777-h8hw4m9f	187	12	of	of	IN
cord-254777-h8hw4m9f	187	13	Intensive	Intensive	NNP
cord-254777-h8hw4m9f	187	14	Care	Care	NNP
cord-254777-h8hw4m9f	187	15	Medicine	Medicine	NNP
cord-254777-h8hw4m9f	187	16	(	(	-LRB-
cord-254777-h8hw4m9f	187	17	ESICM	ESICM	NNP
cord-254777-h8hw4m9f	187	18	)	)	-RRB-
cord-254777-h8hw4m9f	188	1	2017	2017	CD
cord-254777-h8hw4m9f	189	1	Surviving	survive	VBG
cord-254777-h8hw4m9f	189	2	Sepsis	sepsis	NN
cord-254777-h8hw4m9f	189	3	Campaign	campaign	NN
cord-254777-h8hw4m9f	189	4	:	:	:
cord-254777-h8hw4m9f	189	5	International	International	NNP
cord-254777-h8hw4m9f	189	6	Guidelines	Guidelines	NNPS
cord-254777-h8hw4m9f	189	7	for	for	IN
cord-254777-h8hw4m9f	189	8	Management	Management	NNP
cord-254777-h8hw4m9f	189	9	of	of	IN
cord-254777-h8hw4m9f	189	10	Sepsis	Sepsis	NNP
cord-254777-h8hw4m9f	189	11	and	and	CC
cord-254777-h8hw4m9f	189	12	Septic	Septic	NNP
cord-254777-h8hw4m9f	189	13	Shock	Shock	NNP
cord-254777-h8hw4m9f	189	14	:	:	:
cord-254777-h8hw4m9f	189	15	2016	2016	CD
cord-254777-h8hw4m9f	189	16	.	.	.
cord-254777-h8hw4m9f	190	1	Intensive	Intensive	NNP
cord-254777-h8hw4m9f	190	2	Care	Care	NNP
cord-254777-h8hw4m9f	190	3	Med	Med	NNP
cord-254777-h8hw4m9f	190	4	Clinical	clinical	JJ
cord-254777-h8hw4m9f	190	5	evidence	evidence	NN
cord-254777-h8hw4m9f	190	6	does	do	VBZ
cord-254777-h8hw4m9f	190	7	not	not	RB
cord-254777-h8hw4m9f	190	8	support	support	VB
cord-254777-h8hw4m9f	190	9	corticosteroid	corticosteroid	NN
cord-254777-h8hw4m9f	190	10	treatment	treatment	NN
cord-254777-h8hw4m9f	190	11	for	for	IN
cord-254777-h8hw4m9f	190	12	2019-nCoV	2019-ncov	CD
cord-254777-h8hw4m9f	190	13	lung	lung	NN
cord-254777-h8hw4m9f	190	14	injury	injury	NN
cord-254777-h8hw4m9f	190	15	.	.	.
cord-254777-h8hw4m9f	191	1	The	the	DT
cord-254777-h8hw4m9f	191	2	Lancet	Lancet	NNP
cord-254777-h8hw4m9f	191	3	Epidemiological	epidemiological	JJ
cord-254777-h8hw4m9f	191	4	and	and	CC
cord-254777-h8hw4m9f	191	5	clinical	clinical	JJ
cord-254777-h8hw4m9f	191	6	characteristics	characteristic	NNS
cord-254777-h8hw4m9f	191	7	of	of	IN
cord-254777-h8hw4m9f	191	8	99	99	CD
cord-254777-h8hw4m9f	191	9	cases	case	NNS
cord-254777-h8hw4m9f	191	10	of	of	IN
cord-254777-h8hw4m9f	191	11	2019	2019	CD
cord-254777-h8hw4m9f	191	12	novel	novel	JJ
cord-254777-h8hw4m9f	191	13	coronavirus	coronavirus	NN
cord-254777-h8hw4m9f	191	14	pneumonia	pneumonia	NN
cord-254777-h8hw4m9f	191	15	in	in	IN
cord-254777-h8hw4m9f	191	16	Wuhan	Wuhan	NNP
cord-254777-h8hw4m9f	191	17	,	,	,
cord-254777-h8hw4m9f	191	18	China	China	NNP
cord-254777-h8hw4m9f	191	19	:	:	:
cord-254777-h8hw4m9f	191	20	a	a	DT
cord-254777-h8hw4m9f	191	21	descriptive	descriptive	JJ
cord-254777-h8hw4m9f	191	22	study	study	NN
cord-254777-h8hw4m9f	191	23	.	.	.
cord-254777-h8hw4m9f	192	1	The	the	DT
cord-254777-h8hw4m9f	192	2	Lancet	Lancet	NNP
cord-254777-h8hw4m9f	192	3	Risk	Risk	NNP
cord-254777-h8hw4m9f	192	4	Factors	factor	NNS
cord-254777-h8hw4m9f	192	5	Associated	associate	VBN
cord-254777-h8hw4m9f	192	6	With	with	IN
cord-254777-h8hw4m9f	192	7	Acute	acute	JJ
cord-254777-h8hw4m9f	192	8	Respiratory	respiratory	JJ
cord-254777-h8hw4m9f	192	9	Distress	Distress	NNP
cord-254777-h8hw4m9f	192	10	Syndrome	Syndrome	NNP
cord-254777-h8hw4m9f	192	11	and	and	CC
cord-254777-h8hw4m9f	192	12	Death	death	NN
cord-254777-h8hw4m9f	192	13	in	in	IN
cord-254777-h8hw4m9f	192	14	Patients	Patients	NNP
cord-254777-h8hw4m9f	192	15	With	with	IN
cord-254777-h8hw4m9f	192	16	Coronavirus	Coronavirus	NNP
cord-254777-h8hw4m9f	192	17	Disease	Disease	NNP
cord-254777-h8hw4m9f	193	1	A	a	DT
cord-254777-h8hw4m9f	193	2	retrospective	retrospective	JJ
cord-254777-h8hw4m9f	193	3	cohort	cohort	NN
cord-254777-h8hw4m9f	193	4	study	study	NN
cord-254777-h8hw4m9f	193	5	of	of	IN
cord-254777-h8hw4m9f	193	6	methylprednisolone	methylprednisolone	NNP
cord-254777-h8hw4m9f	193	7	therapy	therapy	NN
cord-254777-h8hw4m9f	193	8	in	in	IN
cord-254777-h8hw4m9f	193	9	severe	severe	JJ
cord-254777-h8hw4m9f	193	10	patients	patient	NNS
cord-254777-h8hw4m9f	193	11	with	with	IN
cord-254777-h8hw4m9f	193	12	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	193	13	pneumonia	pneumonia	NN
cord-254777-h8hw4m9f	193	14	Clinical	Clinical	NNP
cord-254777-h8hw4m9f	193	15	Characteristics	characteristic	NNS
cord-254777-h8hw4m9f	193	16	of	of	IN
cord-254777-h8hw4m9f	193	17	138	138	CD
cord-254777-h8hw4m9f	193	18	Hospitalized	hospitalize	VBN
cord-254777-h8hw4m9f	193	19	Patients	patient	NNS
cord-254777-h8hw4m9f	193	20	With	with	IN
cord-254777-h8hw4m9f	193	21	2019	2019	CD
cord-254777-h8hw4m9f	193	22	Novel	Novel	NNP
cord-254777-h8hw4m9f	193	23	Coronavirus	Coronavirus	NNP
cord-254777-h8hw4m9f	193	24	-	-	HYPH
cord-254777-h8hw4m9f	193	25	Infected	infect	VBN
cord-254777-h8hw4m9f	193	26	Pneumonia	Pneumonia	NNP
cord-254777-h8hw4m9f	193	27	in	in	IN
cord-254777-h8hw4m9f	193	28	Potential	potential	JJ
cord-254777-h8hw4m9f	193	29	benefits	benefit	NNS
cord-254777-h8hw4m9f	193	30	of	of	IN
cord-254777-h8hw4m9f	193	31	precise	precise	JJ
cord-254777-h8hw4m9f	193	32	corticosteroids	corticosteroid	NNS
cord-254777-h8hw4m9f	193	33	therapy	therapy	NN
cord-254777-h8hw4m9f	193	34	for	for	IN
cord-254777-h8hw4m9f	193	35	severe	severe	JJ
cord-254777-h8hw4m9f	193	36	2019-nCoV	2019-ncov	CD
cord-254777-h8hw4m9f	193	37	pneumonia	pneumonia	NN
cord-254777-h8hw4m9f	194	1	Translating	translate	VBG
cord-254777-h8hw4m9f	194	2	IL-6	IL-6	NNP
cord-254777-h8hw4m9f	194	3	biology	biology	NN
cord-254777-h8hw4m9f	194	4	into	into	IN
cord-254777-h8hw4m9f	194	5	effective	effective	JJ
cord-254777-h8hw4m9f	194	6	treatments	treatment	NNS
cord-254777-h8hw4m9f	195	1	Interleukin-6	Interleukin-6	NNP
cord-254777-h8hw4m9f	195	2	as	as	IN
cord-254777-h8hw4m9f	195	3	a	a	DT
cord-254777-h8hw4m9f	195	4	therapeutic	therapeutic	JJ
cord-254777-h8hw4m9f	195	5	target	target	NN
cord-254777-h8hw4m9f	195	6	Effective	effective	JJ
cord-254777-h8hw4m9f	195	7	treatment	treatment	NN
cord-254777-h8hw4m9f	195	8	of	of	IN
cord-254777-h8hw4m9f	195	9	severe	severe	JJ
cord-254777-h8hw4m9f	195	10	COVID-19	covid-19	JJ
cord-254777-h8hw4m9f	195	11	patients	patient	NNS
cord-254777-h8hw4m9f	195	12	with	with	IN
cord-254777-h8hw4m9f	195	13	tocilizumab	tocilizumab	JJ
cord-254777-h8hw4m9f	195	14	Tocilizumab	tocilizumab	JJ
cord-254777-h8hw4m9f	195	15	therapy	therapy	NN
cord-254777-h8hw4m9f	196	1	reduced	reduce	VBN
cord-254777-h8hw4m9f	196	2	intensive	intensive	JJ
cord-254777-h8hw4m9f	196	3	care	care	NN
cord-254777-h8hw4m9f	196	4	unit	unit	NN
cord-254777-h8hw4m9f	196	5	admissions	admission	NNS
cord-254777-h8hw4m9f	196	6	and/or	and/or	CC
cord-254777-h8hw4m9f	196	7	mortality	mortality	NN
cord-254777-h8hw4m9f	196	8	in	in	IN
cord-254777-h8hw4m9f	196	9	COVID-19	covid-19	CD
cord-254777-h8hw4m9f	196	10	patients	patient	NNS
cord-254777-h8hw4m9f	197	1	Interleukin-6	Interleukin-6	NNP
cord-254777-h8hw4m9f	198	1	blockade	blockade	NN
cord-254777-h8hw4m9f	198	2	for	for	IN
cord-254777-h8hw4m9f	198	3	severe	severe	JJ
cord-254777-h8hw4m9f	198	4	COVID-19	covid-19	NN
cord-254777-h8hw4m9f	198	5	.	.	.
cord-254777-h8hw4m9f	199	1	medRxiv	medRxiv	NNS
cord-254777-h8hw4m9f	199	2	Tocilizumab	Tocilizumab	NNP
cord-254777-h8hw4m9f	199	3	for	for	IN
cord-254777-h8hw4m9f	199	4	the	the	DT
cord-254777-h8hw4m9f	199	5	treatment	treatment	NN
cord-254777-h8hw4m9f	199	6	of	of	IN
cord-254777-h8hw4m9f	199	7	severe	severe	JJ
cord-254777-h8hw4m9f	199	8	COVID-19	covid-19	JJ
cord-254777-h8hw4m9f	199	9	pneumonia	pneumonia	NN
cord-254777-h8hw4m9f	199	10	with	with	IN
cord-254777-h8hw4m9f	199	11	hyperinflammatory	hyperinflammatory	NNP
cord-254777-h8hw4m9f	199	12	syndrome	syndrome	NN
cord-254777-h8hw4m9f	199	13	and	and	CC
cord-254777-h8hw4m9f	199	14	acute	acute	JJ
cord-254777-h8hw4m9f	199	15	respiratory	respiratory	JJ
cord-254777-h8hw4m9f	199	16	failure	failure	NN
cord-254777-h8hw4m9f	199	17	:	:	:
cord-254777-h8hw4m9f	199	18	A	a	DT
cord-254777-h8hw4m9f	199	19	single	single	JJ
cord-254777-h8hw4m9f	199	20	center	center	NN
cord-254777-h8hw4m9f	199	21	study	study	NN
cord-254777-h8hw4m9f	199	22	of	of	IN
cord-254777-h8hw4m9f	199	23	100	100	CD
cord-254777-h8hw4m9f	199	24	patients	patient	NNS
cord-254777-h8hw4m9f	199	25	in	in	IN
cord-254777-h8hw4m9f	199	26	Use	Use	NNP
cord-254777-h8hw4m9f	199	27	of	of	IN
cord-254777-h8hw4m9f	199	28	tocilizumab	tocilizumab	NNP
cord-254777-h8hw4m9f	199	29	for	for	IN
cord-254777-h8hw4m9f	199	30	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	199	31	infection	infection	NN
cord-254777-h8hw4m9f	199	32	-	-	HYPH
cord-254777-h8hw4m9f	199	33	induced	induce	VBN
cord-254777-h8hw4m9f	199	34	cytokine	cytokine	NN
cord-254777-h8hw4m9f	199	35	release	release	NN
cord-254777-h8hw4m9f	199	36	syndrome	syndrome	NN
cord-254777-h8hw4m9f	199	37	:	:	:
cord-254777-h8hw4m9f	199	38	A	a	DT
cord-254777-h8hw4m9f	199	39	cautionary	cautionary	JJ
cord-254777-h8hw4m9f	199	40	case	case	NN
cord-254777-h8hw4m9f	199	41	report	report	NN
cord-254777-h8hw4m9f	199	42	Use	Use	NNP
cord-254777-h8hw4m9f	199	43	of	of	IN
cord-254777-h8hw4m9f	199	44	siltuximab	siltuximab	NNP
cord-254777-h8hw4m9f	199	45	in	in	IN
cord-254777-h8hw4m9f	199	46	patients	patient	NNS
cord-254777-h8hw4m9f	199	47	with	with	IN
cord-254777-h8hw4m9f	199	48	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	199	49	pneumonia	pneumonia	NN
cord-254777-h8hw4m9f	199	50	requiring	require	VBG
cord-254777-h8hw4m9f	199	51	ventilatory	ventilatory	JJ
cord-254777-h8hw4m9f	199	52	support	support	NN
cord-254777-h8hw4m9f	199	53	.	.	.
cord-254777-h8hw4m9f	200	1	medRxiv	medRxiv	NNS
cord-254777-h8hw4m9f	200	2	Tocilizumab	tocilizumab	JJ
cord-254777-h8hw4m9f	200	3	treatment	treatment	NN
cord-254777-h8hw4m9f	200	4	in	in	IN
cord-254777-h8hw4m9f	200	5	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	200	6	:	:	:
cord-254777-h8hw4m9f	200	7	A	a	DT
cord-254777-h8hw4m9f	200	8	single	single	JJ
cord-254777-h8hw4m9f	200	9	center	center	NN
cord-254777-h8hw4m9f	200	10	experience	experience	NN
cord-254777-h8hw4m9f	200	11	Silencing	silence	VBG
cord-254777-h8hw4m9f	200	12	the	the	DT
cord-254777-h8hw4m9f	200	13	cytokine	cytokine	NN
cord-254777-h8hw4m9f	200	14	storm	storm	NN
cord-254777-h8hw4m9f	200	15	:	:	:
cord-254777-h8hw4m9f	200	16	the	the	DT
cord-254777-h8hw4m9f	200	17	use	use	NN
cord-254777-h8hw4m9f	200	18	of	of	IN
cord-254777-h8hw4m9f	200	19	intravenous	intravenous	JJ
cord-254777-h8hw4m9f	200	20	anakinra	anakinra	NN
cord-254777-h8hw4m9f	200	21	in	in	IN
cord-254777-h8hw4m9f	200	22	haemophagocytic	haemophagocytic	NNP
cord-254777-h8hw4m9f	200	23	lymphohistiocytosis	lymphohistiocytosis	NNP
cord-254777-h8hw4m9f	200	24	or	or	CC
cord-254777-h8hw4m9f	200	25	macrophage	macrophage	NN
cord-254777-h8hw4m9f	200	26	activation	activation	NN
cord-254777-h8hw4m9f	200	27	syndrome	syndrome	NN
cord-254777-h8hw4m9f	200	28	.	.	.
cord-254777-h8hw4m9f	201	1	The	the	DT
cord-254777-h8hw4m9f	201	2	Lancet	Lancet	NNP
cord-254777-h8hw4m9f	201	3	Rheumatology	Rheumatology	NNP
cord-254777-h8hw4m9f	201	4	Interleukin-1	Interleukin-1	NNP
cord-254777-h8hw4m9f	201	5	Receptor	Receptor	NNP
cord-254777-h8hw4m9f	201	6	Blockade	Blockade	NNP
cord-254777-h8hw4m9f	201	7	Is	be	VBZ
cord-254777-h8hw4m9f	201	8	Associated	associate	VBN
cord-254777-h8hw4m9f	201	9	With	with	IN
cord-254777-h8hw4m9f	201	10	Reduced	reduce	VBN
cord-254777-h8hw4m9f	201	11	Mortality	mortality	NN
cord-254777-h8hw4m9f	201	12	in	in	IN
cord-254777-h8hw4m9f	201	13	Sepsis	sepsis	NN
cord-254777-h8hw4m9f	201	14	Patients	patient	NNS
cord-254777-h8hw4m9f	201	15	With	with	IN
cord-254777-h8hw4m9f	201	16	Features	feature	NNS
cord-254777-h8hw4m9f	201	17	of	of	IN
cord-254777-h8hw4m9f	201	18	Macrophage	Macrophage	NNP
cord-254777-h8hw4m9f	201	19	Activation	Activation	NNP
cord-254777-h8hw4m9f	201	20	Syndrome	Syndrome	NNP
cord-254777-h8hw4m9f	201	21	:	:	:
cord-254777-h8hw4m9f	202	1	Reanalysis	reanalysis	NN
cord-254777-h8hw4m9f	202	2	of	of	IN
cord-254777-h8hw4m9f	202	3	a	a	DT
cord-254777-h8hw4m9f	202	4	Prior	Prior	NNP
cord-254777-h8hw4m9f	202	5	Phase	Phase	NNP
cord-254777-h8hw4m9f	202	6	III	III	NNP
cord-254777-h8hw4m9f	202	7	Trial	Trial	NNP
cord-254777-h8hw4m9f	202	8	Interleukin-1	Interleukin-1	NNP
cord-254777-h8hw4m9f	202	9	blockade	blockade	NN
cord-254777-h8hw4m9f	202	10	with	with	IN
cord-254777-h8hw4m9f	202	11	high	high	JJ
cord-254777-h8hw4m9f	202	12	-	-	HYPH
cord-254777-h8hw4m9f	202	13	dose	dose	NN
cord-254777-h8hw4m9f	202	14	anakinra	anakinra	NN
cord-254777-h8hw4m9f	202	15	in	in	IN
cord-254777-h8hw4m9f	202	16	patients	patient	NNS
cord-254777-h8hw4m9f	202	17	with	with	IN
cord-254777-h8hw4m9f	202	18	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	202	19	,	,	,
cord-254777-h8hw4m9f	202	20	acute	acute	JJ
cord-254777-h8hw4m9f	202	21	respiratory	respiratory	JJ
cord-254777-h8hw4m9f	202	22	distress	distress	NN
cord-254777-h8hw4m9f	202	23	syndrome	syndrome	NN
cord-254777-h8hw4m9f	202	24	,	,	,
cord-254777-h8hw4m9f	202	25	and	and	CC
cord-254777-h8hw4m9f	202	26	hyperinflammation	hyperinflammation	NN
cord-254777-h8hw4m9f	202	27	:	:	:
cord-254777-h8hw4m9f	202	28	a	a	DT
cord-254777-h8hw4m9f	202	29	retrospective	retrospective	JJ
cord-254777-h8hw4m9f	202	30	cohort	cohort	NN
cord-254777-h8hw4m9f	202	31	study	study	NN
cord-254777-h8hw4m9f	202	32	.	.	.
cord-254777-h8hw4m9f	203	1	The	the	DT
cord-254777-h8hw4m9f	203	2	Lancet	Lancet	NNP
cord-254777-h8hw4m9f	203	3	Rheumatology	Rheumatology	NNP
cord-254777-h8hw4m9f	203	4	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	203	5	:	:	:
cord-254777-h8hw4m9f	203	6	consider	consider	VB
cord-254777-h8hw4m9f	203	7	cytokine	cytokine	JJ
cord-254777-h8hw4m9f	203	8	storm	storm	NN
cord-254777-h8hw4m9f	203	9	syndromes	syndrome	NNS
cord-254777-h8hw4m9f	203	10	and	and	CC
cord-254777-h8hw4m9f	203	11	immunosuppression	immunosuppression	NN
cord-254777-h8hw4m9f	203	12	.	.	.
cord-254777-h8hw4m9f	204	1	The	the	DT
cord-254777-h8hw4m9f	204	2	Lancet	Lancet	NNP
cord-254777-h8hw4m9f	204	3	Safety	Safety	NNP
cord-254777-h8hw4m9f	204	4	and	and	CC
cord-254777-h8hw4m9f	204	5	efficacy	efficacy	NN
cord-254777-h8hw4m9f	204	6	of	of	IN
cord-254777-h8hw4m9f	204	7	early	early	JJ
cord-254777-h8hw4m9f	204	8	high	high	JJ
cord-254777-h8hw4m9f	204	9	-	-	HYPH
cord-254777-h8hw4m9f	204	10	dose	dose	NN
cord-254777-h8hw4m9f	204	11	IV	IV	NNP
cord-254777-h8hw4m9f	204	12	anakinra	anakinra	NNP
cord-254777-h8hw4m9f	204	13	in	in	IN
cord-254777-h8hw4m9f	204	14	severe	severe	JJ
cord-254777-h8hw4m9f	204	15	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	204	16	lung	lung	NN
cord-254777-h8hw4m9f	204	17	disease	disease	NN
cord-254777-h8hw4m9f	204	18	Effect	Effect	NNP
cord-254777-h8hw4m9f	204	19	of	of	IN
cord-254777-h8hw4m9f	204	20	regular	regular	JJ
cord-254777-h8hw4m9f	204	21	intravenous	intravenous	JJ
cord-254777-h8hw4m9f	204	22	immunoglobulin	immunoglobulin	NN
cord-254777-h8hw4m9f	204	23	therapy	therapy	NN
cord-254777-h8hw4m9f	204	24	on	on	IN
cord-254777-h8hw4m9f	204	25	prognosis	prognosis	NN
cord-254777-h8hw4m9f	204	26	of	of	IN
cord-254777-h8hw4m9f	204	27	severe	severe	JJ
cord-254777-h8hw4m9f	204	28	pneumonia	pneumonia	NN
cord-254777-h8hw4m9f	204	29	in	in	IN
cord-254777-h8hw4m9f	204	30	patients	patient	NNS
cord-254777-h8hw4m9f	204	31	with	with	IN
cord-254777-h8hw4m9f	204	32	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	204	33	Pharmacologic	Pharmacologic	NNP
cord-254777-h8hw4m9f	204	34	Treatments	Treatments	NNP
cord-254777-h8hw4m9f	204	35	for	for	IN
cord-254777-h8hw4m9f	204	36	Coronavirus	Coronavirus	NNP
cord-254777-h8hw4m9f	204	37	Disease	Disease	NNP
cord-254777-h8hw4m9f	204	38	2019	2019	CD
cord-254777-h8hw4m9f	205	1	(	(	-LRB-
cord-254777-h8hw4m9f	205	2	COVID-19	covid-19	VB
cord-254777-h8hw4m9f	205	3	)	)	-RRB-
cord-254777-h8hw4m9f	205	4	:	:	:
cord-254777-h8hw4m9f	205	5	A	a	DT
cord-254777-h8hw4m9f	205	6	Review	Review	NNP
cord-254777-h8hw4m9f	205	7	Convalescent	Convalescent	NNP
cord-254777-h8hw4m9f	205	8	plasma	plasma	NN
cord-254777-h8hw4m9f	205	9	in	in	IN
cord-254777-h8hw4m9f	205	10	Covid-19	covid-19	NN
cord-254777-h8hw4m9f	205	11	:	:	:
cord-254777-h8hw4m9f	205	12	Possible	possible	JJ
cord-254777-h8hw4m9f	205	13	mechanisms	mechanism	NNS
cord-254777-h8hw4m9f	205	14	of	of	IN
cord-254777-h8hw4m9f	205	15	action	action	NN
cord-254777-h8hw4m9f	206	1	The	the	DT
cord-254777-h8hw4m9f	206	2	JAK	JAK	NNP
cord-254777-h8hw4m9f	206	3	/	/	SYM
cord-254777-h8hw4m9f	206	4	STAT	stat	NN
cord-254777-h8hw4m9f	206	5	signaling	signal	VBG
cord-254777-h8hw4m9f	206	6	pathway	pathway	NN
cord-254777-h8hw4m9f	206	7	Complex	Complex	NNP
cord-254777-h8hw4m9f	206	8	Immune	Immune	NNP
cord-254777-h8hw4m9f	206	9	Dysregulation	Dysregulation	NNP
cord-254777-h8hw4m9f	206	10	in	in	IN
cord-254777-h8hw4m9f	206	11	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	206	12	Patients	Patients	NNPS
cord-254777-h8hw4m9f	206	13	with	with	IN
cord-254777-h8hw4m9f	206	14	Severe	severe	JJ
cord-254777-h8hw4m9f	206	15	Respiratory	respiratory	JJ
cord-254777-h8hw4m9f	206	16	Failure	failure	NN
cord-254777-h8hw4m9f	206	17	Baricitinib	Baricitinib	NNP
cord-254777-h8hw4m9f	206	18	for	for	IN
cord-254777-h8hw4m9f	206	19	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	206	20	:	:	:
cord-254777-h8hw4m9f	206	21	a	a	DT
cord-254777-h8hw4m9f	206	22	suitable	suitable	JJ
cord-254777-h8hw4m9f	206	23	treatment	treatment	NN
cord-254777-h8hw4m9f	206	24	?	?	.
cord-254777-h8hw4m9f	207	1	-Authors	-author	NNS
cord-254777-h8hw4m9f	207	2	'	'	POS
cord-254777-h8hw4m9f	207	3	reply	reply	NN
cord-254777-h8hw4m9f	207	4	.	.	.
cord-254777-h8hw4m9f	208	1	The	the	DT
cord-254777-h8hw4m9f	208	2	Lancet	Lancet	NNP
cord-254777-h8hw4m9f	208	3	Infectious	Infectious	NNP
cord-254777-h8hw4m9f	208	4	Diseases	Diseases	NNPS
cord-254777-h8hw4m9f	208	5	JAK	JAK	NNP
cord-254777-h8hw4m9f	208	6	Inhibition	Inhibition	NNP
cord-254777-h8hw4m9f	208	7	as	as	IN
cord-254777-h8hw4m9f	208	8	a	a	DT
cord-254777-h8hw4m9f	208	9	New	New	NNP
cord-254777-h8hw4m9f	208	10	Treatment	Treatment	NNP
cord-254777-h8hw4m9f	208	11	Strategy	Strategy	NNP
cord-254777-h8hw4m9f	208	12	for	for	IN
cord-254777-h8hw4m9f	208	13	Patients	patient	NNS
cord-254777-h8hw4m9f	208	14	with	with	IN
cord-254777-h8hw4m9f	208	15	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	208	16	Janus	Janus	NNP
cord-254777-h8hw4m9f	208	17	kinase	kinase	NN
cord-254777-h8hw4m9f	208	18	inhibitor	inhibitor	NN
cord-254777-h8hw4m9f	208	19	baricitinib	baricitinib	NN
cord-254777-h8hw4m9f	208	20	is	be	VBZ
cord-254777-h8hw4m9f	208	21	not	not	RB
cord-254777-h8hw4m9f	208	22	an	an	DT
cord-254777-h8hw4m9f	208	23	ideal	ideal	JJ
cord-254777-h8hw4m9f	208	24	option	option	NN
cord-254777-h8hw4m9f	208	25	for	for	IN
cord-254777-h8hw4m9f	208	26	management	management	NN
cord-254777-h8hw4m9f	208	27	of	of	IN
cord-254777-h8hw4m9f	208	28	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	208	29	Baricitinib	Baricitinib	NNP
cord-254777-h8hw4m9f	208	30	for	for	IN
cord-254777-h8hw4m9f	208	31	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	208	32	:	:	:
cord-254777-h8hw4m9f	208	33	a	a	DT
cord-254777-h8hw4m9f	208	34	suitable	suitable	JJ
cord-254777-h8hw4m9f	208	35	treatment	treatment	NN
cord-254777-h8hw4m9f	208	36	?	?	.
cord-254777-h8hw4m9f	209	1	The	the	DT
cord-254777-h8hw4m9f	209	2	Lancet	Lancet	NNP
cord-254777-h8hw4m9f	209	3	Infectious	Infectious	NNP
cord-254777-h8hw4m9f	209	4	Diseases	Diseases	NNPS
cord-254777-h8hw4m9f	209	5	Baricitinib	Baricitinib	NNP
cord-254777-h8hw4m9f	209	6	therapy	therapy	NN
cord-254777-h8hw4m9f	209	7	in	in	IN
cord-254777-h8hw4m9f	209	8	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	210	1	:	:	:
cord-254777-h8hw4m9f	210	2	A	a	DT
cord-254777-h8hw4m9f	210	3	pilot	pilot	NN
cord-254777-h8hw4m9f	210	4	study	study	NN
cord-254777-h8hw4m9f	210	5	on	on	IN
cord-254777-h8hw4m9f	210	6	safety	safety	NN
cord-254777-h8hw4m9f	210	7	and	and	CC
cord-254777-h8hw4m9f	210	8	clinical	clinical	JJ
cord-254777-h8hw4m9f	210	9	impact	impact	NN
cord-254777-h8hw4m9f	211	1	Ruxolitinib	Ruxolitinib	NNP
cord-254777-h8hw4m9f	211	2	in	in	IN
cord-254777-h8hw4m9f	211	3	treatment	treatment	NN
cord-254777-h8hw4m9f	211	4	of	of	IN
cord-254777-h8hw4m9f	211	5	severe	severe	JJ
cord-254777-h8hw4m9f	211	6	coronavirus	coronavirus	NN
cord-254777-h8hw4m9f	211	7	disease	disease	NN
cord-254777-h8hw4m9f	211	8	2019	2019	CD
cord-254777-h8hw4m9f	211	9	(	(	-LRB-
cord-254777-h8hw4m9f	211	10	COVID-19	COVID-19	NNP
cord-254777-h8hw4m9f	211	11	)	)	-RRB-
cord-254777-h8hw4m9f	211	12	:	:	:
cord-254777-h8hw4m9f	211	13	A	a	DT
cord-254777-h8hw4m9f	211	14	multicenter	multicenter	JJ
cord-254777-h8hw4m9f	211	15	,	,	,
cord-254777-h8hw4m9f	211	16	single	single	JJ
cord-254777-h8hw4m9f	211	17	-	-	HYPH
cord-254777-h8hw4m9f	211	18	blind	blind	JJ
cord-254777-h8hw4m9f	211	19	,	,	,
cord-254777-h8hw4m9f	211	20	randomized	randomized	JJ
cord-254777-h8hw4m9f	211	21	controlled	control	VBN
cord-254777-h8hw4m9f	211	22	trial	trial	NN
cord-254777-h8hw4m9f	211	23	 	 	_SP
cord-254777-h8hw4m9f	211	24	Table	Table	NNP
cord-254777-h8hw4m9f	211	25	1	1	CD
cord-254777-h8hw4m9f	211	26	 	 	_SP
cord-254777-h8hw4m9f	212	1	;	;	:
cord-254777-h8hw4m9f	212	2	categorical	categorical	JJ
cord-254777-h8hw4m9f	212	3	variables	variable	NNS
cord-254777-h8hw4m9f	212	4	are	be	VBP
cord-254777-h8hw4m9f	212	5	expressed	express	VBN
cord-254777-h8hw4m9f	212	6	as	as	IN
cord-254777-h8hw4m9f	212	7	numbers	number	NNS
cord-254777-h8hw4m9f	212	8	(	(	-LRB-
cord-254777-h8hw4m9f	212	9	percentage	percentage	NN
cord-254777-h8hw4m9f	212	10	)	)	-RRB-
cord-254777-h8hw4m9f	213	1	*	*	NFP
cord-254777-h8hw4m9f	213	2	*	*	NFP
cord-254777-h8hw4m9f	213	3	Comorbidities	comorbiditie	NNS
cord-254777-h8hw4m9f	213	4	include	include	VBP
cord-254777-h8hw4m9f	213	5	asthma	asthma	NN
cord-254777-h8hw4m9f	213	6	,	,	,
cord-254777-h8hw4m9f	213	7	obesity	obesity	NN
cord-254777-h8hw4m9f	213	8	,	,	,
cord-254777-h8hw4m9f	213	9	lupus	lupus	NN
cord-254777-h8hw4m9f	213	10	,	,	,
cord-254777-h8hw4m9f	213	11	autism	autism	NN
cord-254777-h8hw4m9f	213	12	,	,	,
cord-254777-h8hw4m9f	213	13	ADHD	ADHD	NNP
cord-254777-h8hw4m9f	214	1	*	*	NFP
cord-254777-h8hw4m9f	214	2	*	*	NFP
cord-254777-h8hw4m9f	214	3	*	*	NFP
cord-254777-h8hw4m9f	214	4	Gastrointestinal	gastrointestinal	JJ
cord-254777-h8hw4m9f	214	5	symptoms	symptom	NNS
cord-254777-h8hw4m9f	214	6	include	include	VBP
cord-254777-h8hw4m9f	214	7	abdominal	abdominal	JJ
cord-254777-h8hw4m9f	214	8	pain	pain	NN
cord-254777-h8hw4m9f	214	9	,	,	,
cord-254777-h8hw4m9f	214	10	vomiting	vomiting	NN
cord-254777-h8hw4m9f	214	11	,	,	,
cord-254777-h8hw4m9f	214	12	diarrhea	diarrhea	NN
cord-254777-h8hw4m9f	215	1	*	*	NFP
cord-254777-h8hw4m9f	215	2	*	*	NFP
cord-254777-h8hw4m9f	215	3	*	*	NFP
cord-254777-h8hw4m9f	215	4	*	*	NFP
cord-254777-h8hw4m9f	215	5	Reference	reference	NN
cord-254777-h8hw4m9f	215	6	ranges	range	NNS
cord-254777-h8hw4m9f	215	7	may	may	MD
cord-254777-h8hw4m9f	215	8	vary	vary	VB
cord-254777-h8hw4m9f	215	9	per	per	IN
cord-254777-h8hw4m9f	215	10	study	study	NN
cord-254777-h8hw4m9f	215	11	and	and	CC
cord-254777-h8hw4m9f	215	12	laboratory	laboratory	NN
cord-254777-h8hw4m9f	215	13	-Data	-Data	NNP
cord-254777-h8hw4m9f	215	14	not	not	RB
cord-254777-h8hw4m9f	215	15	reported	report	VBD
cord-254777-h8hw4m9f	215	16	CRP	crp	NN
cord-254777-h8hw4m9f	215	17	:	:	:
cord-254777-h8hw4m9f	215	18	C	c	NN
cord-254777-h8hw4m9f	215	19	-	-	HYPH
cord-254777-h8hw4m9f	215	20	reactive	reactive	JJ
cord-254777-h8hw4m9f	215	21	protein	protein	NN
cord-254777-h8hw4m9f	215	22	;	;	:
cord-254777-h8hw4m9f	215	23	NT	NT	NNP
cord-254777-h8hw4m9f	215	24	-	-	HYPH
cord-254777-h8hw4m9f	215	25	proBNP	probnp	NN
cord-254777-h8hw4m9f	215	26	:	:	:
cord-254777-h8hw4m9f	215	27	N	n	CD
cord-254777-h8hw4m9f	215	28	-	-	HYPH
cord-254777-h8hw4m9f	215	29	terminal	terminal	NN
cord-254777-h8hw4m9f	215	30	pro	pro	JJ
cord-254777-h8hw4m9f	215	31	hormone	hormone	NN
cord-254777-h8hw4m9f	215	32	brain	brain	NN
cord-254777-h8hw4m9f	215	33	natriuretic	natriuretic	JJ
cord-254777-h8hw4m9f	215	34	peptide	peptide	NN
cord-254777-h8hw4m9f	215	35	;	;	:
cord-254777-h8hw4m9f	215	36	NP	NP	NNP
cord-254777-h8hw4m9f	215	37	PCR	PCR	NNP
cord-254777-h8hw4m9f	215	38	:	:	:
cord-254777-h8hw4m9f	215	39	nasopharyngeal	nasopharyngeal	JJ
cord-254777-h8hw4m9f	215	40	PCR	PCR	NNP
cord-254777-h8hw4m9f	215	41	 	 	_SP